WO2010057126A1 - Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors - Google Patents

Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors Download PDF

Info

Publication number
WO2010057126A1
WO2010057126A1 PCT/US2009/064643 US2009064643W WO2010057126A1 WO 2010057126 A1 WO2010057126 A1 WO 2010057126A1 US 2009064643 W US2009064643 W US 2009064643W WO 2010057126 A1 WO2010057126 A1 WO 2010057126A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
pyridin
phenyl
yloxy
imidazol
Prior art date
Application number
PCT/US2009/064643
Other languages
French (fr)
Inventor
Jennifer R. Allen
Kaustav Biswas
Frank Chavez, Jr.
Ning Chen
Frenel Fils Demorin
James R. Falsey
Mike Frohn
Paul Harrington
Dan Horne
Essa Hu
Matthew R. Kaller
Roxanne Kunz
Holger Monenschein
Tom Nguyen
Alex Pickrell
Andreas Reichelt
Shannon Rumfelt
Rob Rzasa
Kelvin Sham
Guomin Yao
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2009313773A priority Critical patent/AU2009313773B2/en
Priority to MX2011005093A priority patent/MX2011005093A/en
Priority to JP2011536570A priority patent/JP2012508777A/en
Priority to EA201100749A priority patent/EA201100749A1/en
Priority to CA2742833A priority patent/CA2742833C/en
Priority to BRPI0921598A priority patent/BRPI0921598A2/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to ES09752706T priority patent/ES2413808T3/en
Priority to EP09752706.3A priority patent/EP2364306B1/en
Publication of WO2010057126A1 publication Critical patent/WO2010057126A1/en
Priority to IL212670A priority patent/IL212670A0/en
Priority to TN2011000220A priority patent/TN2011000220A1/en
Priority to MA33931A priority patent/MA32891B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

  • pyridine and pyrimidine compounds that are PDE 10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds.
  • Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDElO, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
  • cAMP and cGMP cyclic nucleotide monophosphates
  • PKA cAMP-dependent protein kinase
  • Downstream mediators of cGMP signaling also include kinases and ion channels. In addition to actions mediated by kinases, cAMP and cGMP bind directly to some cell proteins and directly regulate their activities.
  • Cyclic nucleotides are produced from the actions of adenylyl cyclase and guanylyl cyclase, which convert ATP to cAMP and GTP to cGMP. Extracellular signals, often through the actions of G protein-coupled receptors, regulate the activities of the cyclases. Alternatively, the amount of cAMP and cGMP may be altered by regulating the activities of the enzymes that degrade cyclic nucleotides. Cell homeostasis is maintained by the rapid degradation of cyclic nucleotides after stimulus-induced increases.
  • PDEs 3 ',5 '-cyclic nucleotide-specif ⁇ c phosphodiesterases
  • PDEs 3 ',5 '-cyclic nucleotide-specif ⁇ c phosphodiesterases
  • PDEl-PDEl 1 Eleven PDE gene families (PDEl-PDEl 1) have been identified based on their distinct amino acid sequences, catalytic and regulatory characteristics, and sensitivity to small molecule inhibitors. These families are coded for by 21 genes; and further multiple splice variants are transcribed from many of these genes. Expression patterns of each of the gene families are distinct. PDEs differ with respect to their affinity for cAMP and cGMP. Activities of different PDEs are regulated by different signals. For example, PDEl is stimulated by Ca 2+ /calmodulin.
  • PDE2 activity is stimulated by cGMP.
  • PDE3 is inhibited by cGMP.
  • PDE4 is cAMP specific and is specifically inhibited by rolipram.
  • PDE5 is cGMP-specific.
  • PDE6 is expressed in retina.
  • PDE 10 sequences were identified by using bioinformatics and sequence information from other PDE gene families (Fujishige et al., J. Biol. Chem. 274:18438-18445, 1999; Loughney et al., Gene 234:109-117, 1999; Soderling et al., Proc. Natl. Acad. Sci. USA 96:7071-7076, 1999).
  • the PDElO gene family is distinguished based on its amino acid sequence, functional properties and tissue distribution.
  • the human PDElO gene is large, over 200 kb, with up to 24 exons coding for each of the splice variants.
  • the amino acid sequence is characterized by two GAF domains (which bind cGMP), a catalytic region, and alternatively spliced N and C termini. Numerous splice variants are possible because at least three alternative exons encode N termini and two exons encode C-termini.
  • PDElOAl is a 779 amino acid protein that hydro lyzes both cAMP and cGMP. The K m values for cAMP and cGMP are 0.05 and 3.0 micromolar, respectively.
  • PDE 10 RNA transcripts were initially detected in human testis and brain.
  • the tissue distribution of PDE 10 indicates that PDE 10 inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDElO enzyme, for example, in neurons that comprise the basal ganglia and therefore would be useful in treating a variety of neuropsychiatric conditions involving the basal ganglia such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive compulsive disorder, and the like.
  • the present invention comprises a new class of compounds useful in the treatment of diseases, such as PDE 10 -mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of PDElO-mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention. [0010]
  • the compounds of the invention are represented by the following general
  • X 4 , X 6 , Y and Z are defined below.
  • Each of X 1 , X 2 , X 3 , X 4 , and X 5 is independently N or C; wherein no more than two of
  • X 1 , X 2 , X -3 3 and X 4 are N;
  • X 6 is N or C
  • Each of X 7 , X 9 , X 10 , and X 12 is independently N or C; each of X 8 and X 11 is C; wherein no more than three of X 7 , X 9 , X 10 , and X 12 are N;
  • Z is NH, NR 6 , S, SO, SO 2 , O, or C; wherein Z is only C when X 5 is N; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2;
  • R 1 is selected from the group consisting of
  • each Di and D 2 are independently N or C; and said partially unsaturated 5- membered monocyclic ring is not of formula:
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R 3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk, Ci_ 4 haloalk, or -NR a Ci_ 4 alk;
  • R 4 is independently in each instance, F, Cl, CH 3 , CN, CF 3 , CHF 2 , CH 2 F, 0R a , or NR a R a ;
  • R a is independently, at each instance, H or R b ;
  • R d is a nitrogen-linked saturated, partially-saturated, or unsaturated 5-, 6- or 7- membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_ 4 alk, Ci_ 3 haloalk, -OCi_ 4 alk, -NH 2 , -NHCi_ 4 alk, and [0016]
  • the group is a nitrogen-linked saturated, partially-saturated, or unsaturated 5-, 6- or 7- membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_ 4 alk, Ci_ 3 haloalk, -OCi_ 4 alk, -NH 2 , -
  • Another aspect of the current invention relates to compounds having the general structure of formula (Ie):
  • Another aspect of the current invention relates to compounds having the general structure of formula (If):
  • Y is NH
  • Y is -N-CH 2 -C 6 C 5 -F.
  • Y is -CH 2 -.
  • Y and R 3 form a 5- to 6- membered ring fused to the ring containing both said Y and R 3 ; wherein Y is NH, and R 3 is Ci_ 4 alk or -NR a Ci_ 4 alk.
  • X 1 is N or C, and each of X 2 , X 3 , X 4 , and X 5 is C.
  • X 5 is N.
  • X 5 is C .
  • m is 0 or 1.
  • n is 0 or 1.
  • p is 0 or 1.
  • p is 0.
  • R 1 is selected from the group consisting of H, F, Cl, Br,
  • R 1 is selected from the group consisting of H, F, Cl, Br,
  • R 1 is selected from the group consisting of a saturated
  • R 1 is selected from the group consisting of a saturated, partially-saturated or unsaturated 9- or 10-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3 or 4 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_ 6 alk, Ci_ 4 haloalk, -OR a , -OCi_ 4 haloalk, CN,
  • R 1 is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
  • R 1 is -L-R 7 wherein L is -CH 2 -.
  • R 1 is selected from the group consisting of: Cl, Br, I,
  • R 1 is selected from the group consisting of:
  • R 2 is, independently in each instance, F, Cl, Br, CN,
  • R is, independently in each instance, F, Cl, Br, CN,
  • R 4 is F or CN.
  • R 5 is methyl or -CH 2 -C 6 Hs-F.
  • R 6 is methyl, - CH 2 -CH 2 -F, or R c .
  • R 7 is a saturated 3-, A-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 O atom, which is substituted by 0, 1, 2 or 3 -OR a .
  • R 8 is Ci_ 6 alk substituted by 0 or 1 -OR a .
  • R a is H or Ci_ 6 alk substituted by 0 or 1 -OH, -OCi_ 4 alk,
  • R c is a Co_ 4 alk-linked saturated, partially-saturated or unsaturated 3-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0 or 1 groups selected from F, Ci_6alk,
  • Ci_ 4 haloalk, -OR a , R 7 , or R 8 are Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • R c is a Co_ 4 alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk,
  • Ci_ 4 haloalk, -OR a , R 7 , or R 8 are Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • the group of formula: is selected from the group consisting of
  • the group of formula: is selected from the group consisting of
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (I).
  • Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of psychoses,
  • Parkinson's disease dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder
  • ADHD Alzheimer's disease
  • Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
  • Another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically-acceptable diluent or carrier.
  • Z is NH, NR 6 , S, or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is O, 1, 2, 3 or 4;
  • X 1 is N or C
  • X 5 is N or C
  • X 6 is N or C
  • Ring A is a carbon-linked-saturated- or carbon-linked- partially-unsaturated- 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially- saturated, or nitrogen-linked-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R 4 is independently in each instance, F, Cl, CH 3 , CN, CF 3 , CHF 2 , CH 2 F, OR a , or NR a R a ;
  • R a is independently, at each instance, H or R b ;
  • Z is NH, N-C i_ 4 alk or S .
  • Z is NH .
  • Z is S .
  • X 6 is N.
  • X 6 is C .
  • Another aspect of the current invention relates to compounds having the general structure of formula (Ha): or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R 2 , R 3 , R 4 , and R 9 are as defined in compounds of formula (II), and any other embodiments below.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
  • Another aspect of the current invention relates to compounds having the general structure of formula (lie):
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is a carbon- linked-saturated or carbon- linked- partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a carbon-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a carbon-linked-partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a nitrogen-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a nitrogen-linked-partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a nitrogen-linked-unsaturated A-, 5-, 6-, 8-, 10- , or 12-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.
  • ring A is selected from the group consisting of azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, and tetrahydrothiopyranyl.
  • ring A is selected from the group consisting of oxaspiro[3.5]nonyl, azepanyl, oxepanyl, and quinolinyl.
  • ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
  • ring A is selected from the group consisting of:
  • m is 0 or 1.
  • n is 0 or 1.
  • p is 0 or 1.
  • y is 0, 1 , 2, or 3.
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk.
  • R is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk.
  • R 4 is F or CN.
  • R 6 is methyl, - CH 2 -CH 2 -F, or R c .
  • R 8 is Ci_ 6 alk substituted by 0 or 1 -OR a .
  • R c is a Co_ 4 alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • R c is a Co_ 4 alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by O, 1, or 2 groups selected from F, Ci_6alk,
  • Ci_ 4 haloalk, -OR a , R 7 , or R 8 are Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II).
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II); wherein said condition is selected from the group consisting of psychoses,
  • Parkinson's disease dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder
  • ADHD Alzheimer's disease
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II); wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
  • Another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (II) and a pharmaceutically-acceptable diluent or carrier.
  • Another aspect of the current invention relates to compounds having the general structure of formula (III):
  • Z is NH, NR 6 , S, or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is O, 1, 2, 3 or 4; X 1 is N or C;
  • X 5 is N or C
  • X 6 is N or C
  • Ring A is a carbon-linked-saturated or carbon-linked- partially-unsaturated A-, 5-, 6-, 7- , 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially-saturated, or nitrogen-linked-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R 3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, d_ 4 alk or Ci_ 4 haloalk;
  • R 4 is independently in each instance, F, Cl, CH 3 , CN, CF 3 , CHF 2 , CH 2 F, OR a , or NR a R a ;
  • R a is independently, at each instance, H or R b ;
  • Z is NH, N-C 1-4 alk or S .
  • Z is NH.
  • Z is S.
  • X is N.
  • X 6 is C.
  • Another aspect of the current invention relates to compounds having the general structure of formula (Ilia):
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
  • ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
  • ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
  • ring A is a carbon- linked-saturated or carbon- linked- partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered carbocycle ring containing 0,
  • ring A is a carbon-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a carbon-linked-partially-saturated A-, 5-, 6-,
  • ring A is a nitrogen-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
  • ring A is a nitrogen-linked-partially-saturated A-, 5-, 6-,
  • ring A is a nitrogen-linked-unsaturated A-, 5-, 6-, 8-, 10-
  • ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.
  • ring A is selected from the group consisting of azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, and tetrahydrothiopyranyl.
  • ring A is selected from the group consisting of oxaspiro[3.5]nonyl, azepanyl, oxepanyl, and quinolinyl.
  • ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
  • ring A is selected from the group consisting of:
  • m is 0 or 1.
  • n is 0 or 1.
  • p is 0 or 1.
  • y is 0, 1 , 2, or 3.
  • R 9 is selected from the group consisting of H, F, Cl, Br,
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk.
  • R 3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk.
  • R 4 is F or CN.
  • R 6 is methyl, - CH 2 -CH 2 -F, or R c .
  • R 8 is Ci_ 6 alk substituted by 0 or 1 -OR a .
  • R c is a Co- 4 alk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • R c is a Co- 4 alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_ 4 haloalk, -OR a , R 7 , or R 8 .
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III).
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III); wherein said condition is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
  • a compound of formula (III) wherein said condition is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III); wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
  • Another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (III) and a pharmaceutically-acceptable diluent or carrier.
  • Another aspect of the current invention relates to compounds having the general structure of formula (IV):
  • X 1 is N or C
  • X 2 is N or C
  • X 3 is N or C
  • X 4 is N or C; wherein no more than two of X 1 , X 2 , X 3 and X 4 are N;
  • X 6 is N or C
  • Z is NH, NR 6 , S or O; m is 0, 1, 2, 3 or 4; n is independently in each instance 0, 1 or 2;
  • R 2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R 3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_ 4 alk, Ci_ 4 alk or Ci_ 4 haloalk;
  • R 4 is independently in each instance, F, Me or CN;
  • R a is independently, at each instance, H or R b ;
  • R b is independently, at each instance, phenyl, benzyl or Ci_ 6 alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, Ci_3haloalk, -OCi_ 4 alk, -NH 2 , -NHCi_ 4 alk, and -N(Ci_ 4 alk)Ci_ 4 alk;
  • R d is a nitrogen- linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atoms, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_ 4 alk, d_ 3 haloalk, -OCi_ 4 alk, -NH 2 , -NHCi_ 4 alk, and
  • Z is NH
  • Z is NR 6 .
  • Z is S.
  • Z is O
  • Y is NH
  • Y is NR 5 .
  • Y is CH(OH).
  • Y is C(O).
  • X 1 is N.
  • X 2 is N.
  • X 3 is N.
  • X 4 is N.
  • X 1 , X 2 , X 3 and X 4 are all C.
  • X 6 is N.
  • X 6 is C.
  • R 1 is a saturated 5-, 6-, or 7-membered monocyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S.
  • R 1 is selected from
  • R 1 is selected from
  • n is O.
  • n is 1, and R 4 is F.
  • n is 2; and R 4 is F.
  • n is O.
  • Another aspect of the invention relates to a method of treating schizophrenia, bipolar disorder, or obsessive-compulsive disorder using an effective amount of a compound of formula (IV).
  • Another aspect of the invention relates to a method of treating a disorder treatable by inhibition of PDElO in a patient which method comprises administering to the patient a pharmaceutical composition comprising an effective amount of a compound of formula (IV).
  • Another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (IV) and a pharmaceutically-acceptable diluent or carrier.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of schizophrenia, bipolar disorder, or obsessive-compulsive disorder.
  • Another aspect of the invention relates to compounds selected from the group consisting of:
  • Another aspect of the invention relates to compounds selected from the group consisting of compounds of group (V) below:
  • Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of group (V).
  • Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
  • ADHD attention deficit/hyperactivity disorder
  • Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
  • Another aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of group (V) and a pharmaceutically-acceptable diluent or carrier.
  • the compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
  • the present invention includes all pharmaceutically acceptable isotopically- labelled compounds of the present invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C,
  • isotopically-labelled compounds of the present invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Substitution with positron emitting isotopes such as 11 C, 18 F, 15 O and 13 N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • compositions in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, de- acetone, de-DMSO.
  • Ci_ ⁇ alk means an alkyl group comprising a minimum of ⁇ and a maximum of ⁇ carbon atoms in a branched, cyclical or linear relationship or any combination of the three, wherein ⁇ and ⁇ represent integers.
  • the alkyl groups described in this section may also contain one or two double or triple bonds.
  • a designation of Coalk indicates a direct bond. Examples of Ci_ 6 alkyl include, but are not limited to the following:
  • Halo or "halogen” means a halogen atoms selected from F, Cl, Br and I.
  • Cv-whaloalk means an alk group, as described above, wherein any number—at least one— of the hydrogen atoms attached to the alk chain are replaced by F, Cl, Br or I.
  • the group N(R a )R a and the like include substituents where the two R a groups together form a ring, optionally including a N, O or S atom, and include groups such as:
  • N(C ⁇ - ⁇ alk)C ⁇ - ⁇ alk wherein ⁇ and ⁇ are as defined above, include substituents where the two C ⁇ - ⁇ alk groups together form a ring, optionally including a N, O or S atom, and include groups such as:
  • Carbocycle means a ring comprising by itself or in combination with other terms, represents, unless otherwise stated, cyclic version of "C ⁇ - ⁇ alk". Thus, the term “carbocycle” is meant to be included in the terms “C ⁇ - ⁇ alk”. Examples of carbocycle include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, cyclobutylene, cyclohexylene and the like.
  • Heterocycle means a ring comprising at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:
  • “Pharmaceutically-acceptable salt” means a salt prepared by conventional means, and are well known by those skilled in the art.
  • the “pharmacologically acceptable salts” include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like.
  • Suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like.
  • pharmaceutically acceptable salts see infra and Berge et al, J. Pharm. Sci. 66: 1 (1977).
  • saturated, partially-saturated or unsaturated includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens.
  • leaving group generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
  • Protecting group generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like.
  • Preferred protecting groups are indicated herein where appropriate.
  • amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like.
  • aralkyl examples include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts.
  • aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like.
  • cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like.
  • Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like.
  • a mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group.
  • Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, l,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings.
  • the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl.
  • Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • an addition salt such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups.
  • aralkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
  • Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1 ,2- bis(dimethylsilyl)benzene, 1 ,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-trisilyl derivative.
  • silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group.
  • Suitable silylating agents are, for example, trimethylsilyl chloride, tert- butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF.
  • Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art.
  • Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
  • Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogeno lysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.
  • Prodrugs of the compounds of this invention are also contemplated by this invention.
  • a prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient.
  • the suitability and techniques involved in making and using prodrugs are well known by those skilled in the art.
  • esters for example, methyl, ethyl
  • cycloalkyl for example, cyclohexyl
  • aralkyl for example, benzyl, p-methoxybenzyl
  • alkylcarbonyloxyalkyl for example, pivaloyloxymethyl
  • Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
  • EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
  • the methods in general, comprises the step of administering a therapeutically effective amount of a compound of Formula (I), or an individual stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof to treat the disorder or disease.
  • this invention provides a use of a compound as described herein in the manufacture of a medicament for treating a disorder or disease treatable by inhibition of PDE 10.
  • the compounds of the present invention inhibit PDE 10 enzyme activity, and hence raise the levels of cAMP or cGMP within cells that express PDElO. Accordingly, inhibition of PDElO enzyme activity would be useful in the treatment of diseases caused by deficient amounts of cAMP or cGMP in cells. PDElO inhibitors would also be of benefit in cases wherein raising the amount of cAMP or cGMP above normal levels results in a therapeutic effect. Inhibitors of PDElO may be used to treat disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, gastro-enterological diseases, endocrinological diseases and uro logical diseases.
  • Indications that may be treated with PDE 10 inhibitors, either alone or in combination with other drugs include, but are not limited to, those diseases thought to be mediated in part by the basal ganglia, prefrontal cortex, and hippocampus. These indications include psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
  • ADHD attention deficit/hyperactivity disorder
  • Psychoses are disorders that affect an individual ' s perception of reality. Psychoses are characterized by delusions and hallucinations. The compounds of the present invention are suitable for use in treating patients suffering from all forms of psychoses, including, but not limited to, schizophrenia, late-onset schizophrenia, schizoaffective disorders, prodromal schizophrenia, and bipolar disorders. Treatment can be for the positive symptoms of schizophrenia as well as for the cognitive deficits and negative symptoms.
  • Other indications for PDElO inhibitors include psychoses resulting from drug abuse (including amphetamines and PCP), encephalitis, alcoholism, epilepsy, Lupus, sarcoidosis, brain tumors, multiple sclerosis, dementia with Lewy bodies, or hypoglycemia.
  • Other psychiatric disorders like posttraumatic stress disorder (PTSD), and schizoid personality can also be treated with PDElO inhibitors.
  • Obsessive-compulsive disorder has been linked to deficits in the frontal- striatal neuronal pathways (Saxena et al., Br. J. Psychiatry Suppl, 35:26-37, 1998). Neurons in these pathways project to striatal neurons that express PDElO. PDElO inhibitors cause cAMP to be elevated in these neurons; elevations in cAMP result in an increase in CREB phosphorylation and thereby improve the functional state of these neurons.
  • the compounds of the present invention are therefore suitable for use in the indication of OCD.
  • OCD may result, in some cases, from streptococcal infections that cause autoimmune reactions in the basal ganglia (Giedd et al., Am J Psychiatry. 157:281-283, 2000). Because PDElO inhibitors may serve a neuroprotective role, administration of PDElO inhibitors may prevent the damage to the basal ganglia after repeated streptococcal infections and thereby prevent the development of OCD.
  • cAMP or cGMP In the brain, the level of cAMP or cGMP within neurons is believed to be related to the quality of memory, especially long term memory. Without wishing to be bound to any particular mechanism, it is proposed that, since PDElO degrades cAMP or cGMP, the level of this enzyme affects memory in animals, for example, in humans.
  • a compound that inhibits cAMP phosphodiesterase (PDE) can thereby increase intracellular levels of cAMP, which in turn activate a protein kinase that phosphorylates a transcription factor (cAMP response binding protein).
  • the phosphorylated transcription factor then binds to a DNA promoter sequence to activate genes that are important in long term memory. The more active such genes are, the better is long-term memory. Thus, by inhibiting a phosphodiesterase, long term memory can be enhanced.
  • Dementias are diseases that include memory loss and additional intellectual impairment separate from memory.
  • the compounds of the present invention are suitable for use in treating patients suffering from memory impairment in all forms of dementia.
  • Dementias are classified according to their cause and include: neurodegenerative dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular (e.g., infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld- Jacob Disease, multiple sclerosis, traumatic (e.g., subdural hematoma or traumatic brain injury), infectious (e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals, alcohol, some medications), metabolic (e.g., vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g., depression and schizophrenia), and hydrocephalus.
  • neurodegenerative dementias e.g.
  • the condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information.
  • the present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline.
  • MCI mild cognitive impairment
  • the present invention includes methods of treatment for memory impairment as a result of disease.
  • Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfe Id- Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline.
  • the compounds of the present invention are suitable for use in the treatment of memory impairment due to, for example, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, spinal cord injury, CNS hypoxia, cerebral senility, diabetes associated cognitive impairment, memory deficits from early exposure of anesthetic agents, multiinfarct dementia and other neurological conditions including acute neuronal diseases, as well as HIV and cardiovascular diseases.
  • Alzheimer's disease dementia
  • multiple sclerosis amylolaterosclerosis
  • MSA multiple systems atrophy
  • schizophrenia Parkinson's disease
  • Huntington's disease Huntington's disease
  • Pick's disease Creutzfeld-Jakob disease
  • depression head trauma
  • stroke spinal cord injury
  • CNS hypoxia CNS hypoxia
  • cerebral senility diabetes associated cognitive impairment
  • memory deficits from early exposure of anesthetic agents
  • the compounds of the present invention are also suitable for use in the treatment of a class of disorders known as polyglutamine-repeat diseases. These diseases share a common pathogenic mutation.
  • the expansion of a CAG repeat, which encodes the amino acid glutamine, within the genome leads to production of a mutant protein having an expanded polyglutamine region.
  • Huntington's disease has been linked to a mutation of the protein huntingtin. In individuals who do not have Huntington's disease, huntingtin has a polyglutamine region containing about 8 to 31 glutamine residues. For individuals who have Huntington's disease, huntingtin has a polyglutamine region with over 37 glutamine residues.
  • DRPLA dentatorubral-pallidoluysian atrophy
  • DRPLA dentatorubral-pallidoluysian atrophy
  • ataxin-1 spinocerebellar ataxia type-1
  • ataxin-2 spinocerebellar ataxia type-2
  • ataxin-3 also called Machado-Joseph disease or MJD
  • ataxin-3 spinocerebellar ataxia type-6 (alpha Ia- voltage dependent calcium channel); spinocerebellar ataxia type-7 (ataxin-7); and spinal and bulbar muscular atrophy (SBMA, also know as Kennedy disease).
  • SBMA spinal and bulbar muscular atrophy
  • the basal ganglia are important for regulating the function of motor neurons; disorders of the basal ganglia result in movement disorders. Most prominent among the movement disorders related to basal ganglia function is Parkinson's disease (Obeso et al, Neurology. 62(1 Suppl l):S17-30, 2004). Other movement disorders related to dysfunction of the basal ganglia include tardive dyskinesia, progressive supranuclear palsy and cerebral palsy, corticobasal degeneration, multiple system atrophy, Wilson disease, dystonia, tics, and chorea. The compounds of the invention are also suitable for use to treat movement disorders related to dysfunction of basal ganglia neurons.
  • PDElO inhibitors are useful in raising cAMP or cGMP levels and prevent neurons from undergoing apoptosis.
  • PDElO inhibitors may be anti-inflammatory by raising cAMP in glial cells.
  • any insult to the brain can potentially damage the basal ganglia including strokes, metabolic abnormalities, liver disease, multiple sclerosis, infections, tumors, drug overdoses or side effects, and head trauma.
  • the compounds of the invention can be used to stop disease progression or restore damaged circuits in the brain by a combination of effects including increased synaptic plasticity, neurogenesis, anti-inflammatory, nerve cell regeneration and decreased apoptosis.
  • cAMP and cGMP The growth of some cancer cells is inhibited by cAMP and cGMP.
  • cells may become cancerous by expressing PDElO and reducing the amount of cAMP or cGMP within cells.
  • inhibition of PDElO activity inhibits cell growth by raising cAMP.
  • PDElO may be expressed in the transformed, cancerous cell but not in the parent cell line.
  • PDElO is expressed and PDElO inhibitors reduce the growth rate of the cells in culture.
  • breast cancer cells are inhibited by administration of PDElO inhibitors.
  • Many other types of cancer cells may also be sensitive to growth arrest by inhibition of PDElO.
  • compounds disclosed in this invention can be used to stop the growth of cancer cells that express PDElO.
  • the compounds of the invention are also suitable for use in the treatment of diabetes and related disorders such as obesity, by focusing on regulation of the cAMP signaling system.
  • PDE-IO especially PDE-IOA
  • intracellular levels of cAMP are increased, thereby increasing the release of insulin-containing secretory granules and, therefore, increasing insulin secretion.
  • WO 2005/012485 which is hereby incorporated by reference in its entirety.
  • the compounds of the present invention can also be used to treat diseases disclosed in US Patent application publication No. 2006/019975, the disclosure of which is incorporated herein by reference in its entirety.
  • PDE 10 inhibitory activities of the compounds of the present invention can be tested, for example, using the in vitro and in vivo assays described in the Biological Examples below.
  • the compounds of this invention can be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
  • the actual amount of a compound of this invention, i.e., the active ingredient depends upon numerous factors, such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
  • Therapeutically effective amounts of compounds of the present invention may range from approximately 0.1-1000 mg per day; preferably 0.5 to 250 mg/day, more preferably 3.5 mg to 70 mg per day.
  • compounds of this invention can be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • routes e.g., oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration.
  • the preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction.
  • Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
  • formulations depend on various factors, such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance.
  • pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size.
  • U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules.
  • 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
  • compositions are comprised of, in general, a compound of formula (I) in combination with at least one pharmaceutically acceptable excipient.
  • Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of formula (I).
  • excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
  • Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
  • Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
  • Preferred liquid carriers, particularly for injectable solutions include water, saline, aqueous dextrose, and glycols.
  • Compressed gases may be used to disperse a compound of this invention in aerosol form.
  • Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
  • Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, Gennaro, A. R. (Mack Publishing Company, 18th ed., 1995).
  • the level of the compound in a formulation can vary within the full range employed by those skilled in the art.
  • the formulation contains, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
  • the compound is present at a level of about 1-80 wt %.
  • the compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of psychoses, especially schizophrenia and bipolar disorder, obsessive-compulsive disorder, Parkinson's disease, Alzheimer's disease, cognitive impairment and/or memory loss, e.g., nicotinic ⁇ -7 agonists, PDE4 inhibitors, other PDElO inhibitors, calcium channel blockers, muscarinic ml and m2 modulators, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, canabinoid modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and galanthanamine).
  • each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range, and can be administered either simultaneously or sequentially.
  • Drugs suitable in combination with the compounds of the present invention include, but are not limited to, other suitable schizophrenia drugs such as Clozaril, Zyprexa, Risperidone, and Seroquel; bipolar disorder drugs, including, but not limited to, Lithium, Zyprexa, and Depakote; Parkinson's disease drugs, including, but not limited to, Levodopa, Parlodel, Permax, Mirapex, Tasmar, Contan, Kemadin, Artane, and Cogentin; agents used in the treatment of Alzheimer's disease, including, but not limited to, Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen and Cliquinol; agents used in the treatment of dementia, including, but not limited to, Thioridazine, Haloperidol, Risperidone, Cognex, Aricept, and Exelon; agents used in the treatment of epilepsy, including, but not limited to, other suitable
  • agonists, antagonists such as Rosiglitazone, Troglitazone and Pioglitazone
  • insulin secretagogues e.g., sulfonylurea drugs, such as Glyburide, Glimepiride, Chlorpropamide, Tolbutamide, and Glipizide, and non-sulfonyl secretagogues
  • ⁇ -glucosidase inhibitors such as Acarbose, Miglitol, and Voglibose
  • insulin sensitizers such as the PPAR- ⁇ agonists, e.g., the glitazones; biguanides, PTP-IB inhibitors, DPP-IV inhibitors, and l lbeta- HSD inhibitors
  • hepatic glucose output lowering compounds such as glucagon antagonists and metaformin, e.g., Glucophage and Glucophage XR
  • insulin and insulin derivatives both long and short acting forms and formulations of insulin
  • X 12 ,Y and Z are as described above.
  • reaction mixture was diluted with DCM and then washed with water and brine.
  • organic layer was purified by silica gel chromatography (0-10% MeOH/DCM) to afford (1- methyl-lH-benzo[d]imidazol-2-yl)(4-(3-(2-(trimethylsilyl)ethynyl)pyridin-2-yloxy)phenyl)- methanone.
  • EXAMPLE 3 4-(2-(4-( IH-BENZO [D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)BENZONITRILE.
  • a glass microwave reaction vessel was charged with (lH-benzo[d]imidazol-2- yl)(4-(3-bromopyridin-2-yloxy)phenyl)methanone (0.1427 g, 0.36 mmol), A- cyanophenylboronic acid (0.0760 g, 0.43 mmol), trans-dichlorobis(triphenyl- phosphine)palladium(ii) (0.0314 g, 0.029 mmol), and sodium carbonate monohydrate (0.13 mL, 1.8 mmol) in 1 ,2-dimethoxymethane (3 mL) and water (1 mL).
  • EXAMPLE 4 (4-(3,3'-BIPYRIDIN-2-YLOXY)PHENYL)(lH-IMIDAZO[4,5-B]PYRIDIN-2- YL)METHANONE.
  • the vial was capped and heated in a Personal Chemistry SmithSynthesizer to 120 0 C for 12 minutes.
  • the reaction was diluted with EtOAc (10 ml) and water (10 ml).
  • the organic portion was collected and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine.
  • the organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes.
  • the product obtained form part 1 was taken up in DCM (5ml) and treated with TFA (2 ml) and a few drops of water. The mixture was allowed to stir O/N at RT. The volatiles were removed under vacuum.
  • reaction mixture was allowed to cool to room temperature and diluted with
  • the mixture was extracted (3x) with 10 ml of ethyl acetate.
  • the organic layers were combined and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine.
  • the organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes.
  • the pure fractions were combined and reduced under vacuum to give an oily residue.
  • the residue was dissolved in DCM (10 mL) and treated with ImL of TFA and a few drops of water. The mixture was allowed to stir at room temperature overnight. 10 ml of 2N ammonia in MeOH was added to the reation with was reduced in vacuo.
  • the vial was capped and heated to 80 0 C. After 12 hours, the reaction was partitioned with ethyl acetate and water. The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes to give a clear residue. The residue was dissolved in MeOH (10 mL) and treated with ImL of TFA. The mixture was allowed to stir at room temperature. 10 ml of 2N ammonia in MeOH was added to the reaction with was reduced in vacuo. Th residue was partitioned in water and EtOAc.
  • the crude product was chromatographed through a Redi-Sep ® pre-packed silica gel column (120 g), eluting with a gradient of 0% to 10% EtOAc in hexane, to provide 3-cyclopropyl-2-fluoropyridine as light- yellow oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Description

PYRIDINE AND P YRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10
INHIBITORS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U. S. Provisional Application No.
61/114,595, filed November 14, 2008, and U.S. Provisional Application No. 61/166,215, filed April 02, 2009, which is hereby incorporated by reference.
FIELD OF THE FNVENTION
[0002] Provided herein are certain pyridine and pyrimidine compounds that are PDE 10 inhibitors, pharmaceutical compositions containing such compounds, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDElO, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
BACKGROUND OF THE INVENTION
[0003] Neurotransmitters and hormones, as well as other types of extracellular signals such as light and odors, create intracellular signals by altering the amounts of cyclic nucleotide monophosphates (cAMP and cGMP) within cells. These intracellular messengers alter the functions of many intracellular proteins. Cyclic AMP regulates the activity of cAMP- dependent protein kinase (PKA). PKA phosphorylates and regulates the function of many types of proteins, including ion channels, enzymes, and transcription factors. Downstream mediators of cGMP signaling also include kinases and ion channels. In addition to actions mediated by kinases, cAMP and cGMP bind directly to some cell proteins and directly regulate their activities.
[0004] Cyclic nucleotides are produced from the actions of adenylyl cyclase and guanylyl cyclase, which convert ATP to cAMP and GTP to cGMP. Extracellular signals, often through the actions of G protein-coupled receptors, regulate the activities of the cyclases. Alternatively, the amount of cAMP and cGMP may be altered by regulating the activities of the enzymes that degrade cyclic nucleotides. Cell homeostasis is maintained by the rapid degradation of cyclic nucleotides after stimulus-induced increases. The enzymes that degrade cyclic nucleotides are called 3 ',5 '-cyclic nucleotide-specifϊc phosphodiesterases (PDEs). [0005] Eleven PDE gene families (PDEl-PDEl 1) have been identified based on their distinct amino acid sequences, catalytic and regulatory characteristics, and sensitivity to small molecule inhibitors. These families are coded for by 21 genes; and further multiple splice variants are transcribed from many of these genes. Expression patterns of each of the gene families are distinct. PDEs differ with respect to their affinity for cAMP and cGMP. Activities of different PDEs are regulated by different signals. For example, PDEl is stimulated by Ca2+/calmodulin. PDE2 activity is stimulated by cGMP. PDE3 is inhibited by cGMP. PDE4 is cAMP specific and is specifically inhibited by rolipram. PDE5 is cGMP-specific. PDE6 is expressed in retina.
[0006] PDE 10 sequences were identified by using bioinformatics and sequence information from other PDE gene families (Fujishige et al., J. Biol. Chem. 274:18438-18445, 1999; Loughney et al., Gene 234:109-117, 1999; Soderling et al., Proc. Natl. Acad. Sci. USA 96:7071-7076, 1999). The PDElO gene family is distinguished based on its amino acid sequence, functional properties and tissue distribution. The human PDElO gene is large, over 200 kb, with up to 24 exons coding for each of the splice variants. The amino acid sequence is characterized by two GAF domains (which bind cGMP), a catalytic region, and alternatively spliced N and C termini. Numerous splice variants are possible because at least three alternative exons encode N termini and two exons encode C-termini. PDElOAl is a 779 amino acid protein that hydro lyzes both cAMP and cGMP. The Km values for cAMP and cGMP are 0.05 and 3.0 micromolar, respectively. In addition to human variants, several variants with high homology have been isolated from both rat and mouse tissues and sequence banks. [0007] PDE 10 RNA transcripts were initially detected in human testis and brain.
Subsequent immunohistochemical analysis revealed that the highest levels of PDElO are expressed in the basal ganglia. Specifically, striatal neurons in the olfactory tubercle, caudate nucleus and nucleus accumbens are enriched in PDElO. Western blots did not reveal the expression of PDElO in other brain tissues, although immunoprecipitation of the PDElO complex was possible in hippocampal and cortical tissues. This suggests that the expression level of PDElO in these other tissues is 100-fold less than in striatal neurons. Expression in hippocampus is limited to the cell bodies, whereas PDElO is expressed in terminals, dendrites and axons of striatal neurons.
[0008] The tissue distribution of PDE 10 indicates that PDE 10 inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDElO enzyme, for example, in neurons that comprise the basal ganglia and therefore would be useful in treating a variety of neuropsychiatric conditions involving the basal ganglia such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive compulsive disorder, and the like. SUMMARY OF THE INVENTION
[0009] The present invention comprises a new class of compounds useful in the treatment of diseases, such as PDE 10 -mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of PDElO-mediated diseases and other maladies, such as schizophrenia, bipolar disorder, or obsessive-compulsive disorder, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention. [0010] The compounds of the invention are represented by the following general
structure:
Figure imgf000004_0001
(I); or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12,Y and Z are defined below. [0011] Other compounds of the invention are represented by the following general
structure:
Figure imgf000004_0002
(H); or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, R9, X1, X5
X Λ6 , and Z are defined below. [0012] Other compounds of the invention are represented by the following general
structure:
Figure imgf000005_0001
(in); or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R 2 , r R> 3 , r R> 4 , n R9 , X vl , X V5 X6, and Z are defined below.
[0013] Other compounds of the invention are represented by the following general structure:
Figure imgf000005_0002
or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, X1, X2, X3
X4, X6, Y and Z are defined below.
[0014] The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way. All patents, patent applications and other publications recited herein are hereby incorporated by reference in their entirety.
DETAILED DESCRIPTION OF THE INVENTION
[0015] One aspect of the current invention relates to compounds having the general structure of formula (I):
Figure imgf000005_0003
or any pharmaceutically-acceptable salt thereof, wherein: Each of X1, X2, X3, X4, and X5 is independently N or C; wherein no more than two of
X1, X2, X -33 and X4 are N;
X6 is N or C;
Each of X7, X9, X10, and X12 is independently N or C; each of X8 and X11 is C; wherein no more than three of X7, X9, X10, and X12 are N;
Y is NH, NR5, CH(OH), C(=O), -CRaRb, or CF2; or alternatively Y and R3 form a 5- to 6- membered ring fused to the ring containing both said Y and R ;
Z is NH, NR6, S, SO, SO2, O, or C; wherein Z is only C when X5 is N; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2;
R1 is selected from the group consisting of
(a) H, F, Cl, Br, I, Ci_8alk, Ci_4haloalk, -ORa, -NRaRa, -N(Ra)C(=0)Rb, -C(=0)NRaRa, -C(=O)Rd, -C(=O)-O-Ra, -ORC, -NRaRc, -N(Rc)C(=0)Rb, -N(Ra)C(=0)Rc, -C(=0)NRaRb, or -C(=0)NRaRc;
(b) a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12- membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O and S, and wherein each said ring is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo; with a proviso that said unsaturated 6-membered monocyclic ring is not of formula:
Figure imgf000006_0001
; wherein each Di and D2 are independently N or C; and said partially unsaturated 5- membered monocyclic ring is not of formula:
Figure imgf000007_0001
(c) group -L-R7, wherein L is CH2, NH, N(C1-4alk), -C(=O)NRaRa(Ci_4alk), 0, S, S=O, or S(=0)2; or
(d) Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=0)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -0C(=0)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=0)Rb, -N(Ra)C(=0)0Rb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk, Ci_4haloalk, or -NRaCi_4alk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, 0Ra, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, Ci_4haloalk, or -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2_6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, Ci_3haloalk, -OH, -OCi_4alk, -NH2, -NHC1-4alk, -OC(=O)C1-4alk, or -N(Ci.4alk)Ci.4alk;
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co-4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo; and
Rd is a nitrogen-linked saturated, partially-saturated, or unsaturated 5-, 6- or 7- membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_4alk, Ci_3haloalk, -OCi_4alk, -NH2, -NHCi_4alk, and
Figure imgf000008_0001
[0016] In another embodiment, the group :
Figure imgf000008_0002
is selected from the group consisting of ;
Figure imgf000008_0003
Figure imgf000009_0001
[0017] In another embodiment, the group
Figure imgf000009_0002
[0018] In another embodiment, the group
Figure imgf000009_0003
[0019] In another embodiment, the group
Figure imgf000009_0004
[0020] In another embodiment, the group
Figure imgf000009_0005
[0021] In another embodiment, the group
Figure imgf000009_0006
[0022] In another embodiment, the group
Figure imgf000010_0001
[0023] In another embodiment, the group
Figure imgf000010_0002
[0024] In another embodiment, the group
Figure imgf000010_0003
[0025] In another embodiment, the group
Figure imgf000010_0004
[0026] In another embodiment, the group
Figure imgf000010_0005
[0027] In another embodiment, the group
Figure imgf000010_0006
[0028] In another embodiment, the group
Figure imgf000011_0001
[0029] Another aspect of the current invention relates to compounds having the general structure of formula (Ia):
Figure imgf000011_0002
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X7, X8, X9, X10, X11, X12,Y and Z are as defined in compounds of formula (I), and any other embodiments below.
[0030] Another aspect of the current invention relates to compounds having the general structure of formula (Ib):
Figure imgf000011_0003
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, X7, X8, X9, X10, X11, X12,Y and Z are as defined in compounds of formula (I), and any other embodiments below.
[0031] Another aspect of the current invention relates to compounds having the general structure of formula (Ic):
Figure imgf000011_0004
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R , R , R , R , X , X X3, X4, X5, and Z are as defined in compounds of formula (I), and any other embodiments below. [0032] Another aspect of the current invention relates to compounds having the general structure of formula (Id):
Figure imgf000012_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, and Z are as defined in compounds of formula (I), and any other embodiments below.
[0033] Another aspect of the current invention relates to compounds having the general structure of formula (Ie):
Figure imgf000012_0002
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, and Z are as defined in compounds of formula (I), and any other embodiments below.
[0034] Another aspect of the current invention relates to compounds having the general structure of formula (If):
Figure imgf000012_0003
or a pharmaceutically acceptable salt thereof, wherein m, n, p, R1, R2, R3, R4, X1, X2, X3, X4, X5, and Z are as defined in compounds of formula (I), and any other embodiments below.
[0035] In another embodiment, Y is NH, N-CH3, CF2, or -C(=O).
[0036] In another embodiment, Y is NH.
[0037] In another embodiment, Y is -C(=O) . [0038] In another embodiment, Y is -N-CH2-C6C5-F.
[0039] In another embodiment, Y is -CH2-.
[0040] In another embodiment, Y and R3 form a 5- to 6- membered ring fused to the ring containing both said Y and R3; wherein Y is NH, and R3 is Ci_4alk or -NRaCi_4alk. [0041] In another embodiment, X1 is N or C, and each of X2, X3, X4, and X5 is C.
[0042] In another embodiment, X5 is N.
[0043] In another embodiment, X5 is C .
[0044] In another embodiment, Z is NH, N-C1-4alk N-haloC1-4alk S, or -C=.
[0045] In another embodiment, Z is N or -C=.
[0046] In another embodiment, m is 0 or 1.
[0047] In another embodiment, n is 0 or 1.
[0048] In another embodiment, p is 0 or 1.
[0049] In another embodiment, p is 0.
[0050] In another embodiment, R1 is selected from the group consisting of H, F, Cl, Br,
I, -ORa, Ci_8alk, Ci_4haloalk, -C(=O)-O-Ra, -C(=O)NRaRa, -ORC, and -C(=O)NRaRc. [0051] In another embodiment, R1 is selected from the group consisting of H, F, Cl, Br,
-ORa, -C(=O)NRaRa, -ORC, and -C(=O)NRaRc.
[0052] In another embodiment, R1 is selected from the group consisting of a saturated
A-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1 or 2 groups selected from F, Cl, Br, d_6alk, d_4haloalk, -ORa, -CN, -C(=O)Rb, -C(=O)ORa, and oxo. [0053] In another embodiment, R1 is selected from the group consisting of a partially- saturated or unsaturated 4-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1 or 2 groups selected from F, Cl, Br, d_6alk, d_4haloalk, -ORa, -CN, -C(=O)Rb, -C(=O)ORa, and oxo; with a proviso that said unsaturated 6-membered monocyclic ring and said unsaturated 5-membered monocyclic ring is not of formula:
Figure imgf000013_0001
• wherein each Di and D2 are independently N or C. [0054] In another embodiment, R1 is selected from the group consisting of a saturated, partially-saturated or unsaturated 9- or 10-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3 or 4 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN,
-C(=O)Rb, -C(=O)ORa, -NRaRa, -NRaRc, R7, R8 and oxo.
[0055] In another embodiment, R1 is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
0, 1 or 2 groups selected from F, Cl, Br, d_6alk, d_4haloalk, -ORa, CN, -C(=O)Rb, -C(=O)ORa,
-SRa, R7, and oxo.
[0056] In another embodiment, R1 is -L-R7 wherein L is -CH2-.
[0057] In another embodiment, R1 is Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2_6alkNRaRa, -OC2.6alkORa,
-SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb,
-N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa,
-NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[0058] In another embodiment, R1 is selected from the group consisting of: Cl, Br, I,
Figure imgf000014_0001
Figure imgf000015_0001
[0059] In another embodiment, R1 is selected from the group consisting of:
Figure imgf000015_0002
Figure imgf000016_0001
[0060] In another embodiment, R2 is, independently in each instance, F, Cl, Br, CN,
OH, OCi_4alk, Ci_4alk or Ci_4haloalk.
[0061] In another embodiment, R is, independently in each instance, F, Cl, Br, CN,
OH, OCi_4alk, Ci_4alk or Ci_4haloalk.
[0062] In another embodiment, R4 is F or CN.
[0063] In another embodiment, R5 is methyl or -CH2-C6Hs-F.
[0064] In another embodiment, R6 is methyl, - CH2-CH2-F, or Rc.
[0065] In another embodiment, R7 is a saturated 3-, A-, 5- or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 O atom, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa,
-SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb,
-N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa,
-NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb,
-Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo.
[0066] In another embodiment, R7 is a saturated 3-, A-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 O atom, which is substituted by 0, 1, 2 or 3 -ORa.
[0067] In another embodiment, R8 is Ci_6alk substituted by 0 or 1 -ORa.
[0068] In another embodiment, Ra is H or Ci_6alk substituted by 0 or 1 -OH, -OCi_4alk,
-OC(=O)Ci_4alk, or -N(Ci_4alk)Ci_4alk.
[0069] In another embodiment, Rc is a Co_4alk-linked saturated, partially-saturated or unsaturated 3-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0 or 1 groups selected from F, Ci_6alk,
Ci_4haloalk, -ORa, R7, or R8.
[0070] In another embodiment, Rc is a Co_4alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk,
Ci_4haloalk, -ORa, R7, or R8.
[0071] In another embodiment, the group of formula:
Figure imgf000017_0001
selected from the group consisting of
Figure imgf000017_0002
In another embodiment, the group of formula:
Figure imgf000017_0003
is selected from the group consisting of
Figure imgf000017_0004
In another embodiment, the group of formula:
Figure imgf000017_0005
is selected from the group consisting of
Figure imgf000018_0001
[0072] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (I).
[0073] Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of psychoses,
Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder
(ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
[0074] Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
[0075] Another aspect of the invention relates to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically-acceptable diluent or carrier.
[0076] Another aspect of the current invention relates to compounds having the general structure of formula (II):
Figure imgf000018_0002
or any pharmaceutically-acceptable salt thereof, wherein: Z is NH, NR6, S, or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is O, 1, 2, 3 or 4;
X1 is N or C;
X5 is N or C;
X6 is N or C;
Ring A is a carbon-linked-saturated- or carbon-linked- partially-unsaturated- 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially- saturated, or nitrogen-linked-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, ORa, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2, 3, or 4 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2_6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
R9 is independently selected from the group consisting of H, F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, d_3haloalk, -OH, -OCi_4alk, -NH2, -NHCi_4alk, -OC(=O)Ci_4alk, or -N(Ci_4alk)Ci_4alk; and
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co_4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo.
[0077] In another embodiment, Z is NH, N-C i_4alk or S .
[0078] In another embodiment, Z is NH .
[0079] In another embodiment, Z is S .
[0080] In another embodiment, X6 is N.
[0081] In another embodiment, X6 is C .
[0082] Another aspect of the current invention relates to compounds having the general structure of formula (Ha):
Figure imgf000021_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (II), and any other embodiments below. [0083] In one embodiment of compounds of formula (Ha), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
[0084] In one embodiment of compounds of formula (Ha), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
[0085] In one embodiment of compounds of formula (Ha), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
[0086] In one embodiment of compounds of formula (Ha), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
[0087] In one embodiment of compounds of formula (Ha), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp2 hybridization.
[0088] In another embodiment of compounds of formula (Ha), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0089] In another embodiment of compounds of formula (Ha), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0090] In another embodiment of compounds of formula (Ha), ring A is a 4-membered ring unsaturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0091] In another embodiment of compounds of formula (Ha), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0092] In another embodiment of compounds of formula (Ha), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0093] In another embodiment of compounds of formula (Ha), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[0094] Another aspect of the current invention relates to compounds having the general structure of formula (lib):
Figure imgf000022_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (II), and any other embodiments below. [0095] In one embodiment of compounds of formula (lib), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
[0096] In one embodiment of compounds of formula (lib), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization. [0097] In one embodiment of compounds of formula (lib), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
[0098] In one embodiment of compounds of formula (lib), ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
[0099] In another embodiment of compounds of formula (lib), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00100] In another embodiment of compounds of formula (lib), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00101] In another embodiment of compounds of formula (lib), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00102] In another embodiment of compounds of formula (lib), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00103] In another embodiment of compounds of formula (lib), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00104] In another embodiment of compounds of formula (lib), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo. [00105] Another aspect of the current invention relates to compounds having the general structure of formula (lie):
Figure imgf000024_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (II), and any other embodiments below. [00106] In one embodiment of compounds of formula (lie), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
[00107] In one embodiment of compounds of formula (lie), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
[00108] In one embodiment of compounds of formula (lie), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
[00109] In one embodiment of compounds of formula (lie), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
[00110] In another embodiment of compounds of formula (lie), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00111] In another embodiment of compounds of formula (lie), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00112] In another embodiment of compounds of formula (lie), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00113] In another embodiment of compounds of formula (lie), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00114] In another embodiment of compounds of formula (lie), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00115] In another embodiment of compounds of formula (lie), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00116] Another aspect of the current invention relates to compounds having the general structure of formula (Hd):
Figure imgf000025_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (II), and any other embodiments below. [00117] In one embodiment of compounds of formula (Hd), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
[00118] In one embodiment of compounds of formula (Hd), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization. [00119] In one embodiment of compounds of formula (Hd), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
[00120] In one embodiment of compounds of formula (Hd), ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
[00121] In another embodiment of compounds of formula (Hd), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00122] In another embodiment of compounds of formula (Hd), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00123] In another embodiment of compounds of formula (Hd), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00124] In another embodiment of compounds of formula (Hd), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00125] In another embodiment of compounds of formula (Hd), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00126] In another embodiment of compounds of formula (Hd), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo. [00127] In another embodiment, the group of formula:
Figure imgf000027_0001
is selected from the group consisting of
Figure imgf000027_0002
[00128] In another embodiment, ring A is a carbon- linked-saturated or carbon- linked- partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00129] In another embodiment, ring A is a carbon-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom. [00130] In another embodiment, ring A is a carbon-linked-partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00131] In another embodiment, ring A is a nitrogen-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom. [00132] In another embodiment, ring A is a nitrogen-linked-partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00133] In another embodiment, ring A is a nitrogen-linked-unsaturated A-, 5-, 6-, 8-, 10- , or 12-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00134] In another embodiment, ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, and cycloheptyl. [00135] In another embodiment, ring A is selected from the group consisting of azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, and tetrahydrothiopyranyl.
[00136] In another embodiment, ring A is selected from the group consisting of oxaspiro[3.5]nonyl, azepanyl, oxepanyl, and quinolinyl.
[00137] In another embodiment, ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
0, 1 or 2 groups selected from F, Cl, Br, d_6alk, Ci_4haloalk, -ORa, CN, -C(=O)Rb, -C(=O)ORa,
-SRa, R7, and oxo.
[00138] In another embodiment, ring A is selected from the group consisting of:
Figure imgf000028_0001
Figure imgf000029_0001
[00139] In another embodiment, m is 0 or 1. [00140] In another embodiment, n is 0 or 1. [00141] In another embodiment, p is 0 or 1. [00142] In another embodiment, y is 0, 1 , 2, or 3.
[00143] In another embodiment, R9 is selected from the group consisting of H, F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -NRaRa, -NRaRc, R7, R8 and oxo.
[00144] In another embodiment, R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk.
[00145] In another embodiment, R is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk. [00146] In another embodiment, R4 is F or CN. [00147] In another embodiment, R6 is methyl, - CH2-CH2-F, or Rc. [00148] In another embodiment, R7 is a saturated 3-, A-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 O atom, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo. [00149] In another embodiment, R8 is Ci_6alk substituted by 0 or 1 -ORa. [00150] In another embodiment, Ra is H or Ci_6alk substituted by 0 or 1 -OH, -OCi_4alk, - OC(=O)Ci_4alk, or -N(Ci.4alk)Ci.4alk.
[00151] In another embodiment, Rc is a Co_4alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_4haloalk, -ORa, R7, or R8.
[00152] In another embodiment, Rc is a Co_4alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by O, 1, or 2 groups selected from F, Ci_6alk,
Ci_4haloalk, -ORa, R7, or R8.
[00153] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II).
[00154] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II); wherein said condition is selected from the group consisting of psychoses,
Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder
(ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
[00155] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (II); wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
[00156] Another aspect of the invention relates to a pharmaceutical composition comprising a compound of formula (II) and a pharmaceutically-acceptable diluent or carrier.
[00157] Another aspect of the current invention relates to compounds having the general structure of formula (III):
Figure imgf000030_0001
or any pharmaceutically-acceptable salt thereof, wherein:
Z is NH, NR6, S, or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is O, 1, 2, 3 or 4; X1 is N or C;
X5 is N or C;
X6 is N or C;
Ring A is a carbon-linked-saturated or carbon-linked- partially-unsaturated A-, 5-, 6-, 7- , 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially-saturated, or nitrogen-linked-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, d_4alk or Ci_4haloalk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, ORa, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, d_4haloalk, -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2, 3, or 4 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
R9 is independently selected from the group consisting of H, F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, C^haloalk, a -OH, -OCi_4alk, -NH2, -NHC1-4alk, -OC(=O)CMalk, or -N(Ci.4alk)Ci.4alk; and
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co_4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo.
[00158] In another embodiment, Z is NH, N-C 1-4alk or S .
[00159] In another embodiment, Z is NH. [00160] In another embodiment, Z is S. [00161] In another embodiment, X is N. [00162] In another embodiment, X6 is C. [00163] Another aspect of the current invention relates to compounds having the general structure of formula (Ilia):
Figure imgf000032_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (III), and any other embodiments below. [00164] In one embodiment of compounds of formula (Ilia), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
[00165] In one embodiment of compounds of formula (Ilia), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
[00166] In one embodiment of compounds of formula (Ilia), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
[00167] In one embodiment of compounds of formula (Ilia), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
[00168] In one embodiment of compounds of formula (Ilia), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp2 hybridization.
[00169] In another embodiment of compounds of formula (Ilia), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00170] In another embodiment of compounds of formula (Ilia), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00171] In another embodiment of compounds of formula (Ilia), ring A is a 4-membered ring unsaturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00172] In another embodiment of compounds of formula (Ilia), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00173] In another embodiment of compounds of formula (Ilia), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00174] In another embodiment of compounds of formula (Ilia), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00175] Another aspect of the current invention relates to compounds having the general structure of formula (HIb):
Figure imgf000034_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (III), and any other embodiments below. [00176] In one embodiment of compounds of formula (HIb), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
[00177] In one embodiment of compounds of formula (HIb), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
[00178] In one embodiment of compounds of formula (HIb), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
[00179] In one embodiment of compounds of formula (HIb), ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
[00180] In another embodiment of compounds of formula (HIb), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00181] In another embodiment of compounds of formula (HIb), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00182] In another embodiment of compounds of formula (HIb), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00183] In another embodiment of compounds of formula (HIb), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00184] In another embodiment of compounds of formula (HIb), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00185] In another embodiment of compounds of formula (HIb), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00186] Another aspect of the current invention relates to compounds having the general structure of formula (IIIc):
Figure imgf000035_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (III), and any other embodiments below. [00187] In one embodiment of compounds of formula (IIIc), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp3 hybridization.
[00188] In one embodiment of compounds of formula (IIIc), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp2 hybridization.
[00189] In one embodiment of compounds of formula (IIIc), ring A is bonded to the 3- pyridinyl ring via a carbon atom having an sp hybridization.
[00190] In one embodiment of compounds of formula (IIIc), ring A is bonded to the 3- pyridinyl ring via a nitrogen atom having an sp3 hybridization.
[00191] In another embodiment of compounds of formula (IIIc), ring A is a 5-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00192] In another embodiment of compounds of formula (IIIc), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00193] In another embodiment of compounds of formula (IIIc), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00194] In another embodiment of compounds of formula (IIIc), ring A is a 5-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00195] In another embodiment of compounds of formula (IIIc), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa,
-C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb,
-N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb,
-Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo. [00196] In another embodiment of compounds of formula (IIIc), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00197] Another aspect of the current invention relates to compounds having the general structure of formula (HId):
Figure imgf000037_0001
or a pharmaceutically acceptable salt thereof, wherein m, n, p, y, R2, R3, R4, and R9 are as defined in compounds of formula (III), and any other embodiments below. [00198] In one embodiment of compounds of formula (HId), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp3 hybridization.
[00199] In one embodiment of compounds of formula (HId), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp2 hybridization.
[00200] In one embodiment of compounds of formula (HId), ring A is bonded to the pyrimidinyl ring via a carbon atom having an sp hybridization.
[00201] In one embodiment of compounds of formula (HId), ring A is bonded to the pyrimidinyl ring via a nitrogen atom having an sp3 hybridization.
[00202] In another embodiment of compounds of formula (HId), ring A is a 5 -membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00203] In another embodiment of compounds of formula (HId), ring A is a 6-membered ring saturated heterocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo. [00204] In another embodiment of compounds of formula (HId), ring A is a 4-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00205] In another embodiment of compounds of formula (HId), ring A is a 5 -membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00206] In another embodiment of compounds of formula (HId), ring A is a 6-embered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo.
[00207] In another embodiment of compounds of formula (HId), ring A is a 7-membered ring saturated carbocycle, which is optionally substituted with -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, or oxo. [00208] In another embodiment, the group of formula:
Figure imgf000038_0001
is selected from the group consisting of
Figure imgf000038_0002
[00209] In another embodiment, ring A is a carbon- linked-saturated or carbon- linked- partially-saturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered carbocycle ring containing 0,
1 or 2 N atoms and containing 0 or 1 S or O atom.
[00210] In another embodiment, ring A is a carbon-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00211] In another embodiment, ring A is a carbon-linked-partially-saturated A-, 5-, 6-,
7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or
O atom.
[00212] In another embodiment, ring A is a nitrogen-linked-saturated A-, 5-, 6-, 7- membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00213] In another embodiment, ring A is a nitrogen-linked-partially-saturated A-, 5-, 6-,
7-, 8-, 9-, 10-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or
O atom.
[00214] In another embodiment, ring A is a nitrogen-linked-unsaturated A-, 5-, 6-, 8-, 10-
, or 12-membered carbocycle ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom.
[00215] In another embodiment, ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.
[00216] In another embodiment, ring A is selected from the group consisting of azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, and tetrahydrothiopyranyl.
[00217] In another embodiment, ring A is selected from the group consisting of oxaspiro[3.5]nonyl, azepanyl, oxepanyl, and quinolinyl.
[00218] In another embodiment, ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by
0, 1 or 2 groups selected from F, Cl, Br, C1-6alk, d_4haloalk, -ORa, CN, -C(=O)Rb, -C(=O)ORa,
-SRa, R7, and oxo.
[00219] In another embodiment, ring A is selected from the group consisting of:
Figure imgf000040_0001
[00220] In another embodiment, m is 0 or 1.
[00221] In another embodiment, n is 0 or 1.
[00222] In another embodiment, p is 0 or 1.
[00223] In another embodiment, y is 0, 1 , 2, or 3.
[00224] In another embodiment, R9 is selected from the group consisting of H, F, Cl, Br,
Ci_6alk, Ci_4haloalk, -ORa, -OC1-4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -NRaRa, -NRaRc, R7, R8 and oxo. [00225] In another embodiment, R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk.
[00226] In another embodiment, R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk. [00227] In another embodiment, R4 is F or CN. [00228] In another embodiment, R6 is methyl, - CH2-CH2-F, or Rc. [00229] In another embodiment, R7 is a saturated 3-, 4-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 O atom, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, d_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo. [00230] In another embodiment, R8 is Ci_6alk substituted by 0 or 1 -ORa. [00231 ] In another embodiment, Ra is H or d_6alk substituted by 0 or 1 -OH, -OCi_4alk, - OC(=O)Ci_4alk, or -N(Ci_4alk)Ci_4alk.
[00232] In another embodiment, Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, or 6-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_4haloalk, -ORa, R7, or R8.
[00233] In another embodiment, Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 9- or 10-membered monocyclic ring containing 0 or 1 N atom and 0 or 1 atom selected from O and S, which is substituted by 0, 1, or 2 groups selected from F, Ci_6alk, Ci_4haloalk, -ORa, R7, or R8.
[00234] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III).
[00235] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III); wherein said condition is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
[00236] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of formula (III); wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
[00237] Another aspect of the invention relates to a pharmaceutical composition comprising a compound of formula (III) and a pharmaceutically-acceptable diluent or carrier.
[00238] Another aspect of the current invention relates to compounds having the general structure of formula (IV):
Figure imgf000042_0001
or any pharmaceutically-acceptable salt thereof, wherein:
X1 is N or C;
X2 is N or C;
X3 is N or C;
X4 is N or C; wherein no more than two of X1, X2, X3 and X4 are N;
X6 is N or C;
Y is NH, NR5, CH(OH) or C(=O);
Z is NH, NR6, S or O; m is 0, 1, 2, 3 or 4; n is independently in each instance 0, 1 or 2;
R1 is selected from H, F, Cl, Br, Ci_8alk, Ci_4haloalk, -ORa, -NRaRa, -N(Ra)C(=O)Rb and -C(=O)NRaRa, -C(=O)Rd, -ORC, -NRaRc, -N(Rc)C(=O)Rb, -N(Ra)C(=O)Rc, -C(=O)NRaRc and a saturated or partially saturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring all of which contain 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, d_6alk, d_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2-6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(C1-4alk), O, S, S=O or S(=O)2; or R1 is C3_4alk substituted by O, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo; or R1 is phenyl, 3-pyridyl or 4- pyridyl, all of which are substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R4 is independently in each instance, F, Me or CN;
R5 is Ci_8alk, Ci_4haloalk, or -C(=O)Rb;
R6 is Ci_8alk, Ci_4haloalk, or -C(=O)Rb;
R7 is a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, Ci_3haloalk, -OCi_4alk, -NH2, -NHCi_4alk, and -N(Ci_4alk)Ci_4alk;
Rc is a Co-ialk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, C1-6alk, CMhaloalk, -ORa, -OC1-4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2_6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo; and
Rd is a nitrogen- linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atoms, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_4alk, d_3haloalk, -OCi_4alk, -NH2, -NHCi_4alk, and
Figure imgf000044_0001
[00239] In another embodiment, in conjunction with any above or below embodiment, Z is NH.
[00240] In another embodiment, in conjunction with any above or below embodiment, Z is NR6.
[00241] In another embodiment, in conjunction with any above or below embodiment, Z is S.
[00242] In another embodiment, in conjunction with any above or below embodiment, Z is O.
[00243] In another embodiment, in conjunction with any above or below embodiment, Y is NH.
[00244] In another embodiment, in conjunction with any above or below embodiment, Y is NR5. [00245] In another embodiment, in conjunction with any above or below embodiment, Y is CH(OH).
[00246] In another embodiment, in conjunction with any above or below embodiment, Y is C(O).
[00247] In another embodiment, in conjunction with any above or below embodiment, X1 is N.
[00248] In another embodiment, in conjunction with any above or below embodiment, X2 is N.
[00249] In another embodiment, in conjunction with any above or below embodiment, X3 is N.
[00250] In another embodiment, in conjunction with any above or below embodiment, X4 is N.
[00251] In another embodiment, in conjunction with any above or below embodiment, X1, X2, X3 and X4 are all C.
[00252] In another embodiment, in conjunction with any above or below embodiment, X6 is N.
[00253] In another embodiment, in conjunction with any above or below embodiment, X6 is C.
[00254] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated or partially saturated 3-, A-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring all of which contain 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(d_4alk), O, S, S=O or S(=O)2.
[00255] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated or partially saturated 3-, 4-, 5-, 6-, or 7-membered monocyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2_6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(C1-4alk), O, S, S=O or
SC=O)2.
[00256] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated 3-, A-, 5-, 6-, or 7-membered monocyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, C1-6alk, d_4haloalk, -ORa, -OC1-4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(d_4alk), O, S, S=O or S(=O)2.
[00257] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated 5-, 6-, or 7-membered monocyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, CMhaloalk, -ORa, -OC1-4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(d_4alk), O, S, S=O or S(=O)2.
[00258] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated 5-, 6-, or 7-membered monocyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S.
[00259] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring which contains 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, CMhaloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo; or R1 is -L-R7, wherein L is CH2, NH, N(C1-4alk), O, S, S=O or
SC=O)2.
[00260] In another embodiment, in conjunction with any above or below embodiment, R1 is C3-4alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[00261] In another embodiment, in conjunction with any above or below embodiment, R1 is selected from piperidine, piperazine, pyrrolidine and morpholine, all of which are substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[00262] In another embodiment, in conjunction with any above or below embodiment, R1 is selected from cyclohexyl, cyclopentyl, tetrahydrofuran and tetrahydropyran, all of which are substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[00263] In another embodiment, in conjunction with any above or below embodiment, R1 is phenyl substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2-6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[00264] In another embodiment, in conjunction with any above or below embodiment, R1 is 3-pyridyl or 4-pyridyl, both of which are substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo. [00265] In another embodiment, in conjunction with any above or below embodiment, R1 is selected from tetrahydropyran, tetrahydrofuran, piperidine, piperazine, pyrrolidine and morpholine, all of which are substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2_6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
[00266] In another embodiment, in conjunction with any above or below embodiment, R1 is a saturated 5- or 6-membered carbocyclic ring substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2_6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo. [00267] In another embodiment, in conjunction with any above or below embodiment, R1 is selected from
Figure imgf000049_0001
Figure imgf000049_0002
[00268] In another embodiment, in conjunction with any above or below embodiment, R1 is selected from
Figure imgf000049_0003
[00269] In another embodiment, in conjunction with any above or below embodiment, m is O.
[00270] In another embodiment, in conjunction with any above or below embodiment, m is 1, and R4 is F.
[00271] In another embodiment, in conjunction with any above or below embodiment, m is 2; and R4 is F.
[00272] In another embodiment, in conjunction with any above or below embodiment, n is O.
[00273] Another aspect of the invention relates to a method of treating schizophrenia, bipolar disorder, or obsessive-compulsive disorder using an effective amount of a compound of formula (IV).
[00274] Another aspect of the invention relates to a method of treating a disorder treatable by inhibition of PDElO in a patient which method comprises administering to the patient a pharmaceutical composition comprising an effective amount of a compound of formula (IV).
[00275] Another aspect of the invention relates to a pharmaceutical composition comprising a compound of formula (IV) and a pharmaceutically-acceptable diluent or carrier.
[00276] Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.
[00277] Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of schizophrenia, bipolar disorder, or obsessive-compulsive disorder.
[00278] Another aspect of the invention relates to compounds selected from the group consisting of:
(lH-Benzo[d]imidazol-2-yl)(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)methanone;
(4-(3-Ethynylpyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2-yl)methanone;
4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile;
(4-(3,3'-Bipyridin-2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone;
(4-(3-(9H-purin-6-yl)pyridin-2-yloxy)phenyl)(lH-benzo[d]imidazol-2-yl)methanone;
2-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)benzyl)-lH-benzo[d]imidazole;
(lH-benzo[d]imidazol-2-yl)(4-(3-(piperidin-l-yl)pyridin-2-yloxy)phenyl)methanone;
(4-(3-chloropyridin-2-yloxy)phenyl)(6-fluoro-lH-benzo[d]imidazol-2-yl)methanone;
(4-(3-bromopyridin-2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone;
(5 -fluoro- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(trifluoromethyl)pyridin-2-yloxy)- phenyl)methanone;
( 1 H-imidazo [4,5 -b]pyridin-2-yl)(4-(3 -(trifluoromethyl)pyridin-2- yloxy)phenyl)methanone;
(5,6-difluoro-lH-benzo[d]imidazol-2-yl)(4-(3-(trifluoromethyl)pyridin-2- yloxy)phenyl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(3-bromopyridin-2-yloxy)phenyl)methanone;
(4-(3 -bromopyridin-2-yloxy)phenyl)( 1 -methyl- 1 H-benzo [d]imidazol-2-yl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3-hydroxy-3 -methylbut- 1 -ynyl)pyridin-2- yloxy)phenyl)methanone;
4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzoic acid;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile;
(1 H-benzo [d]imidazol-2-yl)(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)methanone; (lH-benzo[d]imidazol-2-yl)(4-(3-(2-methylpyridin-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-(trifluoromethyl)pyridin-4-yl)pyridin-2- yloxy)phenyl)methanone; tert-butyl 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-5,6- dihydropyridine- 1 (2H)-carboxylate;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzoic acid;
(lH-benzo[d]imidazol-2-yl)(4-(3-(4-(methylsulfonyl)phenyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3 -(methylsulfonyl)phenyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(4-methoxyphenyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3 -methoxyphenyl)pyridin-2- yloxy)phenyl)methanone;
(4-(3 -bromopyridin-2-yloxy)phenyl)( 1 -(tetrahydro-2H-pyran-2-yl)- 1 H- benzo[d]imidazol-2-yl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(pyrimidin-5 -yl)pyridin-2-yloxy)phenyl)methanone;
(4-(3,3'-bipyridin-2-yloxy)phenyl)(lH-benzo[d]imidazol-2-yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(quinolin-5 -yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(quinolin-4-yl)pyridin-2-yloxy)phenyl)methanone;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-3,4'-bipyridine-2'-carbonitrile;
(lH-benzo[d]imidazol-2-yl)(4-(2'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(3 -(2 -methoxyquino lin-3 -yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-methoxyphenyl)pyridin-2- yloxy)phenyl)methanone; (4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)(l-methyl-lH-benzo[d]imidazol-2- yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(pyrrolidin-l-yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-morpholinopyridin-2-yloxy)phenyl)methanone;
(4-(2',6'-dimethoxy-3,3'-bipyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(4'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5'-(methylthio)-3,3'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-chloro-3,4'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)methanone;
(4-(2'-chloro-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
(l-methyl-l/f-benzo[d]imidazol-2-yl)(4-(2'-methyl-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-fluoro-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-hydroxy-3,4'-bipyridin-2-yloxy)phenyl)methanone;
2-(4-(2'-(trifluoromethyl)-3,4'-bipyridin-2-yloxy)benzyl)-lH-benzo[d]imidazole;
(lH-benzo[d]imidazol-2-yl)(4-(4-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(4-(4-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
4-(2-(4-(l -methyl- 1 H-benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)pyridin- 2(lH)-one;
(6-fluoro-l -methyl- lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)pheny l)methanone and (5 -fluoro- 1 -methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 - (tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone;
(4-(5-chloro-2'-methyl-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- 1 H-benzo [d]imidazol- 2-yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2',5-dimethyl-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(4-(2',5-dimethyl-3,4'-bipyridin-2-yloxy)phenyl)(l-methyl-lH-benzo[d]imidazol-2- yl)methanone; (lH-benzo[d]imidazol-2-yl)(4-(5-chloro-2'-methyl-3,4'-bipyridin-2- yloxy)phenyl)methanone;
N-(4-(3-Cyclopropylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)nicotinic acid;
2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)-N-(cyclopropylmethyl)nicotinamide;
N-(4-(3-Morpholinopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3 -(4-methoxypiperidin- 1 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-morpholinopyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine;
2-(4-( 1 -methyl- 1 H-benzo [d]imidazol-2-ylamino)phenoxy)nicotinonitrile ;
1 -methyl-N-(4-(3 -(morpholinomethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol- 2-amine; benzo[d]thiazol-2-yl(4-(3-bromopyridin-2-yloxy)phenyl)methanone;
Benzo[d]thiazol-2-yl(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanol;
N-(4-(3-(l,2,3,6-Tetrahydropyridin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine;
1 -(4-(2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperazin- 1 -yl)ethanone;
N-(4-(3,3'-Bipyridin-2-yloxy)phenyl)-N-methylbenzo[d]thiazol-2-amine;
N-(4-(3,3'-Bipyridin-2-yloxy)phenyl)-l -methyl- lH-benzo[d]imidazol-2-amine;
N-(4-(3 -(T etrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)-l H-benzo [d]imidazol-2- amine;
N-(4-(3-bromopyridin-2-yloxy)phenyl)-l H-benzo [d]imidazol-2-amine;
6,7-difluoro-N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
6,7-difluoro-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol- 2-amine; l-methyl-N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; l-methyl-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine; 4-methyl-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(4-(pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3 -fluoropyridin-2-yloxy)pheny I)- 1 -methyl- 1 H-benzo [d]imidazol-2-amine;
5 -fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
2-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenylamino)- 1 H-benzo [d]imidazole-5 - carbonitrile;
6-chloro-5 -fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-l-methyl-lH-benzo[d]imidazol-2-amine;
N-(4-(3-chloropyridin-2-yloxy)phenyl)-l -methyl- lH-benzo[d]imidazol-2-amine;
4-fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
5 ,7-difluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol- 2-amine;
5 ,6-difluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol- 2-amine;
N-(2-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
1 -isopropyl-5 -(trifluoromethyl)-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- IH- benzo[d]imidazol-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-7H-purin-8-amine;
1 -methyl-5 -(trifluoromethyl)-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
5 -fluoro- 1 -methyl-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
5 -chloro- 1 -ethyl-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
4-fluoro-N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol- 2-amine; 4,6-difluoro-N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH- benzo[d]imidazol-2-amine;
N-(4-(3-fluoropyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(3-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(6-(3-(trifluoromethyl)pyridin-2-yloxy)pyridin-3-yl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-morpholinopyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(2-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(5-(3-(trifluoromethyl)pyridin-2-yloxy)pyridin-2-yl)-lH-benzo[d]imidazol-2-amine;
2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)-N-(furan-2-ylmethyl)nicotinamide;
N-(4-(3-bromopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
1 -((2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)pyridin-3 -yl)methyl)pyrrolidin-3 -ol;
4-(2-(4-(benzo[d]thiazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile;
(4-(3,3'-bipyridin-2-yloxy)phenyl)(benzo[d]thiazol-2-yl)methanone; benzo[d]thiazol-2-yl(4-(3-morpholinopyridin-2-yloxy)phenyl)methanone;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzonitrile;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzonitrile;
N-(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3 -(2-methoxypyrimidin-5 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
N-(4-(3 -(pyrimidin-5 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine; methyl 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzoate;
N-(4-(3-(3-methoxyphenyl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(6'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(6'-chloro-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(2'-methyl-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(quinolin-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol- 2-amine;
N-(4-(3-(2,3-dihydrobenzofuran-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(benzo[d][l,3]dioxol-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-cyclohexenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(quinolin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(2'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; l-methyl-N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(5'-(methylthio)-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(4'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-Imidazo [4,5 -b]pyridin-2-yl)(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanol;
2-(difluoro(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methyl)- 1 H- benzo[d]imidazole;
(4-(3 -(3 ,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)( 1 -methyl- 1 H- benzo[d]imidazol-2-yl)methanone;
( 1 -methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
1 -(4-Methoxybenzyl)-N-(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
7-Methoxy-N-(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
N-(4-(3-(Tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(4-(3-(4-fluorotetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)tetrahydro-2H-pyran-4-ol;
(lH-benzo[d]imidazol-2-yl)(4-(3-(4-(difluoromethyl)tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)methanone; (lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-3-yl)pyridin-2- yloxy)phenyl)methanone;
N-(4-(3 -(Tetrahydro-2/f-pyran-3 -yl)pyridin-2-yloxy)phenyl)benzo [ J]thiazol-2-amine;
(±)-N-(4-(3-(tetrahydro-2H-pyran-2-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,4R)-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,4S)-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohex-3-enol;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lr,4r)-4-hydroxy-4-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lR,4R)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(lH-Benzo[d]imidazol-2-yl)(4-(3-((lS,4S)-4-hydroxy-4- (trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone;
(l/f-Benzo[J]imidazol-2-yl)(4-(3-((li?,4i?)-4-hydroxy-4- (trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone;
(l/f-benzo[J]imidazol-2-yl)(4-(3-((15',4lS)-4-ethyl-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(l/f-benzo[J]imidazol-2-yl)(4-(3-((li?,4i?)-4-ethyl-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(4.(3.((4SJS)- 1 -Oxaspiro [3.5 ]nonan-7-yl)pyridin-2-yloxy)phenyl)( IH- benzo[<i]imidazol-2-yl)methanone;
4-(2-(4-(l/f-Benzo[J]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclohexanone;
4-(2-(4-(Benzo[J]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanone;
4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cycloheptanone;
(l/f-Benzo[J]imidazol-2-yl)(4-(3-(oxepan-4-yl)pyridin-2-yloxy)phenyl)methanone;
Λ/-(4-(3-(oxepan-4-yl)pyridin-2-yloxy)phenyl)benzo[<i]thiazol-2-amine;
5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)azepan-2-one;
5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l-methylazepan-2- one;
(rac)-cώ-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol; (rac)-trα/?5-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(rac)-£-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
4-(2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l-methylpiperidin-2-one;
4-(2-(4-(lH-Benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l-methylpiperidin- 2-one;
(i?)-4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l- methylpyrrolidin-2-one;
(5)-4-(2-(4-(l/f-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l- methylpyrrolidin-2-one;
4-(2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)pyridin-3 -yl)- 1 -methylpyrrolidin-2-one l-(4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone; l-(4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-5,6-dihydropyridin- l(2H)-yl)ethanone; l-(4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone; tert-butyl 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidine- 1-carboxylate;
(lH-benzo[d]imidazol-2-yl)(4-(3-(piperidin-4-yl)pyridin-2-yloxy)phenyl)methanone; l-(5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-3,4- dihydropyridin- 1 (2H)-yl)ethanone;
(S)-l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone ;
(R)-I -(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l - yl)ethanone;
(S)- 1 -(3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin- 1 - yl)ethanone ;
(R)-l-(3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone;
(R)-I -(2-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l - yl)ethanone ;
(S)-I -(2-(2-(4-(I H-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone; l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)pyrrolidin-l- yl)ethanone; l-(3-(3-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-l- yl)ethanone;
N-(4-(3-(tetrahydrofuran-2-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(R)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone (S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone;
N-(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
( 1 -(2-fluoroethyl)- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
3 -(2-(4-(I H-benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopent-2-enone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopent-2-enone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l-methylcyclopentanol; lH-benzimidazol-2-yl(4-((3-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-2- pyridinyl)oxy)phenyl)methanone;
N-(4-(5-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-yloxy)phenyl)benzo[d]thiazol-2- amine;
(lH-benzo[d]imidazol-2-yl)(4-(5-(l,2,3,6-tetrahydropyridin-4-yl)pyrimidin-4- yloxy)phenyl)methanone; l-(4-(4-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyrimidin-5-yl)-5,6-dihydropyridin- l(2H)-yl)ethanone;
(lH-Benzo[<i]imidazol-2-yl)(4-(2'-fluoro-6-methoxy-3,4'-bipyridin-2- yloxy)phenyl)methanone; (lH-benzo[d]imidazol-2-yl)(4-(3-(4-fluorotetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
(4-(3 -(4-fluorotetrahydro-2H-pyran-4-y l)pyridin-2-y loxy)phenyl)( 1 -methyl- 1 H- benzo[d]imidazol-2-yl)methanone; l-(4-(2-(4-(l-methyl-lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3- yl)piperidin- 1 -yl)ethanone;
(±)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-2-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((ls,4s)-4-hydroxy-4-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(ls,4s)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(rac)-cώ-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(rac)-trα/?5-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(rac)-E-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxy-3-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(pyridin-2- yl)ethyl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-phenethylnicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2- pheny lpropy l)nicotinamide ;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-phenylpropan- 2-yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-phenylpropan- 2-yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-methoxy-3-phenylpropan- 2-yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(thiophen-2- yl)ethyl)nicotinamide; (S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-methoxypropan-2- yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(pyridin-2- yl)ethyl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-hydroxyethyl)nicotinamide;
(rac)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-methyl-2-(pyridin-2- y l)propy l)nicotinamide ;
2-(4-( 1 H-benzo [d]imidazole-2-carbonyl)phenoxy)-N-( 1 - benzylcyclopropyl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-(4- methoxyphenyl)propan-2-yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-(4- hydroxyphenyl)propan-2-yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2,3-dihydro-lH-inden-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2- pheny lpropy l)nicotinamide ;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)-2- methylpropan-2-yl)nicotinamide;
(rac)-2-(4-(l H-benzo [d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan- 2-yl)nicotinamide;
(R)-( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
(S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-3-yl)pyridin-2- yloxy)phenyl)methanone;
(R)-N-(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
(S)-N-(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
(S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone;
(R)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone; (lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 R,3 S)-3 -(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 S ,3R)-3 -(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lr,4r)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lr,4s)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(R)-I -(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l - yl)ethanone;
(S)-I -(3 -(2-(4-(I H-benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3 -yl)piperidin-l- yl)ethanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone; (lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(S)-3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
(R)-3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan-2- yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- y l)nicotinamide . ; (lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 S ,3 S)-3 -hydroxy-3 -methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone; or any pharmaceutically-acceptable salt thereof.
Another aspect of the invention relates to compounds selected from the group consisting of compounds of group (V) below:
(4-(3,4'-bipyridin-2-yloxy)phenyl)(l H-benzo [d]imidazol-2-yl)methanone
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-methoxypyridin-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(l -methyl- lH-pyrazol-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(l-cyclopropyl-lH-pyrazol-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)methanone;
(5 -fluoro-1 H-benzo [d]imidazol-2-yl)(4-(2'-fluoro-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)methanone;
N-(4-(3,4'-Bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
4,6-difluoro-N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4-fluoro-N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4-fluoro-N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
4,6-difluoro-N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(2'-(trifluoromethyl)-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(lH-Benzo[<i]imidazol-2-yl)(4-(5-(2-fluoropyridin-4-yl)-2-methoxypyrimidin-4- yloxy)phenyl)methanone; or any pharmaceutically acceptable salt thereof. [00279] Another aspect of the invention relates to a method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound of group (V).
[00280] Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
[00281] Another aspect of the invention relates to a method wherein said condition that may be treated with PDElO inhibitors is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
[00282] Another aspect of the invention relates to a pharmaceutical composition comprising a compound of group (V) and a pharmaceutically-acceptable diluent or carrier. [00283] The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
[00284] The present invention includes all pharmaceutically acceptable isotopically- labelled compounds of the present invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
[00285] Examples of isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C,
C and C, chlorine, such as Cl, fluorine, such as F, iodine, such as I and I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulphur, such as 35S. [00286] Certain isotopically-labelled compounds of the present invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. [00287] Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. [00288] Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
[00289] Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[00290] Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de- acetone, de-DMSO.
[00291] Specific embodiments of the present invention include the compounds exemplified in the Examples below and their pharmaceutically acceptable salts, complexes, solvates, polymorphs, stereoisomers, metabolites, prodrugs, and other derivatives thereof, Unless otherwise specified, the following definitions apply to terms found in the specification and claims:
[00292] "Cα-βalk" means an alkyl group comprising a minimum of α and a maximum of β carbon atoms in a branched, cyclical or linear relationship or any combination of the three, wherein α and β represent integers. The alkyl groups described in this section may also contain one or two double or triple bonds. A designation of Coalk indicates a direct bond. Examples of Ci_6alkyl include, but are not limited to the following:
Figure imgf000066_0001
[00293] "Benzo group", alone or in combination, means the divalent radical C4H4=, one representation of which is -CH=CH-CH=CH-, that when vicinally attached to another ring forms a benzene-like ring—for example tetrahydronaphthylene, indole and the like. [00294] The terms "oxo" and "thioxo" represent the groups =0 (as in carbonyl) and =S (as in thiocarbonyl), respectively.
[00295] "Halo" or "halogen" means a halogen atoms selected from F, Cl, Br and I. [00296] "Cv-whaloalk" means an alk group, as described above, wherein any number—at least one— of the hydrogen atoms attached to the alk chain are replaced by F, Cl, Br or I. [00297] The group N(Ra)Ra and the like include substituents where the two Ra groups together form a ring, optionally including a N, O or S atom, and include groups such as:
Figure imgf000067_0001
[00298] The group N(Cα-βalk)Cα-βalk, wherein α and β are as defined above, include substituents where the two Cα-βalk groups together form a ring, optionally including a N, O or S atom, and include groups such as:
Figure imgf000067_0002
[00299] "Carbocycle" means a ring comprising by itself or in combination with other terms, represents, unless otherwise stated, cyclic version of "Cα-βalk". Thus, the term "carbocycle" is meant to be included in the terms "Cα-βalk". Examples of carbocycle include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, cyclobutylene, cyclohexylene and the like.
[00300] "Heterocycle" means a ring comprising at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:
Figure imgf000067_0003
Figure imgf000068_0001
[00301] "Pharmaceutically-acceptable salt" means a salt prepared by conventional means, and are well known by those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable salts," see infra and Berge et al, J. Pharm. Sci. 66: 1 (1977). [00302] "Saturated, partially-saturated or unsaturated" includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens. [00303] "Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
[00304] "Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, l,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
[00305] Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1 ,2- bis(dimethylsilyl)benzene, 1 ,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-trisilyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert- butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
[00306] Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogeno lysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.
[00307] It should be noted that compounds of the invention may contain groups that may exist in tautomeric forms, such as cyclic and acyclic amidine and guanidine groups, heteroatom substituted heteroaryl groups (Y' = O, S, NR), and the like, which are illustrated in the following examples:
Figure imgf000071_0001
OH O O O O OH
R R' R R' R R' and though one form is named, described, displayed and/or claimed herein, all the tautomeric forms are intended to be inherently included in such name, description, display and/or claim. [00308] Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use. [00309] The specification and claims contain listing of species using the language "selected from . . . and . . ." and "is . . . or . . ." (sometimes referred to as Markush groups). When this language is used in this application, unless otherwise stated it is meant to include the group as a whole, or any single members thereof, or any subgroups thereof. The use of this language is merely for shorthand purposes and is not meant in any way to limit the removal of individual elements or subgroups as needed.
UTILITY AND METHODS OF USE
[00310] Provided herein are methods for treating a disorder or disease by inhibiting PDElO enzyme. The methods, in general, comprises the step of administering a therapeutically effective amount of a compound of Formula (I), or an individual stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof to treat the disorder or disease.
[00311] In certain embodiments, this invention provides a use of a compound as described herein in the manufacture of a medicament for treating a disorder or disease treatable by inhibition of PDE 10.
[00312] The compounds of the present invention inhibit PDE 10 enzyme activity, and hence raise the levels of cAMP or cGMP within cells that express PDElO. Accordingly, inhibition of PDElO enzyme activity would be useful in the treatment of diseases caused by deficient amounts of cAMP or cGMP in cells. PDElO inhibitors would also be of benefit in cases wherein raising the amount of cAMP or cGMP above normal levels results in a therapeutic effect. Inhibitors of PDElO may be used to treat disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, gastro-enterological diseases, endocrinological diseases and uro logical diseases.
[00313] Indications that may be treated with PDE 10 inhibitors, either alone or in combination with other drugs, include, but are not limited to, those diseases thought to be mediated in part by the basal ganglia, prefrontal cortex, and hippocampus. These indications include psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
[00314] Psychoses are disorders that affect an individual ' s perception of reality. Psychoses are characterized by delusions and hallucinations. The compounds of the present invention are suitable for use in treating patients suffering from all forms of psychoses, including, but not limited to, schizophrenia, late-onset schizophrenia, schizoaffective disorders, prodromal schizophrenia, and bipolar disorders. Treatment can be for the positive symptoms of schizophrenia as well as for the cognitive deficits and negative symptoms. Other indications for PDElO inhibitors include psychoses resulting from drug abuse (including amphetamines and PCP), encephalitis, alcoholism, epilepsy, Lupus, sarcoidosis, brain tumors, multiple sclerosis, dementia with Lewy bodies, or hypoglycemia. Other psychiatric disorders, like posttraumatic stress disorder (PTSD), and schizoid personality can also be treated with PDElO inhibitors.
[00315] Obsessive-compulsive disorder (OCD) has been linked to deficits in the frontal- striatal neuronal pathways (Saxena et al., Br. J. Psychiatry Suppl, 35:26-37, 1998). Neurons in these pathways project to striatal neurons that express PDElO. PDElO inhibitors cause cAMP to be elevated in these neurons; elevations in cAMP result in an increase in CREB phosphorylation and thereby improve the functional state of these neurons. The compounds of the present invention are therefore suitable for use in the indication of OCD. OCD may result, in some cases, from streptococcal infections that cause autoimmune reactions in the basal ganglia (Giedd et al., Am J Psychiatry. 157:281-283, 2000). Because PDElO inhibitors may serve a neuroprotective role, administration of PDElO inhibitors may prevent the damage to the basal ganglia after repeated streptococcal infections and thereby prevent the development of OCD.
[00316] In the brain, the level of cAMP or cGMP within neurons is believed to be related to the quality of memory, especially long term memory. Without wishing to be bound to any particular mechanism, it is proposed that, since PDElO degrades cAMP or cGMP, the level of this enzyme affects memory in animals, for example, in humans. A compound that inhibits cAMP phosphodiesterase (PDE) can thereby increase intracellular levels of cAMP, which in turn activate a protein kinase that phosphorylates a transcription factor (cAMP response binding protein). The phosphorylated transcription factor then binds to a DNA promoter sequence to activate genes that are important in long term memory. The more active such genes are, the better is long-term memory. Thus, by inhibiting a phosphodiesterase, long term memory can be enhanced.
[00317] Dementias are diseases that include memory loss and additional intellectual impairment separate from memory. The compounds of the present invention are suitable for use in treating patients suffering from memory impairment in all forms of dementia. Dementias are classified according to their cause and include: neurodegenerative dementias (e.g., Alzheimer's, Parkinson's disease, Huntington's disease, Pick's disease), vascular (e.g., infarcts, hemorrhage, cardiac disorders), mixed vascular and Alzheimer's, bacterial meningitis, Creutzfeld- Jacob Disease, multiple sclerosis, traumatic (e.g., subdural hematoma or traumatic brain injury), infectious (e.g., HIV), genetic (down syndrome), toxic (e.g., heavy metals, alcohol, some medications), metabolic (e.g., vitamin B12 or folate deficiency), CNS hypoxia, Cushing's disease, psychiatric (e.g., depression and schizophrenia), and hydrocephalus. [00318] The condition of memory impairment is manifested by impairment of the ability to learn new information and/or the inability to recall previously learned information. The present invention includes methods for dealing with memory loss separate from dementia, including mild cognitive impairment (MCI) and age-related cognitive decline. The present invention includes methods of treatment for memory impairment as a result of disease. Memory impairment is a primary symptom of dementia and can also be a symptom associated with such diseases as Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfe Id- Jakob disease, HIV, cardiovascular disease, and head trauma as well as age-related cognitive decline. The compounds of the present invention are suitable for use in the treatment of memory impairment due to, for example, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, spinal cord injury, CNS hypoxia, cerebral senility, diabetes associated cognitive impairment, memory deficits from early exposure of anesthetic agents, multiinfarct dementia and other neurological conditions including acute neuronal diseases, as well as HIV and cardiovascular diseases.
[00319] The compounds of the present invention are also suitable for use in the treatment of a class of disorders known as polyglutamine-repeat diseases. These diseases share a common pathogenic mutation. The expansion of a CAG repeat, which encodes the amino acid glutamine, within the genome leads to production of a mutant protein having an expanded polyglutamine region. For example, Huntington's disease has been linked to a mutation of the protein huntingtin. In individuals who do not have Huntington's disease, huntingtin has a polyglutamine region containing about 8 to 31 glutamine residues. For individuals who have Huntington's disease, huntingtin has a polyglutamine region with over 37 glutamine residues. Aside from Huntington's disease (HD), other known polyglutamine-repeat diseases and the associated proteins include dentatorubral-pallidoluysian atrophy, DRPLA (atrophin-1); spinocerebellar ataxia type-1 (ataxin-1); spinocerebellar ataxia type-2 (ataxin-2); spinocerebellar ataxia type-3 (also called Machado-Joseph disease or MJD) (ataxin-3); spinocerebellar ataxia type-6 (alpha Ia- voltage dependent calcium channel); spinocerebellar ataxia type-7 (ataxin-7); and spinal and bulbar muscular atrophy (SBMA, also know as Kennedy disease). [00320] The basal ganglia are important for regulating the function of motor neurons; disorders of the basal ganglia result in movement disorders. Most prominent among the movement disorders related to basal ganglia function is Parkinson's disease (Obeso et al, Neurology. 62(1 Suppl l):S17-30, 2004). Other movement disorders related to dysfunction of the basal ganglia include tardive dyskinesia, progressive supranuclear palsy and cerebral palsy, corticobasal degeneration, multiple system atrophy, Wilson disease, dystonia, tics, and chorea. The compounds of the invention are also suitable for use to treat movement disorders related to dysfunction of basal ganglia neurons.
[00321] PDElO inhibitors are useful in raising cAMP or cGMP levels and prevent neurons from undergoing apoptosis. PDElO inhibitors may be anti-inflammatory by raising cAMP in glial cells. The combination of anti-apoptotic and anti-inflammatory properties, as well as positive effects on synaptic plasticity and neurogenesis, make these compounds useful to treat neurodegeneration resulting from any disease or injury, including stroke, spinal cord injury, Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), and multiple systems atrophy (MSA).
[00322] Autoimmune diseases or infectious diseases that affect the basal ganglia may result in disorders of the basal ganglia including ADHD, OCD, tics, Tourette's disease, Sydenham chorea. In addition, any insult to the brain can potentially damage the basal ganglia including strokes, metabolic abnormalities, liver disease, multiple sclerosis, infections, tumors, drug overdoses or side effects, and head trauma. Accordingly, the compounds of the invention can be used to stop disease progression or restore damaged circuits in the brain by a combination of effects including increased synaptic plasticity, neurogenesis, anti-inflammatory, nerve cell regeneration and decreased apoptosis.
[00323] The growth of some cancer cells is inhibited by cAMP and cGMP. Upon transformation, cells may become cancerous by expressing PDElO and reducing the amount of cAMP or cGMP within cells. In these types of cancer cells, inhibition of PDElO activity inhibits cell growth by raising cAMP. In some cases, PDElO may be expressed in the transformed, cancerous cell but not in the parent cell line. In transformed renal carcinoma cells, PDElO is expressed and PDElO inhibitors reduce the growth rate of the cells in culture. Similarly, breast cancer cells are inhibited by administration of PDElO inhibitors. Many other types of cancer cells may also be sensitive to growth arrest by inhibition of PDElO. Therefore, compounds disclosed in this invention can be used to stop the growth of cancer cells that express PDElO. [00324] The compounds of the invention are also suitable for use in the treatment of diabetes and related disorders such as obesity, by focusing on regulation of the cAMP signaling system. By inhibiting PDE-IO, especially PDE-IOA, intracellular levels of cAMP are increased, thereby increasing the release of insulin-containing secretory granules and, therefore, increasing insulin secretion. See, for example, WO 2005/012485, which is hereby incorporated by reference in its entirety. The compounds of the present invention can also be used to treat diseases disclosed in US Patent application publication No. 2006/019975, the disclosure of which is incorporated herein by reference in its entirety.
TESTING
[00325] The PDE 10 inhibitory activities of the compounds of the present invention can be tested, for example, using the in vitro and in vivo assays described in the Biological Examples below.
ADMINISTRATION AND PHARMACEUTICAL COMPOSITIONS
[00326] In general, the compounds of this invention can be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of a compound of this invention, i.e., the active ingredient, depends upon numerous factors, such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors.
[00327] Therapeutically effective amounts of compounds of the present invention may range from approximately 0.1-1000 mg per day; preferably 0.5 to 250 mg/day, more preferably 3.5 mg to 70 mg per day.
[00328] In general, compounds of this invention can be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
[00329] The choice of formulation depends on various factors, such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area, i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
[00330] The compositions are comprised of, in general, a compound of formula (I) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of formula (I). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. [00331] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
[00332] Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. [00333] Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, Gennaro, A. R. (Mack Publishing Company, 18th ed., 1995).
[00334] The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation contains, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula (I) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.
[00335] The compounds can be administered as the sole active agent or in combination with other pharmaceutical agents such as other agents used in the treatment of psychoses, especially schizophrenia and bipolar disorder, obsessive-compulsive disorder, Parkinson's disease, Alzheimer's disease, cognitive impairment and/or memory loss, e.g., nicotinic α-7 agonists, PDE4 inhibitors, other PDElO inhibitors, calcium channel blockers, muscarinic ml and m2 modulators, adenosine receptor modulators, ampakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, canabinoid modulators, and cholinesterase inhibitors (e.g., donepezil, rivastigimine, and galanthanamine). In such combinations, each active ingredient can be administered either in accordance with their usual dosage range or a dose below their usual dosage range, and can be administered either simultaneously or sequentially.
[00336] Drugs suitable in combination with the compounds of the present invention include, but are not limited to, other suitable schizophrenia drugs such as Clozaril, Zyprexa, Risperidone, and Seroquel; bipolar disorder drugs, including, but not limited to, Lithium, Zyprexa, and Depakote; Parkinson's disease drugs, including, but not limited to, Levodopa, Parlodel, Permax, Mirapex, Tasmar, Contan, Kemadin, Artane, and Cogentin; agents used in the treatment of Alzheimer's disease, including, but not limited to, Reminyl, Cognex, Aricept, Exelon, Akatinol, Neotropin, Eldepryl, Estrogen and Cliquinol; agents used in the treatment of dementia, including, but not limited to, Thioridazine, Haloperidol, Risperidone, Cognex, Aricept, and Exelon; agents used in the treatment of epilepsy, including, but not limited to, Dilantin, Luminol, Tegretol, Depakote, Depakene, Zarontin, Neurontin, Barbita, Solfeton, and Felbatol; agents used in the treatment of multiple sclerosis, including, but not limited to, Detrol, Ditropan XL, OxyContin, Betaseron, Avonex, Azothioprine, Methotrexate, and Copaxone; agents used in the treatment of Huntington's disease, including, but not limited to, Amitriptyline, Imipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine, Setraline, Terabenazine, Haloperidol, Chloropromazine, Thioridazine, Sulpride, Quetiapine, Clozapine, and Risperidone; agents useful in the treatment of diabetes, including, but not limited to, PPAR ligands (e.g. agonists, antagonists, such as Rosiglitazone, Troglitazone and Pioglitazone), insulin secretagogues (e.g., sulfonylurea drugs, such as Glyburide, Glimepiride, Chlorpropamide, Tolbutamide, and Glipizide, and non-sulfonyl secretagogues), α-glucosidase inhibitors (such as Acarbose, Miglitol, and Voglibose), insulin sensitizers (such as the PPAR-γ agonists, e.g., the glitazones; biguanides, PTP-IB inhibitors, DPP-IV inhibitors, and l lbeta- HSD inhibitors), hepatic glucose output lowering compounds (such as glucagon antagonists and metaformin, e.g., Glucophage and Glucophage XR), insulin and insulin derivatives (both long and short acting forms and formulations of insulin); and anti-obesity drugs, including, but not limited to, β-3 agonists, CB-I agonists, neuropeptide Y5 inhibitors, Ciliary Neurotrophic Factor and derivatives (e.g., Axokine), appetite suppressants (e.g., Sibutramine), and lipase inhibitors (e.g., Orlistat).
EXPERIMENTAL
[00337] In the following schemes, the compounds of the invention, along with their definitions, such as m, n, p, R1, R2, R3, R4, R9, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11,
X12,Y and Z, are as described above.
[00338] Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. All parts are by weight and temperatures are in degrees centigrade unless otherwise indicated. All microwave assisted reactions were conducted with a
Smith Synthesizer™ from Biotage™. All compounds showed NMR spectra consistent with their assigned structures. Melting points were determined on a Buchi apparatus and are uncorrected. Mass spectral data was determined by electrospray ionization technique. All examples were purified to >90% purity as determined by high-performance liquid chromatography. Unless otherwise stated, reactions were run at RT.
[00339] The following abbreviations are used:
DCM dichloromethane
DMSO - dimethyl sulfoxide
DMF - Λ/,Λ/-dimethylformamide
THF - tetrahydrofuran
Et2O - diethyl ether
EtOAc - ethyl acetate
MeOH - methyl alcohol
EtOH - ethyl alcohol
IPA- isopropyl alcohol
MeCN - acetonitrile
MeI - iodomethane
NMP - l-methyl-2-pyrrolidinone
DCM - dichloromethane
TFA - trifuoroacetic acid
MTBE- methyl tert-butyl ether
DIPEA- diisopropylethyl amine
HBTU- 2-( 1 H-Benzotriazole- 1 -yl)- 1 , 1 ,3 ,3-tetramethylaminium hexafluorophosphate
HATU- O-(7-Azobenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate Sat. - saturated h - hour min - min rnL - milliliters g - grams mg - milligrams
RT - RT
[00340] All compounds were divided in five classes based on their IC50 values against PDElO. The range of the IC50 in each class is as follows:
"+" designates an IC50 value in the range beginning from 1.0 uM and ending at 5.0 uM; "++" designates an IC50 value in the range beginning from 250 nM and ending at 1.0 uM; "+++" designates an IC50 value in the range beginning from 100 nM and ending at 250 nM; "++++" designates an IC50 value in the range beginning from 25 nM and ending at 100 nM; and "+++++" designates an IC50 value of less than 25 nM.
SCHEME 1
Figure imgf000080_0001
EXAMPLE 1 : ( IH-BENZO [D]IMID AZOL-2-YL)(4-(3-(TPJFLUOROMETHYL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
Figure imgf000081_0001
STEP 1. ETHYL 4-(3-(TRIFLUOROMETHYL)PYRIDIN-I-YLOXY)BENZOATE
[00341] 2-Fluoro-3-(trifluoromethyl)pyridine (848 mg, 5137 μmol), cesium carbonate (2008 mg, 6164 μmol) and ethyl 4-hydroxybenzoate (854 mg, 5137 μmol) were combined in DMSO (12 mL) and heated to 80 0C overnight. After complete disappearance of starting material, the mixture was cooled to RT and diluted with water and extracted with ethyl acetate. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated to give the desired product which was used without further purification.
Figure imgf000081_0002
STEP 2. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(TRIFLUOROMETHYL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
[00342] A solution of benzene- 1 ,2-diamine (175 mg, 1618 μmol), triethyl ortho formate (665 μL, 4353 μmol), and benzenesulfonic acid (10 mg, 65 μmol) in toluene (1.6 mL) was heated to reflux for 4 h and then slowly distilled to remove half of the solvent. The mixture was then cooled to RT and neutralized with diisopropyl amine, followed by addition of a solution of ethyl 4-(3-(trifluoromethyl)pyridin-2-yloxy)benzoate (554 mg, 1780 μmol) in 1.7 mL of THF. The mixture was cooled to -78 0C and 1.2 equiv of LDA (0.971 mL, 2.0M) was added. After aging at -78 0C for 1.5 h, the mixture was warmed to RT and stirred for 1.5 h and then 2N HCl was added and the mixture was agitated for 15 min. Following that, the mixture was adjusted to pH 9 with IN NaOH. Ethyl acetate was added and the layers were separated, the aqueous was extracted with ethyl acetate (3x), and the combined organics were washed with brine, dried over Na2SO4, filtered and concentrated. Following purification, (lH-benzo[d]imid- azol-2-yl)(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)methanone was obtained. MS (ESI, pos. ion) m/z: 384 (M+l). IC50 (uM) +++++. SCHEME 2
Figure imgf000082_0001
EXAMPLE 2: (4-(3 -ETHYNYLP YRIDIN-2-YLOXY)PHENYL)(l -METHYL- IH- BENZO[D]IMID AZOL-2-YL)METHANONE
Figure imgf000082_0002
STEP 1. (4-(3-BROMOPYRIDIN^-YLOXY)PHENYL)(I-METHYL-IH-BENZO[D]IMID- AZ0L-2-YL)METHAN0NE
[00343] To a solution of (lH-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2-yloxy)- phenyl)methanone (0.5 g, 1 mmol) in DMF (3 niL) was added cesium carbonate (0.5 g, 2 mmol) and iodomethane (0.2 g, 1 mmol). Reaction was stirred at RT overnight. Reaction mixture was diluted with DCM and washed with water and brine. Purification by prep HPLC produced the desired product.
Figure imgf000082_0003
STEP 2. (1-METHYL-1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(2-(TRIMETHYLSILYL)- ETHYNYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00344] A solution of (4-(3-bromopyridin-2-yloxy)phenyl)(l-methyl-lH-benzo[d]imid- azol-2-yl)methanone (0.18 g, 0.44 mmol), triethylamine (0.12 mL, 0.88 mmol), copper iodide (0.0084 g, 0.044 mmol), dichlorobis(triphenyl-phosphine)palladium (0.015 g, 0.022 mmol), trimethylsilylacetylene (0.093 mL, 0.66 mmol) in 1 mL DMF was heated to 110 0C overnight. The reaction mixture was diluted with DCM and then washed with water and brine. The organic layer was purified by silica gel chromatography (0-10% MeOH/DCM) to afford (1- methyl-lH-benzo[d]imidazol-2-yl)(4-(3-(2-(trimethylsilyl)ethynyl)pyridin-2-yloxy)phenyl)- methanone.
Figure imgf000083_0001
STEP 3. (4-(3-ETHYNYLPYRIDIN-2-YLOXY)PHENYL)(l-METHYL-lH- BENZO[D]IMID AZOL-2-YL)METHANONE
[00345] (1 -Methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(2-(trimethylsilyl)ethynyl)pyridin-2- yloxy)phenyl)methanone (0.19 g, 0.44 mmol) and potassium carbonate (0.12 g, 0.88 mmol) was suspended in 1 mL MeOH. The mixture was stirred for 2 h at RT. Purification by prep- plate TLC (10% MeOH/DCM) afforded (4-(3-ethynylpyridin-2-yloxy)phenyl)(l -methyl- IH- benzo[d]imidazol-2-yl)methanone. MS (ESI, pos. ion) m/z: 354.0 (M+ 1). IC50 (uM) +++.
SCHEME 3
Figure imgf000083_0002
Figure imgf000084_0001
[00346] EXAMPLE 3: 4-(2-(4-( IH-BENZO [D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)BENZONITRILE.
[00347] A glass microwave reaction vessel was charged with (lH-benzo[d]imidazol-2- yl)(4-(3-bromopyridin-2-yloxy)phenyl)methanone (0.1427 g, 0.36 mmol), A- cyanophenylboronic acid (0.0760 g, 0.43 mmol), trans-dichlorobis(triphenyl- phosphine)palladium(ii) (0.0314 g, 0.029 mmol), and sodium carbonate monohydrate (0.13 mL, 1.8 mmol) in 1 ,2-dimethoxymethane (3 mL) and water (1 mL). The reaction mixture was stirred and heated in a Biotage™ Initiator™ microwave reactor at 135 0C for 10 min. The solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage™ pre-packed silica gel column (25M), eluting with a gradient of 10% to 80% ethyl acetate in hexane, to provide 4-(2-(4-(lH-benzo[d]imidazole-2- carbonyl)phenoxy)pyridin-3-yl)benzonitrile. MS (ESI, pos. ion) m/z: All .5 (M+ 1). IC50 (uM) +++++.
Figure imgf000084_0002
EXAMPLE 4: (4-(3,3'-BIPYRIDIN-2-YLOXY)PHENYL)(lH-IMIDAZO[4,5-B]PYRIDIN-2- YL)METHANONE.
[00348] To a round bottomed flask was added (4-(3 -bromopyridin-2-yloxy)phenyl)( 1 H- imidazo[4,5-b]pyridin-2-yl)methanone (.250 g, 0.633 mmol), pyridin-3-ylboronic acid (0.233 g, 1.898 mmol), PdCl2(dppf) (0.035 g, 0.063 mmol), and sodium carbonate (0.335 g, 3.16 mmol) in DMSO (1.581 mL) and Water (0.527 mL) at 80 0C to stir overnight. The reaction was worked up via seperatory funnel. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 25% to 100% over 15 min to provide (4-(3,3'-bipyridin-2- yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone. MS (ESI, pos. ion) m/z: 394.0 (M+l). IC50 (uM) +++++.
SCHEME 4
Figure imgf000085_0001
EXAMPLE 5 : (4-(3 ,4'-BIPYRIDIN^-YLOXY)PHENYL)(I H-BENZO [D]IMID AZOL-2- YL)METHANONE
Figure imgf000085_0002
STEP 1 : (4-(3-BROMOPYRIDIN-I-YLOXY)PHENYL)(I-(TETRAHYDRO-IH-PYRAN-I- YL)-1H-BENZO[D]IMID AZ0L-2-YL)METHAN0NE
[00349] A solution of l-(tetrahydro-2H-pyran-2-yl)-lH-benzo[d]imidazole (39.5 g, 195 mmol) in anhydrous THF (300 ml) was cooled to 00C and treated with lithium bis(trimethylsilyl)amide (212 ml, 212 mmol) added dropwise over a 30 mins period. The reaction was allowed to stir for 1 hour and then methyl 4-(2-bromophenoxy)benzoate (50.00 g, 163 mmol), dissolved in 100 ml of anhydrous THF was added slowly to the reaction. The reaction was stirred for 1 hour at 00C and allowed to warm up to RT. After 1 hour, the reaction was cooled down to 00C and quenched with water (50 ml) dropwise. The reaction was diluted with 400 ml of Ethyl acetate and 400 ml of water. The layers were separated. The aqueous layer was extracted 2x (100 ml) with ethyl acetate. All the organic layers were combined, washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and reduced to a smaller volume. The solid that precipitated out was filtered off, washed well with ether and dried to give product as solid. The mother liquor was concentrated and purified by column chromatography on silica gel using a gradient of 10 to 60 % EtOAc in hexanes to give another batch of product.
Figure imgf000086_0001
STEP 2 : (4-(3 ,4'-BIP YRIDIN-2-YLOXY)PHENYL)( 1 H-BENZO [D]IMID AZOL-2- YL)METHANONE
[00350] A clear microwave vial was charged with (4-(3 -bromopyridin-2- yloxy)phenyl)(l-(tetrahydro-2H-pyran-2-yl)-lH-benzo[d]imidazol-2-yl)methanone (0.300 g, 0.627 mmol), pyridin-4-ylboronic acid (0.093 g, 0.753 mmol), bis (di-tert-butyl(4- dimethylaminophenyl)phosphoine)dichloropalldium (II) (0.022 g, 0.031 mmol), potassium acetate (0.123 g, 1.254 mmol), Dioxane (4.5 mL) and Water (0.500 mL). The vial was capped and heated in a Personal Chemistry SmithSynthesizer to 120 0C for 12 minutes. The reaction was diluted with EtOAc (10 ml) and water (10 ml). The organic portion was collected and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes. [00351] The product obtained form part 1 was taken up in DCM (5ml) and treated with TFA (2 ml) and a few drops of water. The mixture was allowed to stir O/N at RT. The volatiles were removed under vacuum. The residue was taken up in 2M ammonia in MeOH (10 ml) and again reduced under vacuum. The residue was dissolved in ethyl acetate and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and reduced. The residue obtained was triturated with ether, collected by suction filtration and dried to give product. MS (ESI, pos. ion) m/z: 392.9 (M+l). IC50 (uM) +++++.
SCHEME 5
ene
Figure imgf000087_0001
EXAMPLE 6: (4-(3-(9H-PURIN-O-YL)PYRIDIN-I-YLOXY)PHENYL)(IH- BENZO[D]IMID AZOL-2-YL)METHANONE
Figure imgf000087_0002
STEP 1 : 6-BROMO-Q-(TETRAHYDRO-IH-PYRAN-I-YL)-QH-PURINE
[00352] A mixture of 6-bromopurine (2.0 g, 10 mmol), 3,4-dihydro-2h-pyran (1.0 ml, 11 mmol), and p-toluenesulfonic acid monohydrate (0.050 g, 0.26 mmol) in EtOAc (30 mL) was stirred at reflux under a reflux condenser for 48 h. The reaction mixture (suspension) was allowed to cool to room temperature and the solid was removed by suction filtration and washed with EtOAc (50 mL). The combined wash was concentrated in vacuo to afford 2.1 g as oil. The oil was chromatographed through a Redi-Sep® pre-packed silica gel column, eluting with a gradient of 30% to 60% EtOAc in hexane, to provide product.
Figure imgf000088_0001
STEP II O-(I-FLUOROPYRIDIN-S-YL)-Q-(TETRAHYDRO-IH-PYRAN-I-YL)-QH-PURINE
[00353] To a round bottom flask, under a reflux condenser, was added 6-bromo-9- (tetrahydro-2H-pyran-2-yl)-9H-purine (1.0 g, 3.5 mmol), 2-fluoropyridin-3-ylboronic acid (0.75 g, 5.3 mmol), potassium acetate (1.0 g, 11 mmol), 1-butanol (50 mL) and DI water (10 mL). The mixture was purged with Ar (vacuum/purge three times) to remove oxygen, then PdCl2(P -tert-Bu2Ph)2 (0.026 g, 0.042 mmol) was added. The reaction mixture was stirred in a 100 0C oil bath for 45 min (complete by TLC, 80% EtO Ac/hex).
[00354] The reaction mixture was allowed to cool to room temperature and diluted with
Et2O (500 mL). The mixture was washed with water (3 x 100 L), then saturated NaCl solution (100 mL). The solution was dried over Na2SO4, filtered and concentrated in vacuo. The butanol was removed in vacuo by azeotrope with toluene (2 x 200 mL) to afford 1 g as a yellow oily residue; 83947-12-1. The crude product was chromatographed through a Redi-Sep® prepacked silica gel column (40 g), eluting with a gradient of 80% to 100% EtOAc in hexane, to provide product.
Figure imgf000088_0002
STEP 3: (4-(3-(9H-PURIN-O-YL)PYRIDIN^-YLOXY)PHENYL)(IH- BENZO[D]IMID AZOL-2-YL)METHANONE
[00355] A screw cap heavy wall flask was charged with (lH-benzo[d]imidazol-2-yl)(4- hydroxyphenyl)methanone (0.350 g, 1.469 mmol), 6-(2-fluoropyridin-3-yl)-9-(tetrahydro-2H- pyran-2-yl)-9H-purine (0.440 g, 1.469 mmol), cesium carbonate (0.957 g, 2.94 mmol) and DMF (6 mL). The vial was capped and heated to 100 0C. After 12 hours, the reaction was allowed to cool to RT and diluted with 20 ml of water. The mixture was extracted (3x) with 10 ml of ethyl acetate. The organic layers were combined and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes. The pure fractions were combined and reduced under vacuum to give an oily residue. The residue was dissolved in DCM (10 mL) and treated with ImL of TFA and a few drops of water. The mixture was allowed to stir at room temperature overnight. 10 ml of 2N ammonia in MeOH was added to the reation with was reduced in vacuo. Th residue was partitioned in water and EtOAc. The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and reduced. The residue obtained was triturated in 1 : 1 ethyl acetate: ether and then dired in a vacuum oven to give product as solid. MS (ESI, pos. ion) m/z: 434.0 (M+l). IC50 (uM) +++++.
SCHEME 6
Figure imgf000089_0001
Figure imgf000090_0001
EXAMPLE 7 : 2-(4-(3 -(2-METHYLP YRIDIN-4- YL)P YPJDIN-2-YLOXY)BENZYL)- 1 H- BENZO[D]IMIDAZOLE
Figure imgf000090_0002
STEP 1. 4-((lH-BENZO[D]IMID AZOL-2-YL)METHYL)PHENOL.
[00356] A mixture of methyl 2-(4-hydroxyphenyl)acetate (40.0 g, 241 mmol) and benzene- 1,2-diamine (26.0 g, 241 mmol) in a sealed vessel was heated to 150 0C for 18 h. After cooling to room temperature, the mixture was diluted with MeOH and heated to 100 C for 1 h. The mixture was cooled to -20 C overnight, then filtered to collect 25.8 g (48%) of a lavender solid. MS (ESI, pos. ion) m/z: 225 (M+ 1).
Figure imgf000090_0003
STEP 2. 2-(4-(3-(2-METHYLPYRIDIN-4-YL)PYRIDIN-2-YLOXY)BENZYL)-l/f- BENZO[D]IMIDAZOLE.
[00357] A mixture of 2-fluoro-3-(2-methylpyridin-4-yl)pyridine (1.00 g, 5.31 mmol), 4- ((l/f-benzo[d]imidazol-2-yl)methyl)phenol (1.43 g, 6.38 mmol) and cesium carbonate (2.60 g, 7.97 mmol) was heated to 80 0C for 16 h. After cooling to room temperature, the mixture was diluted with H2O and extracted with 25% z-PrOH/CHCl3 (3X). The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified using column chromatography (Acetone/Hexanes = 0→80%) to give the title compound. MS (ESI, pos. ion) m/z: 393 (M+l). IC50 (uM) ++++. SCHEME 7
Figure imgf000091_0001
EXAMPLE 8: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3 -(PIPERIDIN- 1-YL)P YRIDIN-2- YLOXY)PHENYL)METHANONE
[00358] A heavy- walled vial was charged with (4-(3 -bromopyridin-2-yloxy)phenyl)( 1 - (tetrahydro-2H-pyran-2-yl)-lH-benzo[d]imidazol-2-yl)methanone (0.150 g, 0.314 mmol), piperidine (0.041 mL, 0.470 mmol), cesium carbonate (0.204 g, 0.627 mmol), (r)-binap (0.020 g, 0.031 mmol), Pd3dba3 (0.014 g, 0.016 mmol) and Toluene (4 mL). Nitrogen was bubbled into the flask for 5 mins. The vial was capped and heated to 80 0C. After 12 hours, the reaction was partitioned with ethyl acetate and water. The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 60 % EtOAc in hexanes to give a clear residue. The residue was dissolved in MeOH (10 mL) and treated with ImL of TFA. The mixture was allowed to stir at room temperature. 10 ml of 2N ammonia in MeOH was added to the reaction with was reduced in vacuo. Th residue was partitioned in water and EtOAc. The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and reduced. The residue obtained was triturated in 1 : 1 ethyl acetate: ether and then dried in a vacuum oven to give product as solid. MS (ESI, pos. ion) m/z: 398.8 (M+l). IC50 (uM) ++++. TABLE IA: EXAMPLES 9 TO 71 ARE TABULATED BELOW:
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0002
TABLE IB: EXAMPLES 9 TO 71 WERE PREPARED AS FOLLOWS:
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
SCHEME 8
Figure imgf000111_0001
EXAMPLE 72. N-(4-(3 -C YCLOPROP YLPYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000111_0002
STEP 1. 4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOL
[00359] The solution of 2-chlorobenzothiazole (2.47 niL, 20 mmol) and 4-aminophenol (2.18 g, 20.0 mmol) in N-methylpyrrolidone (16 mL) was heated at 160 0C for 7 h. The reaction mixture was quenched with aqueous 2N NaOH and then extracted with EtOAc. The organic layer was washed with 2N NaOH. To the combined aqueous layer was added aqueous 5N HCl until pH 6, then the product was extracted with EtOAc (2x), dried (Na2SO4) and concentrated. The crude product was dissolved in MeOH and treated with SiO2. Chromatography through a Redi-Sep® pre-packed silica gel column (120 g), eluting with a gradient of 0% to 50% EtOAc in hexane, provided 4-(benzo[d]thiazol-2-ylamino)phenol as a tan solid.
Figure imgf000111_0003
STEP 2. 3-CYCLOPROPYL-I-FLUOROPYRIDINE
[00360] To a solution of 3-bromo-2-fluoropyridine (1.56 g, 8.86 mmol), cyclopropylboronic acid (990 mg, 11.5 mmol), potassium phosphate (6.59 g, 31.0 mmol) and tricyclohexylphosphine (249 mg, 0.89 mmol) in a mixed solvent of toluene (40 mL) and water (2 mL) under a nitrogen atmosphere was added palladium(ii) acetate (99.5 mg, 0.443 mmol). The reaction mixture was heated at 100 0C for 3 h. The mixture was allowed to cool to RT, filtered through a pad of Celite™ and washed with EtOAc. The crude product was chromatographed through a Redi-Sep® pre-packed silica gel column (120 g), eluting with a gradient of 0% to 10% EtOAc in hexane, to provide 3-cyclopropyl-2-fluoropyridine as light- yellow oil.
Figure imgf000112_0001
STEP 3. N-(4-(3-CYCLOPROPYLPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2- AMINE
[00361] To a solution of 4-(benzo[d]thiazol-2-ylamino)phenol (1.17 g, 4.81 mmol) in DMSO (40 mL) was added cesium carbonate (1.88 g, 5.78 mmol) and 3-cyclopropyl-2- fluoropyridine (660 mg, 4.81 mmol). The resulting mixture was heated to 125 0C for 16 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with water and brine several times to remove DMSO. The aqueous layer was back extracted with EtOAc (3χ) and the combined organic layer was dried (Na2SO4) and concentrated. The crude product was chromatographed through a Redi-Sep® pre-packed silica gel column (120 g), eluting with a gradient of 0% to 30% EtOAc in hexane, to provide N-(4-(3-cyclopropylpyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine as tan solid. MS (ESI, pos. ion) m/z: 360.0 (M+ 1). IC50 (uM) +++++.
Figure imgf000112_0002
- I l l - EXAMPLE 73: 2-(4-(BENZO[D]THIAZOL-I-YLAMINO)PHENOXY)NICOTINIC ACID.
Figure imgf000113_0001
STEP 1. METHYL 2-(4-(BENZO[D]THIAZOL-I-YLAMINO)PHENOXY)NICOTINATE.
[00362] To a solution of 4-(benzo[d]thiazol-2-ylamino)phenol (900 mg, 3.71 mmol) and methyl 2-fluoronicotinate (576 mg, 3.71 mmol) in DMSO (15 mL) was added cesium carbonate (1.45 g, 4.46 mmol). The mixture was heated to 80 0C for 2 h.
[00363] The mixture was cooled to room temperature, diluted with EtOAc and brine, the layers were separated and the aqueous was extracted with EtOAc (3χ). The combined organics were dried over Na2SO4, filtered and concentrated. The crude product was chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with a gradient of 0% to 50% EtOAc in hexane, to provide methyl 2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)nicotinate as white solid. MS (ESI, pos. ion) m/z: 378.0 (M+ 1).
Figure imgf000113_0002
STEP 2. 2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)NICOTINIC ACID
[00364] To a solution of methyl 2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)nicotinate (0.70 g, 1.84 mmol) in a mixed solvent of THF (6 mL) and water (2 mL) was added lithium hydroxide monohydrate (0.39 mg, 9.2 mmol). The reaction mixture was stirred at RT for 16 h. The reaction was quenched with aqueous 2N HCl to pH 5. The precipitate formed was collected by filtration, washed with water, dried to provide 2-(4-(benzo[d]thiazol-2-ylamino)- phenoxy)nicotinic acid as off-white solid. MS (ESI, pos. ion) m/z: 364.0 (M+ 1). IC50 (uM) +.
Figure imgf000113_0003
EXAMPLE 74: 2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)-N- (CYCLOPROPYLMETHYL)NICOTINAMIDE
[00365] To a lOO niL round bottomed flask was added 2-(4-(benzo[d]thiazol-2- ylamino)phenoxy)nicotinic acid (0.3031 g, 0.834 mmol), cyclopropylmethanamine (0.0869 g, 1.22 mmol), and triethylamine (0.347 mL, 2.50 mmol) in N,N-dimethylformamide (3 mL) to stir for 5 min. HATU (0.3955 g, 0.917 mmol) was then added and allowed to stir overnight. The reaction mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The organic extract was washed with water (1x 10 mL), saturated sodium chloride (1 χ 10 mL), saturated sodium bicarbonate (Ix 10 mL), dried with magnesium sulfate, filtered, and concentrated. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Gemini™ column, 5 micron, 150 χ 30 mm, 0.1% trifluoroacetic acid in acetonitrile/water, gradient 10% to 100% over 15 min. The product was taken up in DCM and extracted with saturated sodium bicarbonate to remove TFA salts to provide 2-(4- (benzo[d]thiazol-2-ylamino)phenoxy)-N-(cyclopropylmethyl)nicotinamide as a white powder. MS (ESI, pos. ion) m/z: All (M+l). IC50 (uM)
Figure imgf000114_0001
EXAMPLE 75: N-(4-(3-MORPHOLINOPYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE.
Figure imgf000114_0002
STEP 1. 4-(2-CHLOROPYRIDIN-3-YL)MORPHOLINE.
[00366] To a glass microwave vial was added 3-bromo-2-chloropyridine (0.5489 g, 2.85 mmol), Pd2(dba)3 (0.131 g, 0.143 mmol), xantphos (0.165 g, 0.285 mmol), and sodium tert- butoxide (0.524 mL, 4.28 mmol). The vial was capped and placed under vacuum for 5 minutes. Morpholine (0.248 mL, 2.85 mmol) and toluene (2 mL) were added. The reaction was allowed to stir at 100 0C. Upon completion, the reaction was allowed to cool to room temperature. Solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (25M), eluting with a gradient of 10% to 80% EtOAc in hexane, to provide 4-(2-chloropyridin-3-yl)morpholine. MS: [M+H] = 199.0.
Figure imgf000115_0001
STEP 2. N-(4-(3-MORPHOLINOPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2- AMINE.
[00367] To a round bottomed flask was added 4-(2-chloropyridin-3 -yl)morpholine (0.2076 g, 1.045 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (0.304 g, 1.254 mmol), and cesium carbonate (0.409 g, 1.254 mmol) in DMSO (3.48 mL) at 80 0C for two days. The reaction was allowed to cool to room temperature. The reaction mixture was diluted with a 50% sodium chloride solution and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (25M), eluting with a gradient of 10% to 100% EtOAc in hexane, to provide N-(4-(3- morpholinopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine. MS (ESI, pos. ion) m/z: 405 (M+l). IC50 (uM) +++++.
Figure imgf000115_0002
EXAMPLE 76. N-(4-(3-(4-METHOXYPIPERIDIN-l-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000116_0001
STEP 1. 2-CHLORO-3-(4-METHOXYPIPERIDIN-l-YL)PYRIDINE
[00368] A round-bottomed flask was charged with 3 -bromo-2-chloropyridine (620 mg, 3.22 mmol), 4-methoxy-piperidine (371 mg, 3.22 mmol), tris(dibenzylideneacetone)dipalladium(0) (147 mg, 0.161 mmol), 9,9-dimethyl-4,5- bis(diphenylphosphino)xanthene (186 mg, 0.322 mmol), and sodium tert-butoxide (464 mg, 4.83 mmol) in toluene (6442 μL) , sealed and then sparged with argon for 5 min. The reaction mixture was heated at 1000C with stirring for 2 h. After cooling to RT, the reaction mixture was filtered through a pad of celite and purified by chromatography through a Redi-Sep prepacked silica gel column (40 g), eluting with a gradient of 0% to 40% EtOAc in hexane, to provide 2-chloro-3-(4-methoxypiperidin-l-yl) as orange oil. MS (ESI, pos. ion) m/z: 226.8 (M+l).
Figure imgf000116_0002
STEP 2. N-(4-(3-(4-METHOXYPIPERIDIN-l-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00369] The mixture of 2-chloro-3-(4-methoxypiperidin-l-yl)pyridine (25.0 mg, 0.11 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (32.1 mg, 0.132 mmol), Pd2(dba)3 (5.05 mg, 5.51 μmol), 2,2'-bis(diphenylphosphino)-l,r-binaphthyl (5.15 mg, 8.27 μmol) and sodium 2- methylpropan-2-olate (26.5 mg, 0.276 mmol) in toluene (440 μL) was sparged under argon for 5 min. The mixture was heated to 120 0C in a microwave reactor for 10 min. More phenol (32 mg) was added and the reaction mixture was heated at 120 0C in microwave for another 25 min. After cooling to RT, the mixture was filtered through celite and washed with DCM. The crude product was purified by silica gel chromatography (12 g, 0-50% EtOAc-hexane) to give N-(4-(3-(4-methoxypiperidin- 1 -yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine as off- white solid. MS (ESI, pos. ion) m/z: 433.0 (M+ 1). IC50 (uM) ++H
SCHEME 9
Figure imgf000117_0001
EXAMPLE 77. N-(4-(3-METHYLPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2- AMINE
Figure imgf000117_0002
STEP 1. 4-(3-METHYLPYRIDIN-2-YLOXY)BENZENAMINE
[00370] To a solution of 4-aminophenol (0.87 g, 8.0 mmol) in DMSO (12 mL) was added cesium carbonate (3.1 g, 9.6 mmol) and 2-fluoro-3-picoline (0.89 g, 8.0 mmol). The resulting mixture was heated to 80 0C for 16 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with water and brine several times to remove DMSO. The aqueous layer was back extracted with EtOAc and the combined organic layer was dried (Na2SO4) and concentrated. The crude product was chromatographed through a Redi-Sep® prepacked silica gel column (120 g), eluting with a gradient of 0% to 30% EtOAc in hexane, to provide 4-(3-methylpyridin-2-yloxy)benzenamine as tan solid. MS (ESI, pos. ion) m/z: 201.2 (M+l).
Figure imgf000118_0001
STEP 2. 2-(4-ISOTHIOCYANATOPHENOXY)-S-METHYLPYRIDINE
[00371] In a round bottomed flask were added 4-(3 -methylpyridin-2-yloxy)benzenamine (100 mg, 0.5 mmol), 0,0-dipyridin-2-yl carbonothioate (122 mg, 0.52 mmol) and DCM (2 rnL). The reaction mixture was stirred at RT for 16 h. The reaction was partitioned between DCM and water, brine. The aqueous layer was extracted with DCM and the combined organics was dried (Na2SO4) and concentrated to give 2-(4-isothiocyanatophenoxy)-3-methylpyridine as tan solid. MS (ESI, pos. ion) m/z: 243.1 (M+l).
Figure imgf000118_0002
STEP 3. N-(4-(3-METHYLPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00372] A mixture of 2-(4-isothiocyanatophenoxy)-3 -methylpyridine (136 mg, 0.56 mmol), 2-aminothiophenol (72 μL, 0.67 mmol), and N, N'-dicyclohexylcarbodiimide (174 mg, 0.84 mmol) in THF (5 mL) was heated at 75 0C for 16 h. The solvent was evaporated and the crude product was purified by reverse-phase preparative HPLC using a Phenomenex Gemini™ column (10 micron, C18, 110 A, 150 x 30 mm), 0.1% TFA in CH3CN/H2O as eluent, a gradient 10% to 100% over 14 min., to provide the TFA salt of N-(4-(3-methylpyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine as off-white solid. MS (ESI, pos. ion) m/z: 334.1 (M+l). IC50 (uM) ++++.
Figure imgf000118_0003
EXAMPLE 78. N-(4-(3-METHYLPYRIDIN-2-YLOXY)PHENYL)BENZO[D]OXAZOL-2- AMINE
[00373] The mixture of 2-(4-isothiocyanatophenoxy)-3-methylpyridine (136 mg, 0.56 mmol), 2-aminophenol (74 mg, 0.67 mmol), and N, N'-dicyclohexylcarbodiimide (174 mg, 0.84 mmol) in THF (5 mL) was heated at 75 0C for 16 h. The solvent was evaporated and the crude product was chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with a gradient of 0% to 30% EtOAc in hexane, to provide N-(4-(3-methylpyridin-2- yloxy)phenyl)benzo[d]oxazol-2-amine as white solid. MS (ESI, pos. ion) m/z: 318.1 (M+l).
Figure imgf000119_0001
EXAMPLE 79. N-(4-(3 -(2-METHYLP YRIDIN-4-YL)PYRIDIN-2- YLOXY)PHENYL)- IH- BENZO[D]IMID AZ0L-2-AMINE.
Figure imgf000119_0002
STEP 1. 4-(2-FLUOROPYRIDIN-S-YL)^-METHYLPYRIDINE.
[00374] To a round bottomed flask was added 3-bromo-2-fluoropyridine (1.0376 g, 5.9 mmol), 2-methylpyridin-4-ylboronic acid (1.6154 g, 12 mmol), tris(dibenzylideneacetone)dipalladium(o) (0.5501 g, 0.59 mmol), 2-dicyclohexylphosphino- 2',6'-dimethoxy-l,l'-biphenyl (0.4846 g, 1.2 mmol), and sodium carbonate (0.74 mL, 18 mmol) in acetonitrile: water (5:1 ratio) at 85 0C to stir overnight. The reaction was monitored by LCMS. Upon completion, the solvents were evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage™ pre-packed silica gel column (40S), eluting with a gradient of 0.5% to 5% methanol in DCM, to provide 4-(2-fluoropyridin- 3-yl)-2-methylpyridine. [M+l] = 189.0.
Figure imgf000119_0003
STEP 2. 4-(3-(2-METHYLPYRIDIN-4-YL)PYRIDIN-2-YLOXY)BENZENAMINE.
[00375] To a 25 mL round bottomed flask was added 2-fluoro-3 -(2-methylpyridin-4- yl)pyridine (0.7204 g, 3.828 mmol), 4-aminophenol (0.4254 g, 3.832 mmol), and cesium carbonate (1.6144 g, 4.593 mmol) in dimethyl sulfoxide at 90 0C. Upon completion, the reaction was filtered through Celite™ and the filtrate was condensed. The reaction mixture was diluted with water (50 mL) and extracted with DCM (3 x 20 mL). The organic extract was washed with water (3 x 15 mL), brine (3 x 15 mL), dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage™ pre-packed silica gel column (40M), eluting with a gradient of 1% to 5% methanol in DCM, to provide 4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)benzenamine.
Figure imgf000120_0001
STEP 3. N-(4-(3-(2-METHYLPYRIDIN-4-YL)PYRIDIN-2-YLOXY)PHENYL)-lH- BENZO[D]IMID AZOL-2-AMINE.
[00376] To a l5 mL round bottomed flask was added 4-(3-(2-methylpyridin-4- yl)pyridin-2-yloxy)benzenamine (0.0978 g, 0.35 mmol) and sodium carbonate (0.0823 g, 0.78 mmol) in chloroform. Thiophosgene (0.030 mL, 0.39 mmol) was slowly added and allowed to stir overnight. The solution was filtered and concentrated to give 2-(4-isothiocyanatophenoxy)- 3-(2-methylpyridin-4-yl)pyridine. To the flask was then added 1 ,2-phenylenediamine (0.0470 g, 0.410 mmol), and N,N'-dicyclohexylcarbodiimide (0.1032 g, 0.5200 mmol) in tetrahydrofuran at 75 0C to stir overnight. Upon completion, the solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage™ pre-packed silica gel column (25M), eluting with a gradient of 1% to 5% methanol in DCM, to provide N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine. MS (ESI, pos. ion) m/z: 394.1(M+1). IC50 (uM) ++H
Figure imgf000120_0002
EXAMPLE 80. N-(4-(3 -METH YLP YRIDIN-2- YLOXY)PHENYL)- IH- BENZO[D]IMID AZOL-2-AMINE.
[00377] A mixture of 4-(3 -methy lpyridin-2-yloxy)benzenamine (1.00 g, 4.99 mmol) and 2-chlorobenzimidazole (0.860 g, 5.64 mmol) in 10 mL of iPrOH was heated at 170 0C for 30 min in the microwave. The reaction mixture was evaporated onto silica gel. Purification by flash chromatography (2M NH3 in MeOHiCH2Cl2) afforded N-(4-(3-methylpyridin-2- yloxy)phenyl)-lH-benzo[d]imidazol-2-amine as solid. MS (ESI, pos. ion) m/z: 317.1 (M+l). IC50 (uM) ++++.
Figure imgf000121_0001
EXAMPLE 81. N-(4-(3-MORPHOLINOPYRIDIN-2-YLOXY)PHENYL)-lH-IMIDAZO[4,5- B]PYPJDIN-2-AMINE.
Figure imgf000121_0002
STEP 1. 4-(2-FLUOROPYPJDIN-3-YL)MORPHOLINE .
[00378] A microwave reaction vessel was charged with 2-fluoro-3 -iodopyridine ( 1.0211 g, 4.579 mmol), morpholine (0.3989 mL, 4.579 mmol), Pd2(dba)3 (0.2633 g, 0.2748 mmol), 2- dicyclohexylphosphino-2',6'-dimethoxy-l,r-biphenyl (0.2232 g, 0.5495 mmol), and sodium t- butoxide (1.1363 g, 13.74 mmol) in toluene (15 mL). The reaction mixture was stirred and heated in a Discover® model microwave reactor (CEM, Matthews, NC) at 150 0C for 20 min (125 watts, Powermax™ feature on, ramp time 5 min). The solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage™ prepacked silica gel column (40M), eluting with a gradient of 1% to 5% methanol in DCM, to provide 4-(2-fluoropyridin-3-yl)morpholine.
Figure imgf000121_0003
STEP 2. 4-(3-MORPHOLINOPYRIDIN-2-YLOXY)BENZENAMINE
[00379] To a 25 mL round-bottomed flask were added 4-(2-fluoropyridin-3 - yl)morpholine (0.523 g, 2.87 mmol), 4-aminophenol (0.451 g, 2.88 mmol), cesium carbonate (1.18 g, 3.45 mmol) and DMSO (5 mL). The reaction mixture was heated at 1200C for 8 h. After cooling to room temperature, the reaction mixture was filtered through SCX cartridges, and rinsed with DCM, MeOH, and 2.0 ammonia in MeOH. The ammonia rinses were combined and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40M), eluting with a gradient of 1% to 5% MeOH in CH2Cl2, to provide 4-(3-morpholinopyridin-2- yloxy)benzenamine. MS: [M+l] = 272.1
Figure imgf000122_0001
STEP 3. N-(4-(3-MORPHOLINOPYRIDIN-2-YLOXY)PHENYL)-lH-IMIDAZO[4,5- B]PYRIDIN-2-AMINE
[00380] To a l5 mL round-bottomed flask was added 4-(3-morpholinopyridin-2- yloxy)benzenamine (0.313 g, 1.15 mmol) and SODIUM CARBONATE (0.271 g, 2.54 mmol) in CHCI3. Thiophosgene (0.098 ml, 1.27 mmol) was slowly added and the reaction was allowed to stir at RT for 16 h. The reaction mixture was filtered and the filtrate was concentrated to give the title compound. MS: [M+l] = 314.0. IC50 (uM) ++++.
SCHEME 10
Figure imgf000122_0002
Figure imgf000123_0001
EXAMPLE 82. 2-(4-(1-METHYL-IH-BENZO[D]IMIDAZOL^- YLAMINO)PHENOXY)NICOTINONITRILE
Figure imgf000123_0002
STEP 1. (4-BENZYL0XY-PHENYL)-(l -METHYL-I H-BENZOIMID AZ0L-2-YL)-AMINE
[00381] To a solution of 4-benzyloxy-phenylamine (2 g, 8.4 mmol) in 30 mL of DCM was added triethylamine (1 mL) and di-2-pyridylthionocarbonate (2.5 g, 8.4 mmol). The resulting mixture was stirred at RT for 2 h. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was then dried over Na2SO4, filtered and concentrated. The residue was dissolved in 30 mL DMF, N-methyl-benzene-l,2-diamine (1.5 g, 12.7 mmol) and EDCI (2 g, 10.5 mmol). The resulting mixture was heated at 70 0C for 4 h. The reaction was cooled to RT, diluted with ethyl acetate and washed with water and brine. Purification by silica gel chromatography (98:2 chlorforma/MeOH) afforded the desired product (4-benzyloxy-phenyl)-(l -methyl- lH-benzoimidazol-2-yl)-amine. [M+l] = 330.1
Figure imgf000123_0003
STEP 2. 4-(1-METHYL-IH-BENZOIMIDAZOL^-YLAMINO)-PHENOL
[00382] To a solution of compound (4-benzyloxy-phenyl)-( 1 -methyl- 1 H-benzoimidazol- 2-yl)-amine (1.8 g, 5.4 mmol) in 18 mL of THF and 18 mL of MeOH was added Pd(OH)2 (0.36 g, 20%) and 9 mL of acetic acid. The resulting mixture was kept and kept at 50 psi H2 atmosphere for 3 h. The reaction mixture was then filtered over a cake of Celite™. The filtrate was concentrated and purified by silica gel column chromatography (EtOAc/hexane) to get desired product 4-(l -methyl- lH-benzoimidazol-2-ylamino)-phenol. [M+ 1] = 240
Figure imgf000124_0001
STEP 3. 2-(4-(1-METHYL-IH-BENZO[D]IMIDAZOL^- YLAMINO)PHENOXY)NICOTINONITRILE.
[00383] To a solution of 4-(l-methyl-lH-benzo[d]imidazol-2-ylamino)phenol (120 mg, 0.5 mmol) in DMSO (1 mL) was added cesium carbonate (196 mg, 0.6 mmol) and 2- fluoronicotinonitrile (61 mg, 0.5 mmol). The resulting mixture was heated to 80 0C for 16 h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with water and brine several times to remove DMSO. The aqueous layer was back extracted with EtOAc (3χ) and the combined organic layer was dried (Na2SO4) and concentrated. The crude product was chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with a gradient of 0% to 5% of MeOH in CH2Cl2, followed by trituation with ether, to provide 2-(4- (1 -methyl- lH-benzo[d]imidazol-2-ylamino)phenoxy)nicotinonitrile as off- white solid. MS (ESI, pos. ion) m/z: 342.2 (M+l). IC50 (uM) +++++.
Figure imgf000124_0002
EXAMPLE 83. 1 -METHYL-N-(4-(3 -(MORPHOLINOMETHYL)P YRIDIN-2- YLOXY)PHENYL)-1H-BENZO[D]IMID AZ0L-2-AMINE
Figure imgf000124_0003
STEP 1. 2-(4-(1-METHYL-IH-BENZO[D]IMIDAZOL^-YLAMINO)PHENOXY)NICOTIN- ALDEHYDE
[00384] A solution of 2-chloropyridine-3-carboxaldehyde (3g, 21 mmol), 4-(l-methyl- lH-benzo[d]imidazol-2-ylamino)phenol (5g, 21 mmol), CESIUM CARBONATE (1Og, 32 mmol) in DMSO (60 mL) was heated to 80 0C overnight. Purification by aqueous workup (water, brine) and DCM extraction then Biotage (0-10% DCM/MeOH) produced product which partially solidified.
Figure imgf000125_0001
STEP 2. 1 -METHYL-N-(4-(3-(MORPHOLINOMETHYL)PYRIDIN-2-YLOXY)PHENYL)- 1H-BENZO[D]IMID AZOL-2-AMINE
[00385] To a suspension of 2-(4-(l -methyl- lH-benzo [d]imidazol-2- ylamino)phenoxy)nicotinaldehyde (0.2 g, 0.6 mmol) in DCM (2 mL) was added morpholine (0.05 mL, 0.6 mmol). Sodium triacetoxyborohydride (0.1 g, 0.6 mmol) was added and the resulting mixture was stirred for 3 h at RT. LC/MS showed complete conversion. The reaction mixture was purified by silica gel chromatography (0-10% MeOH/DCM) to afford product 1- methyl-N-(4-(3-(morpholinomethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine as solid. MS (ESI, pos. ion) m/z: 416.1(M+1). IC50 (uM) ++H
SCHEME 11
Figure imgf000126_0001
EXAMPLE 84: N-(4-(3,4'-BIPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2- AMINE.
Figure imgf000126_0002
STEP 1. 4-(3,4'-BIPYRIDIN-2-YLOXY)ANILINE.
[00386] To a 50 niL round-bottomed flask was added 2-chloro-3 -(pyridin-4-yl)pyridine (.75031 g, 3.9 mmol), 4-aminophenol (.4302 g, 3.9 mmol), cesium carbonate (0.38 ml, 4.7 mmol) in DMSO at 80 0C. Upon completion, the reaction was allowed to cool to room temperature. The reaction mixture was diluted with water (10ml) and extracted with DCM (3 15 mL). The organic extract was washed with water (1 1OmL), brine (1 10 mL), dried with magnesium sulfate, filtered and concentrated. The residue was taken up in DCM and was loaded onto a SCX cartridge. The impurities were filtered off with DCM and MeOH. 4-(3,4'- Bipyridin-2-yloxy)aniline was filtered from cartridge using 2.0M ammonia in MeOH (MS 264.0).
Figure imgf000127_0001
STEP 2. N-(4-(3,4'-BIPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE.
[00387] A 25ml round bottomed flask was charged with 4-(3 -(pyridin-4-yl)pyridin-2- yloxy)benzenamine (.1531 g, 0.58 mmol), 2-bromobenzo[d]thiazole (.1874 g, 0.88 mmol), Palladium acetate (.0264 g, 0.12 mmol), 2-(dicyclohexylphosphino)biphenyl (.0878 g, 0.23 mmol), and cesium carbonate (0.077 ml, 0.81 mmol) in toluene/t-BuOH (5/1) at 100 °C overnight. Upon completion, the reaction was allowed to cool to room temperature. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage prepacked silica gel column (25M), eluting with a gradient of 1% to 5% MeOH in DCM. Further purification was performed by reverse-phase preparative HPLC using a Phenomenex Gemini column, 5 micron, 150 X 30 mm, 0.1% TFA in ACN/H2O, gradient 10% to 100% over 15 min. The product peak fractions were collected and organic solvents were removed. The aqueous solution was diluted with water (5 mL) and sodium bicarbonate was added until the pH ~ 10. The solution was extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated to provide N-(4-(3,4'-bipyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine. MS (ESI, pos. ion) m/z: 397.0 (M+l). IC50 (uM)
SCHEME 12
Figure imgf000127_0002
Figure imgf000128_0001
EXAMPLE 85: BENZO[D]THIAZOL-2-YL(4-(3-BROMOPYRIDIN-2- YLOXY)PHENYL)METHANONE
Figure imgf000128_0002
STEP 1. BENZOTHIAZOL-2-YL-[4-(3-BROMO-PYRIDIN-2-YLOXY)-PHENYL]- METHANONE
[00388] In a 250 niL round-bottommed flask was added methyl 4-hydroxybenzoate (6 g, 38.7 mmol) and 100 ml of DMF. 3-Bromo-2-chloro-pyridine (7.43 g, 38.7 mmol) and cesium carbonate (20 g, 76.4 mmol) were added to the mixture and the reaction was stirred at 900C for 6 h. The reaction mixture was diluted with cold water to let the product precipitate out. The solid was collected by filtration and the crude product was purified by silica gel column chromatography with hexane and ethyl acetate to give the title compound.
Figure imgf000128_0003
STEP-2. BENZOTHIAZOL-2-YL-[4-(3-BROMO-PYRIDIN-2-YLOXY)-PHENYL]- METHANONE
[00389] In a 250ml round-bottommed flask were charged benzothiazol-2-yl-[4-(3- bromo-pyridin-2-yloxy)-phenyl]-methanone (4 g, 15.2 mmol), benzothiozole (2.06 g, 15.2 mmol) and 100 mL dry THF. The reaction mixture was cooled to -700C, LDA (2.0 M, 45.6 mL) was added slowly for 5min and the resulting mixture was stirred at -700C for 2 h. The reaction mixture was quenched with IN HCl and extracted to ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulphate and concentrated. The crude product was recrystalized from hexane/ethyl acetate mixture to give the title compound. MS (ESI, pos. ion) m/z: 413 (M+l). IC50 (uM) +.
Figure imgf000129_0001
EXAMPLE 86: BENZO[D]THIAZOL-2-YL(4-(3-(3,6-DIHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)METHANOL.
Figure imgf000129_0002
STEP 1. BENZO[D]THIAZOL-2-YL(4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHANONE.
[00390] To a glass microwave vial was added benzo[d]thiazol-2-yl(4-(3-bromopyridin-2- yloxy)phenyl)methanone (1.0902 g, 2.65 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5- tetramethyl-l,3,2-dioxaborolane (1.114 g, 5.30 mmol), trans-dichlorobis(triphenylphosphine) palladium (II) (0.149 g, 0.212 mmol), and sodium carbonate (0.843 g, 7.95 mmol) in DMF (6.63 mL) and water (2.209 mL). The reaction mixture was stirred and heated in a Biotage Initiator microwave reactor at 120 0C for 20 min. Solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40S), eluting with a gradient of 5% to 50% EtOAc in hexane, to provide benzo[d]thiazol-2-yl(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 414.8 (M+l).
Figure imgf000129_0003
STEP 2. BENZO[D]THIAZOL-2-YL(4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHANOL.
[00391] To a round bottomed flask was added benzo[d]thiazol-2-yl(4-(3-(3,6-dihydro- 2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone (0.6000 g, 1.448 mmol) in THF (4.83 niL). Palladium hydroxide (0.051 g, 0.072 mmol) was added. The round bottomed flask was flushed with N2(g) followed by vacuum repeating the process three times. A balloon of H2(g) was then added to the reaction. Reaction was filtered through celite. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 50% to 100% over 15 min to provide benzo[d]thiazol-2-yl(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanol. MS (ESI, pos. ion) m/z: 416.9 (M+l). IC50 (uM) +++.
SCHEME 13
Figure imgf000130_0001
Y= NH, or CO
Figure imgf000130_0002
EXAMPLE 87: N-(4-(3-(l ,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE.
Figure imgf000130_0003
STEP 1. TERT-BIJTYL 4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN- 3-YL)-S5O-DIHYDROPYRIDINE-I(IH)-CARBOXYLATE.
[00392] To a round-bottommed flask was added N-(4-(3 -bromopyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine (0.5770 g, 1.449 mmol), l-(tert-butoxycarbonyl)- l,2,3,6-tetrahydropyridin-4-ylboronic acid (0.987 g, 4.35 mmol), PdCl2(dppf) (0.080 g, 0.145 mmol), and sodium carbonate (0.768 g, 7.24 mmol) in DME (3.62 mL) and Water (1.207 mL) at 80 0C to stir overnight. Reaction allowed to cool to room temperature. Solvent was removed. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with a gradient of 5% to 80% EtOAc in hexane, to provide tert-butyl 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3- yl)-5,6-dihydropyridine-l(2H)-carboxylate. MS (ESI, pos. ion) m/z: 501.0 (M+l).
Figure imgf000131_0001
STEP 2. N-(4-(3-(l,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE.
[00393] Tert-butyl 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-5, 6- dihydropyridine-l(2H)-carboxylate (501.9mg) was taken up in DCM and TFA was added. Upon completion, the solvent was evaporated. The residue was taken up in DCM and loaded onto an Agilent SCX cartridge. The impurities were washed from the cartridge with DCM and MeOH. N-(4-(3-(l,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine was filtered from cartridge using 2.0M ammonia in MeOH. MS (ESI, pos. ion) m/z: 401.0 (M+l). IC50 (uM) +++++. SCHEME 14
Figure imgf000132_0001
EXAMPLE 88: 1-(4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)PIPERAZIN- 1 -YL)ETHANONE.
Figure imgf000132_0002
STEP 1. 7Εi?r-BUTYL BENZO[D]THIAZOL-2-YL(4-(3-BROMOPYRIDIN-2- YLOXY)PHENYL)CARBAMATE.
[00394] To a round bottomed flask was added N-(4-(3-bromopyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine (4.41 g, 11.06 mmol), di-t-butyl dicarbonate (2.449 g, 11.22 mmol), and dmap (2.095 g, 17.14 mmol) to stir overnight in THF at 500C. Upon completion, the solvent was evaporated. The crude product was taken up in water and extracted with DCM. The organic layer was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated to provide tert-Butyl benzo[d]thiazol-2-yl(4-(3- bromopyridin-2-yloxy)phenyl)carbamate. MS (ESI, pos. ion) m/z: 499.9 (M+l).
Figure imgf000132_0003
STEP 2. 1-(4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)PIPERAZIN- 1 -YL)ETHAN0NE.
[00395] To a round bottomed flask was added tert-butyi benzo[d]thiazol-2-yl(4-(3- bromopyridin-2-yloxy)phenyl)carbamate (0.2713 g, 0.544 mmol), l-(piperazin-l-yl)ethanone (0.140 g, 1.089 mmol), Pd2(dba)3 (0.050 g, 0.054 mmol), binap (0.068 g, 0.109 mmol), and cesium carbonate (0.174 mL, 2.177 mmol) in toluene to stir at 1000C overnight. Reaction was allowed to cool to room temperature. Solvent was evaporated. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 10% to 100% over 15 min to provide tert-butyi 4-(3-(4-acetylpiperazin-l-yl)pyridin-2-yloxy)phenyl(benzo[d]thiazol-2-yl)carbamate (MS 545.6). It was taken up in DCM and TFA was added. After purification the title compound was obtained. MS (ESI, pos. ion) m/z: 446.1 (M+ 1). IC50 (uM) +++++.
SCHEME 15
Figure imgf000133_0001
EXAMPLE 89: N-(4-(3,3'-BIPYRIDIN-2-YLOXY)PHENYL)-N- METHYLBENZO[D]THIAZOL-2-AMINE.
[00396] To a solution of N-(4-(3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine (Example 4 from Table Ia; 0.377 g, 0.950 mmol) in DMF (3.17 mL) was added sodium hydride (0.095 g, 2.375 mmol). The reaction was allowed to stir for 10 minutes. Methyl iodide (0.059 mL, 0.950 mmol) was added and allowed to stir. The reaction mixture was diluted with water to quench and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 10% to 100% over 15 min to provide N-(4- (3,3'-Bipyridin-2-yloxy)phenyl)-N-methylbenzo[d]thiazol-2-amine. MS (ESI, pos. ion) m/z: 410.9 (M+l). IC50 (uM) +++++.
SCHEME 16
Figure imgf000134_0001
R6 = H or Me
Figure imgf000134_0002
EXAMPLE 90: N-(4-(3, 3 '-BIPYRIDIN-2- YLOXY)PHENYL)-1 -METHYL- IH- BENZO[D]IMID AZ0L-2-AMINE.
Figure imgf000134_0003
[00397] STEP 1. N-(4-(3 -BR0M0PYRIDIN-2- YLOXY)PHENYL)-1 -METHYL- IH- BENZO[D]IMID AZ0L-2-AMINE.
[00398] To a round bottomed flask was added 4-(l-methyl-lH-benzo[d]imidazol-2- ylamino)phenol (1.0058 g, 4.20 mmol), 3-bromo-2-chloropyridine (1.213 g, 6.31 mmol), and cesium carbonate (2.74 g, 8.41 mmol) in DMSO (14.01 mL) at 100 0C to stir. Upon completion, reaction was allowed to cool to room temperature. The reaction mixture was diluted with water (10 mL)/Brine (1OmL) and extracted with DCM (3 X 15mL). A precipitate formed during extraction. The solid was filtered to provide N-(4-(3-bromopyridin-2- yloxy)phenyl)- 1 -methyl- 1 H-benzo[d]imidazol-2-amine.
Figure imgf000134_0004
STEP 2. N-(4-(3,3'-BIPYRIDIN-2-YLOXY)PHENYL)-l-METHYL-lH- BENZO[D]IMID AZOL-2-AMINE
[00399] To a microwave vial was added N-(4-(3 -bromopyridin-2-yloxy)phenyl)- 1 - methyl-lH-benzo[d]imidazol-2-amine (0.2082 g, 0.527 mmol), pyridin-3-ylboronic acid (0.194 g, 1.580 mmol), PdCl2(PPh2zPr2)2 (0.020 g, 0.032 mmol), and sodium carbonate (0.279 g, 2.63 mmol) in DME (1.317 mL) and Water (0.439 mL). The reaction mixture was stirred and heated in a Discover® model microwave reactor (CEM, Matthews, NC) at 1000C for 15 min (60 watts, Powermax feature on, ramp time 5 min). The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with a gradient of 1% to 5% MeOH in DCM, to provide N-(4-(3,3'-bipyridin-2- yloxy)phenyl)-l-methyl-lH-benzo[d]imidazol-2-amine. MS (ESI, pos. ion) m/z: 394.0 (M+ 1). IC50 (uM) +++++.
Figure imgf000135_0001
EXAMPLE 91 : N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)-1H-BENZO[D]IMID AZOL-2-AMINE.
Figure imgf000135_0002
STEP 1. N-(4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-YLOXY)PHENYL)-lH- BENZO[D]IMID AZOL-2-AMINE.
[00400] To a round bottomed flask was added N-(4-(3 -bromopyridin-2-yloxy)phenyl)- lH-benzo[d]imidazol-2-amine (0.5674 g, 1.488 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5- tetramethyl-l,3,2-dioxaborolane (0.938 g, 4.47 mmol), PdCl2(PPhtBu2)2 (0.093 g, 0.149 mmol), and potassium acetate (0.698 mL, 11.16 mmol) in ACN (3.72 mL) and water (1.240 mL) at 100 0C to stir. Upon completion, reaction allowed to cool to room temperature. Solvent was evaporated. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 25% to 90% over 20 min to provide N-(4-(3-(3,6-dihydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine. MS (ESI, pos. ion) m/z: 385.0 (M+ 1).
Figure imgf000136_0001
STEP 2. N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-YLOXY)PHENYL)-lH- BENZO[D]IMID AZOL-2-AMINE.
[00401] To a round bottomed flask was added N-(4-(3-(3,6-dihydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine (0.0784 g, 0.204 mmol), palladium, 10% wt. on activated carbon (0.043 g, 0.041 mmol), and acetic acid (0.023 niL, 0.408 mmol) in THF (a few drops of MeOH was added to help solubility). To remove oxygen from the round bottomed flask, the flask was flushed by nitrogen and the placed under vacuum repeatedly. Hydrogen gas was then introduced to the reaction and allowed to stir. Upon completion, the reaction was filtered through celite. The crude product was run through a SCX cartridge. Impurities were removed from column using DCM and MeOH. The product was flushed from the cartridge using 2.0 ammonia in MeOH to provide N-(4-(3-(Tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine. MS (ESI, pos. ion) m/z: 387.0 (M+l). IC50 (uM) +++++.
TABLE IIA: EXAMPLES 92 TO 170 ARE TABULATED BELOW:
Figure imgf000136_0002
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
IC50
Ex# Structure (uM) IUPAC names MS
5-chloro-l -ethyl-N-(4-(3- (trifluoromethyl)pyridin- 2-yloxy)phenyl)- 1 H-
Figure imgf000141_0001
benzo[d]imidazol-2-
118 + amine 433.1
4,6-difluoro-N-(4-(3- (pyrimidin-4-yl)pyridin- 2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-
119 ++++ amine 417
4-fluoro-N-(4-(3- (pyrimidin-4-yl)pyridin- 2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-
120 +++++ amine 398.8
4-fluoro-N-(4-(3-(2- methylpyridin-4- yl)pyridin-2- yloxy)phenyl)- 1 H- benzo[d]imidazol-2-
121 +++++ amine 412.1
4,6-difluoro-N-(4-(3-(2- methylpyridin-4- yl)pyridin-2- yloxy)phenyl)- 1 H- benzo[d]imidazol-2-
122 +++H amine 430
4-fluoro-N-(4-(3- (pyridin-4-yl)pyridin-2- yloxy)phenyl)- 1 H- benzo[d]imidazol-2-
123
Figure imgf000141_0002
+++H amine 398
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
TABLE HB: EXAMPLES 92 TO 170 WERE PREPARED AS FOLLOWS:
Figure imgf000149_0002
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0003
SCHEME 17
Figure imgf000160_0001
EXAMPLE 171 : (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
Figure imgf000160_0002
STEP 1. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(3,6-DIHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00402] A clear 150 ml pressure tube was charged with (lH-benzo[d]imidazol-2-yl)(4- (3-bromopyridin-2-yloxy)phenyl)methanone (1.5 g, 3.80 mmol), 2-(3,6-dihydro-2H-pyran-4- yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (0.959 g, 4.57 mmol), Bis-[4-(di-tert- butylphosphino)-N,N-dimethylbenzenamine]Palladium dichloride (2.69 g, 3.80 mmol), potassium acetate (0.373 g, 3.80 mmol), Dioxane (9 mL) and Water (1.000 mL). The reaction flask was flushed with nitrogen and capped. The reaction was heated to 100 0C for 16 hours. The reaction was then cooled down to RT and partitioned with ethyl acetate (50 ml) and water (50 ml). The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and then filtered. The volatile were reduced to a smaller volume and the solid that precipitated out was filtered off. The cake obtained was suspended in hot MeOH, filtered and dried to give (lH-benzo[d]imidazol-2-yl)(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone as a yellow solid. MS (ESI, pos. ion) m/z: 397.9 (M+l).
Figure imgf000161_0001
STEP 2. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)METHANOL
[00403] A 350 ml heavy-walled vessel was charged with (lH-benzo[d]imidazol-2-yl)(4- (3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone (1.2 g, 3.02 mmol) and ammonium formate (5.71 g, 91 mmol) in THF (20 mL) and MeOH (20.00 mL). The reaction was evacuated 2x and treated with palladium on carbon 10% (0.321 g, 0.302 mmol) under nitrogen. The vessel was capped and the mixture was heated to 70 0C. After 6 hours, the reaction was allowed to cool down to RT and filtered through celite. The filtrate was reduced under vacuum and the resulting residue was partition with DCM and water. The DCM layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 2 to 12 %MEOH in DCM to give (IH- benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanol as a white solid. MS (ESI, pos. ion) m/z: 401.9 (M+ 1).
Figure imgf000162_0001
STEP 3. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
[00404] A suspension of (lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)methanol (0.500 g, 1.245 mmol) in Chloroform (50 mL) and THF (50.0 mL) was treated with manganese dioxide (1.083 g, 12.45 mmol) at RT under nitrogen. The mixture was heated to 50 0C while stirring. After 40 mins, the reaction was filtered while warm through a small pad of celite. The filtrate was reduced and purified by column chromatography on silica gel using a gradient of 0 to 10 % MeOH is DCM. The pure fractions were reduced and the residue was triturated in ethyl ether to give (lH-benzo[d]imidazol-2- yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone as an off- white solid. MS (ESI, pos. ion) m/z: 399.9 (M+l). IC50 (uM) +++++.
Figure imgf000162_0002
EXAMPLE 172: (lH-IMIDAZO[4,5-B]PYRIDIN-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN- 4-YL)PYRIDIN-2-YLOXY)PHENYL)METHANOL.
Figure imgf000163_0001
STEP 1. (4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-YLOXY)PHENYL)(lH- IMIDAZO[4,5-B]PYRIDIN-2-YL)METHANONE.
[00405] To a glass microwave vial was added (4-(3-bromopyridin-2-yloxy)phenyl)(lH- imidazo[4,5-b]pyridin-2-yl)methanone (1.1099 g, 2.81 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane (1.180 g, 5.62 mmol), trans- dichlorobis(triphenylphosphine) palladium (II) (0.158 g, 0.225 mmol), and sodium carbonate (0.893 g, 8.43 mmol) in DMF (7.02 mL) and water (2.340 mL). The reaction mixture was stirred and heated in a Biotage Initiator microwave reactor at 120 0C for 20 min. The reaction mixture was diluted with water and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40M), eluting with a gradient of 1% to 5% MeOH in DCM, to provide (4-(3-(3,6- dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone. MS (ESI, pos. ion) m/z: 398.9 (M+ 1).
Figure imgf000163_0002
STEP 2. (lH-IMIDAZO[4,5-B]PYRIDIN-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)METHANOL.
[00406] To a round bottomed flask was added (4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin- 2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone (0.3642 g, 0.914 mmol) in THF (3.05 mL). Palladium hydroxide (0.032 g, 0.046 mmol) was added. The round bottomed flask was flushed with N2(g) followed by vacuum repeating the process three times. A balloon of H2(g) was then added to the reaction. Upon completion, reaction was filtered. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage prepacked silica gel column (40S), eluting with a gradient of 0.5% to 10% MeOH in DCM, to provide (lH-imidazo[4,5-b]pyridin-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanol. MS (ESI, pos. ion) m/z: 403.0 (M+l).
Figure imgf000164_0001
STEP 3. (lH-IMIDAZO[4,5-B]PYRIDIN-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYPJDIN-2-YLOXY)PHENYL)METHANONE.
[00407] To a round bottomed flask was added (lH-imidazo[4,5-b]pyridin-2-yl)(4-(3- (tetrahydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)methanol (0.992 g, 2.459 mmol) and manganese dioxide (1.069 g, 12.29 mmol) to stir in chloroform (8.20 mL) for 1 hr. Reaction was filtered through celite. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 15O x 30 MM, 0.1% TFA in ACN/H2O, gradient 40% to 80% over 18 min to provide (lH-Imidazo[4,5-b]pyridin-2-yl)(4-(3- (tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 401.9 (M+l). IC50 (uM) +++++.
Figure imgf000164_0002
EXAMPLE 173: 2-(DIFLUORO(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHYL)-1H-BENZO[D]IMIDAZOLE
[00408] A solution of (lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)methanone (0.100 g, 0.250 mmol) was treated with (diethylamino)sulfur trifluoride (DAST) (0.662 mL, 5.01 mmol) at RT. After 6 hours, the reaction was partitioned with water and DCM. The organic layer was washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 20 to 70 % EtOAc in hexanes to give 2-(difluoro(4-(3-(tetrahydro-2H- pyran-4-yl)pyridin-2-yloxy)phenyl)methyl)-lH-benzo[d]imidazole as white solid. MS (ESI, pos. ion) m/z: 421.9 (M+l) . IC50 (uM) +++++.
Figure imgf000165_0001
EXAMPLE 174: (4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)( 1 -METHYL- 1 H-BENZO [D]IMID AZOL-2- YL)METHANONE
[00409] A solution of (lH-benzo[d]imidazol-2-yl)(4-(3-(3,6-dihydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)methanone (0.350 g, 0.881 mmol) in DMF (5 mL) was treated with iodomethane (0.083 mL, 1.321 mmol). The mixture was stirred at RT and afetr 4 hours, it was diluted with water and extracted (2x) with DCM. The organic portions were combined and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate, reduced and purified by column chromatography on silica gel using a gradient of 30 to 80 % EtOAc in hexanes to afford (4-(3 -(3 ,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)( 1 -methyl- 1 H- benzo[d]imidazol-2-yl)methanone as white solid. MS (ESI, pos. ion) m/z: 411.9 (M+l). IC50 (uM) +++++.
Figure imgf000165_0002
EXAMPLE 175: (l-METHYL-lH-BENZO[D]IMIDAZOL-2-YL)(4-(3-(TETRAHYDRO-2H- PYRAN-4-YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00410] A solution of (4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)(l- methyl-lH-benzo[d]imidazol-2-yl)methanone (0.120 g, 0.292 mmol) in THF (10 mL) was evacuated and treated with Pd(OH)2 (20 mg) under nitrogen. The reaction was stirred under a hydrogen atmosphere with a baloon. After 24 hours, the reaction was filtered through a small plug of celite and the filtrate was treated with manganese dioxide (0.254 g, 2.92 mmol). The reaction was stirred at 50 0C for 1 hour and filtered through celite. The filtered was reduced under vacuum. The residue was taken up in DCM and washed (2x) with an aqueous saturated solution of sodium bicarbonate, then with water and then brine. The organic layer was then dried with sodium sulfate and purified by column chromatography on silica gel using a gradient of 30 to 80 % EtOAc in hexanes to give (1 -methyl- lH-benzo [d]imidazol-2-yl)(4-(3 - (tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone as a white solid. MS (ESI, pos. ion) m/z: 414.0. IC50 (uM) +++++.
SCHEME 18
Figure imgf000166_0001
EXAMPLE 176: 1 -(4-METHOXYBENZ YL)-N-(4-(3 -(TETRAH YDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)-lH-BENZO[D]IMIDAZOL-2-AMINE.
Figure imgf000167_0001
STEP 1. 3-(3,6-DIHYDRO-2H-PYRAN-4-YL)-2-FLUOROPYRIDINE.
[00411] To a round bottomed flask was added 3-bromo-2-fluoropyridine (5.2201 g, 29.7 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (7.79 g, 37.1 mmol), trans-dichlorobis(triphenylphosphine) palladium (II) (1.666 g, 2.373 mmol), and sodium carbonate (15.72 g, 148 mmol) in DME (47.5 mL) and Water (11.86 mL) to stir at 80 0C overnight. Reaction was allowed to cool to room temperature. The reaction mixture was diluted with water and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40M), eluting with a gradient of 10% to 100% EtOAc in hexane, to provide 3-(3,6-dihydro- 2H-pyran-4-yl)-2-fluoropyridine. MS (ESI, pos. ion) m/z: 180.1 (M+ 1).
Figure imgf000167_0002
STEP 2. 2-FLUORO-3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDINE.
[00412] To a round bottomed flask was added 3-(3,6-dihydro-2H-pyran-4-yl)-2- fluoropyridine (3.5962 g, 20.07 mmol) and palladium hydroxide on carbon (1.409 g, 2.007 mmol) in EtOAc (66.9 mL). The round bottomed flask was flushed with argon and then placed under vacuum three times. A hydrogen balloon was then attached to the reaction. Upon completion, the reaction was filtered through celite to produce 2-Fluoro-3-(tetrahydro-2H- pyran-4-yl)pyridine. MS (ESI, pos. ion) m/z: 182.1 (M+l).
Figure imgf000168_0001
STEP 3. 4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-YLOXY)ANILINE.
[00413] To a round bottomed flask was added 2-fluoro-3 -(tetrahydro-2H-pyran-4- yl)pyridine (3.4590 g, 19.09 mmol), 4-aminophenol (3.12 g, 28.6 mmol), and cesium carbonate (18.66 g, 57.3 mmol) in DMSO (63.6 mL) at 110 0C to stir overnight. Reaction was allowed to cool to room temperature. The reaction mixture was diluted with water and extracted with DCM. The organic extract was washed 50% sodium chloride solution, dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40M), eluting with a gradient of 1% to 5% MeOH in DCM, to provide 4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)aniline. MS (ESI, pos. ion) m/z: 271.1 (M+ 1).
STEP 4. 2-CHLORO-l-(4-METHOXYBENZYL)-lH-BENZO[D]IMIDAZOLE.
[00414] To a round bottomed flask was added 2-chloro-lH-benzo[d]imidazole (1.000 g, 6.55 mmol), l-(chloromethyl)-4-methoxybenzene (1.540 g, 9.83 mmol), and potassium carbonate (1.359 g, 9.83 mmol) in DMF (21.85 mL) to stir overnight. Reaction was allowed to cool to room temperature. The reaction mixture was diluted with water and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated to provide 2-Chloro-l-(4-methoxybenzyl)-lH-benzo[d]imidazole. MS (ESI, pos. ion) m/z: 273.2 (M+l).
Figure imgf000169_0001
STEP 5. l-(4-METHOXYBENZYL)-N-(4-(3-(TETRAHYDRO-2H-PYRAN-4- YL)PYRIDIN-2-YLOXY)PHENYL)-lH-BENZO[D]IMIDAZOL-2-AMINE.
[00415] A glass microwave reaction vessel was charged with 4-(3 -(tetrahydro-2H-pyran- 4-yl)pyridin-2-yloxy)aniline (0.2573 g, 0.952 mmol) and 2-chloro-l-(4-methoxybenzyl)-lH- benzo[d]imidazole (0.312 g, 1.142 mmol) in IPA. The reaction mixture was stirred and heated in a Biotage Initiator microwave reactor at 1700C for 30 min. Solvent was evaporated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40S), eluting with a gradient of 10% to 80% EtOAc in hexane, to provide 1 -(4-methoxybenzyl)-N-(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine. IC50 (uM) +++++.
Figure imgf000169_0002
EXAMPLE 177: 7-METHOXY-N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)-1H-BENZO[D]IMID AZOL-2-AMINE.
Figure imgf000169_0003
STEP 1. 4-METHOXY-lH-BENZO[D]IMID AZOL-2(3H)-ONE
[00416] To a round bottomed flask was added 2-amino-3-methoxybenzoic acid (2.2705 g, 13.58 mmol), diphenyl phosphorazidate (3.51 mL, 16.30 mmol), and triethylamine (3.79 mL, 27.2 mmol) in THF to stir at 80 0C. Upon completion the reaction was allowed to cool to room temperature. Solvent was evaporated. The residue was taken up in DCM. The reaction mixture was diluted with water and extracted with DCM. A white precipitate was noted to form during extraction The solid was filtered to provide 4-methoxy-lH-benzo[d]imidazol- 2(3H)-one. MS (ESI, pos. ion) m/z: 165.0 (M+l).
Figure imgf000170_0001
STEP 2. 2-CHLORO-7-METHOXY-lH-BENZO[D]IMIDAZOLE
[00417] To a round bottomed flask was added 4-methoxy-lH-benzo[d]imidazol-2(3H)- one (1.8163 g, 11.06 mmol). POCI3 (1.031 mL, 11.06 mmol) was added and the reaction was brought to reflux. Upon completion, POCL3 was evaporated off. The residue was taken up in DCM. The reaction mixture was diluted with water and saturated sodium bicarbonate and extracted with DCM. The organic extract was washed with sat. sodium bicarbonate solution, water, brine, dried with ,magnesium sulfate, filtered, and concentrated to provide 2-Chloro-7- methoxy-lH-benzo[d]imidazole. MS (ESI, pos. ion) m/z: 182.9 (M+l).
Figure imgf000170_0002
STEP 3. 7-METHOXY-N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)-1H-BENZO[D]IMID AZOL-2-AMINE
[00418] A glass microwave reaction vessel was charged with 4-(3 -(tetrahydro-2H-pyran- 4-yl)pyridin-2-yloxy)aniline (0.1130 g, 0.418 mmol) and 2-chloro-7-methoxy-lH- benzo[d]imidazole (0.092 g, 0.502 mmol) in IPA. The reaction mixture was stirred and heated in a Biotage Initiator microwave reactor at 1700C for 30 min. The reaction mixture was diluted with water and extracted with DCM. The organic extract was washed with water, brine, dried with magnesium sulfate, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (40S), eluting with a gradient of 1% to 5% MeOH in DCM, to provide 7-methoxy-N-(4-(3- (tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine. MS (ESI, pos. ion) m/z: All .0 (M+l). IC50 (uM) +++++.
Figure imgf000171_0001
EXAMPLE 178: N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE.
[00419] A glass microwave reaction vessel was charged with 2-fluoro-3-(tetrahydro-2H- pyran-4-yl)pyridine (0.3904 g, 2.154 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (0.783 g, 3.23 mmol), and cesium carbonate (2.106 g, 6.46 mmol) in N-Methyl-2-pyrrolidinone (7.18 mL). The reaction mixture was stirred and heated in a Biotage Initiator microwave reactor at 1800C for 30 min. Reaction was worked up via seperatory funnel. The crude product was purified by reverse-phase preparative HPLC using a Phenomenex Synergi column, 4 micron, MAX-RP, 80 A, 150 x 30 MM, 0.1% TFA in ACN/H2O, gradient 15% to 100% over 15 min. Further purification was pursued by absorbing crude product onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (25M), eluting with a gradient of 5% to 60% EtOAc in hexane, to provide N-(4-(3-(tetrahydro-2H-pyran-4- yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine. MS (ESI, pos. ion) m/z: 404.0 (M+l). IC50 (uM) +++++.
SCHEME 19
Br Br
Cl HCL Cs2CO3 CX.
VNH, ^NH,
Figure imgf000171_0002
EXAMPLE 179: N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]OXAZOL-2-AMINE.
Figure imgf000172_0001
STEP 1. 4-(3-BROMOPYRIDIN-2-YLOXY)BENZENAMINE.
[00420] A mixture of 3-bromo-2-chloropyridine (75.50 g, 392.3 mmol, Aldrich), 4- aminophenol (51.46 g, 471.6 mmol, TCI America) and cesium carbonate (256.80 g, 788.2 mmol, Strem) in DMSO (400 mL) in a IL flask and heated at 80 °C overnight. The reaction was cooled (0 0C) and diluted with water. After stirring for 30 min the mixture was filtered and the solid was partitioned between 50% EtOAc/hexane (1 L) and water (300 mL). The organic layer was washed with water (3x 300 mL) and with brine (Ix 200 mL) then dried over Na2SO4. Filtration and concentration in vacuo gave a brown amorphous solid. MS (ESI, pos. ion) m/z: 264.9, 266.9 (M+l).
Figure imgf000172_0002
STEP 2. N-(4-(3-BROMOPYRIDIN-2-YLOXY)PHENYL)BENZO[D]OXAZOL-2-AMINE
[00421] A mixture of 4-(3 -bromopyridin-2-yloxy)aniline (1.73 g, 6.53 mmol) and 2- chlorobenzoxazole (1.00 g, 6.51 mmol, TCI America) in NMP (3 mL) was sealed in a screw- cap flask and heated at 170 0C for 20 h. The reaction was cooled to rt and partitioned with water/EtOAc. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were evaporated onto silica gel and purified by flash chromatography (Isco (80 gram)) eluting with EtOAc:hexanes (0:1 → 1 :2) a tan amorphous solid. MS (ESI, pos. ion) m/z: 382.0, 383.9 (M+l).
Figure imgf000172_0003
STEP 3. N-(4-(3-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]OXAZOL-2-AMINE
[00422] A glass microwave reaction vessel was charged with N-(4-(3-bromopyridin-2- yloxy)phenyl)benzo[d]oxazol-2-amine (0.500 g, 1.308 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane (0.414 g, 1.971 mmol), sodium carbonate anhydrous (0.700 g, 6.60 mmol) and trans-dichlorobis(triphenyl-phosphine)palladium (II) (0.092 g, 0.131 mmol, Strem). A mixture of 7:3:2 DME:H2θ:EtOH (11 mL) was added and the reaction mixture was sealed under argon and heated in a Emrys Optmizer microwave reactor (Personal Chemistry, Biotage AB, Inc., Upssala, Sweden) at 140 0C for 15 min. The reaction mixture was partitioned between EtOAc/water and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were evaporated onto silica gel and purified by flash chromatography (Isco (80 gram)) eluting with EtOAc:hexanes (0:1 → 1 :2) to give a light-orange amorphous solid. MS (ESI, pos. ion) m/r. 386.0 (M+l). IC50 (uM) +++++.
Figure imgf000173_0001
STEP 4. N-(4-(3-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]OXAZOL-2-AMINE
[00423] A flask containing a mixture of N-(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)benzo[d]oxazol-2-amine (0.277 g, 0.719 mmol) and palladium hydroxide, 20 wt% Pd (dry basis) on carbon, wet (0.505 g, 0.719 mmol) in THF (6 mL) was equipped with a vacuum adapter and evacuated/purged with hydrogen (1 atm). The mixture was continued to stir at rt overnight and the mixture was filtered and concentrated to dryness to give a tan solid. The material was dissolved in DCM and loaded onto an SCX II cartridge eluting with DCM then 2M NH3 in MeOH/DCM (1 :9) to give a tan crystalline solid. MS (ESI, pos. ion) m/z: 388.1 (M+l). IC50 (uM) +++++. SCHEME 20
Figure imgf000174_0001
EXAMPLE 180: N-(4-(3-(4-FLUOROTETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000174_0002
STEP 1 : 4-(2-CHLOROP YRIDIN-3-YL)TETRAHYDRO-2H-PYRAN-4-OL
[00424] To a solution of 3-bromo-2-chloropyridine (0.33 g, 1.715 mmol) in THF (2 mL) at room temperature was added isopropylmagnesium chloride (0.857 mL, 1.715 mmol, 2M solution). Reaction mixture was stirred for lhr at room temperature before addition of dihydro- 2H-pyran-4(3H)-one (0.158 mL, 1.715 mmol). After overnight stirring, reaction mixture was quenched with saturated NH4Cl solution followed by aqueous workup. Purification by Prep- plate TLC (10% MeOH/DCM) produced product that was advanced to the next step.
Figure imgf000174_0003
STEP 2: 2-CHLORO-3-(4-FLUOROTETRAHYDRO-2H-PYRAN-4-YL)PYRIDINE
[00425] To a solution of 4-(2-chloropyridin-3-yl)tetrahydro-2H-pyran-4-ol (0.11 g, 0.515 mmol) in DCM (1 niL, 15.54 mmol) was added dropwise DAST (0.102 niL, 0.772 mmol) at room temperature, followed by one drop of MeOH. The resulting mixture was stirred at room temperature for 3hr. Reaction was quenched with water and extracted with DCM. The recovered residue was advanced to the next step.
Figure imgf000175_0001
STEP 3: N-(4-(3-(4-FLUOROTETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00426] To 2-chloro-3-(4-fluorotetrahydro-2H-pyran-4-yl)pyridine (0.1 Ig, 0.510 mmol) was added to 4-(benzo[d]thiazol-2-ylamino)phenol (0.124 g, 0.510 mmol) with cesium carbonate (0.332 g, 1.020 mmol) in DMSO (1 mL). The resulting mixture was heated to 90 0C overnight. Aqeuous work up and purification by prep-plate TLC (3%MeOH/DCM) produced desired product. MS (ESI, pos. ion) m/z: 422 (M+l). IC50 (uM) +++++.
SCHEME 21
Figure imgf000175_0002
EXAMPLE 181 : 4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)TETRAHYDRO-2H-PYRAN-4-OL
Figure imgf000176_0001
STEP 1 : 4-(2-FLUOROPYRIDIN-3-YL)TETRAHYDRO-2H-PYRAN-4-OL
[00427] To a solution of 3-bromo-2-fluoropyridine (0.93 g, 5.28 mmol) in THF (5 niL) was added dropwise isopropylmagnesium chloride (2.64 rnL, 5.28 mmol, 2M solution) at room temperature. After overnight stirring, dihydro-2H-pyran-4(3H)-one (0.486 mL, 5.28 mmol) was added dropwise. Reaction was quenched with saturated NH4Cl solution and extracted with DCM. Purification by Biotage (0-10%MeOH/DCM) produced the desired product.
Figure imgf000176_0002
STEP 2: 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)TETRAHYDRO-2H-PYRAN-4-OL
[00428] To a solution of 4-(benzo[d]thiazol-2-ylamino)phenol (0.123 g, 0.507 mmol) and 4-(2-fluoropyridin-3-yl)tetrahydro-2H-pyran-4-ol (0.1 g, 0.507 mmol) in DMSO (1 mL) was added cesium carbonate (0.330 g, 1.014 mmol). The resulting mixture was heated to 100 0C and stirred overnight. Aqueous work up with multiple water and brine washes to remove DMSO and extraction with DCM. Purification by Biotage (0-10% MeOH/DCM) produced product. MS (ESI, pos. ion) m/z: 420 (M+l). IC50 (uM) +++++. SCHEME 22
Figure imgf000177_0001
Figure imgf000177_0003
Figure imgf000177_0002
Figure imgf000177_0004
EXAMPLE 182: ( IH-BENZO [D]IMID AZOL-2-YL)(4-(3 -(4-
(DIFLUOROMETHYL)TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-
YLOXY)PHENYL)METHANONE
Figure imgf000177_0005
STEP 1 : 4-(2-FLUOROPYRIDIN-3-YL)TETRAHYDRO-2H-PYRAN-4-CARBALDEHYDE
[00429] Into a sealed tube was added tetrahydro-2H-pyran-4-carbaldehyde (0.25 g, 2.190 mmol), 3-bromo-2-fluoropyridine (0.321 g, 1.825 mmol), palladium(ii) acetate (0.016 g, 0.073 mmol), cesium carbonate (0.714 g, 2.190 mmol), water (1.644 μL, 0.091 mmol), BINAP (0.068 g, 0.110 mmol) in Dioxane (7.30 mL). The resulting mixture was heated to 100 0C overnight. More catalyst and ligand (palladium(ii) acetate (0.016 g, 0.073 mmol), binap (0.068 g, 0.110 mmol)) were added and the resulting mixture was heated to 1130C until the starting material was completely consumed. Aqueous work up followed by DCM extraction. Purification by Biotage (0-100% MeOH/DCM) & prep-plate TLC (5% MeOH/DCM) produced product which was advanced to the next step.
Figure imgf000178_0001
STEP 2: 3-(4-(DIFLUOROMETHYL)TETRAHYDRO-IH-PYRAN^-YL)-I- FLUOROPYRIDINE
[00430] To a solution of 4-(2-fluoropyridin-3 -yl)tetrahydro-2H-pyran-4-carbaldehyde (0.1 g, 0.478 mmol) in DCM (2 niL) at 0 0C was added DAST (0.126 niL, 0.956 mmol). The mixture was gradually warmed to room temperature overnight. Reaction mixture was quenched with saturated bicarbonate solution and extracted with DCM. The recovered residue was advanced to next step.
Figure imgf000178_0002
STEP 3: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(4-
(DIFLUOROMETHYL)TETRAHYDRO-2H-PYRAN-4-YL)PYRIDIN-2-
YLOXY)PHENYL)METHANONE
[00431] To a solution of 3 -(4-(difluoromethyl)tetrahydro-2H-pyran-4-yl)-2- fluoropyridine (0.1 g, 0.432 mmol) in NMP was added cesium carbonate (0.282 g, 0.865 mmol) and(lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.155 g, 0.649 mmol). The resulting mixture was heated to 175 0C overnight. Purification by prep-plate TLC (5% MeOH/DCM & 75% EtOAc/hexane) produced product. MS (ESI, pos. ion) m/z: 450 (M+l). IC50 (uM) +++++. SCHEME 23
Figure imgf000179_0001
EXAMPLE 183 : (IH-BENZO[D]IMID AZOL-2-YL)(4-(3 -(TETRAH YDRO-2H-PYRAN-3- YL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
Figure imgf000179_0002
STEP 1. TETRAHYDRO-2H-PYRAN-3-OL
[00432] To a stirred solution of 3,4-dihydro-2H-pyran (5.42 mL, 59.4 mmol) in TΗF (100 mL) at 0 0C under a nitrogen atmosphere was added borane tetrahydrofuran complex, (29.7 mL, 29.7 mmol, 1.0 M in TΗF) via syringe. The reaction mixture was stirred at 0 0C for 3 h before a mixture of 5 M aqueous sodium hydroxide (40 mL) and 30% aqueous hydrogen peroxide (20 mL) was added. The reaction mixture was warmed to room temperature and stirred for 3 h. Sat. aqueous sodium bicarbonate was added, and the mixture was extracted with EtOAc (2x). The combined organic layers were washed with sat. aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo to give tetrahydro-2H-pyran- 3-ol.
Figure imgf000180_0001
STEP 2. DIHYDRO-2H-PYRAN-3(4H)-ONE
[00433] To a stirred mixture of pyridinium chlorochromate ( 11.02 g, 51.1 mmol) and 3 A molecular sieves (10.0 g) in DCM (100 mL) was added a solution of tetrahydro-2H-pyran-3-ol (3.48 g, 34.1 mmol) in DCM (100 mL). The reaction mixture was refluxed for 3 h before being cooled to room temperature and partially concentrated in vacuo. The mixture was then diluted with EtOAc and filtered through Celite. The filtrate was concentrated in vacuo and purified by silica gel chromatography to give dihydro-2H-pyran-3(4H)-one.
STEP 3. 5,6-DIHYDRO-2/f-PYRAN-3-YL TRIFLUOROMETHANESULFONATE
[00434] To a stirred solution of diisopropylamine (3.06 mL, 21.8 mmol) in THF (50 mL) at -78 0C under an argon atmosphere was added butyllithium (8.73 mL, 21.8 mmol, 2.5 M in hexanes). The mixture was stirred for 5 min before dihydro-2H-pyran-3(4H)-one (1.82 g, 18.2 mmol) in THF (15 mL) was added slowly via syringe. The mixture was stirred for an additional 15 min before n-phenyltrifluoromethanesulfonimide (7.14 g, 20.0 mmol) in THF (15 mL) was added slowly via syringe. The reaction mixture was then stirred at -78 0C for an additional 15 min before being allowed to warm to room temperature and stirred for 1 h. Sat. aqueous sodium bicarbonate was added, and the mixture was extracted with EtOAc (2x). The combined organic layers were washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude oil was purified by silica gel chromatography to give 5,6-dihydro-2H-pyran-3-yl trifluoromethanesulfonate.
Figure imgf000180_0003
STEP 4. 3-(5,6-DIHYDRO-2H-PYRAN-3-YL)-2-FLUOROPYRIDINE
[00435] Sodium carbonate (29.0 rnL, 58.0 mmol, 2.0 M in water) was added via syringe to a stirred mixture of 5,6-dihydro-2H-pyran-3-yl trifluoromethanesulfonate (4.49 g, 19.3 mmol), 2-fluoropyridine-3-boronic acid (2.72 g, 19.3 mmol), and tetrakis(triphenylphosphine)palladium (1.12 g, 0.97 mmol) in DME (82 mL) under an argon atmosphere. The reaction mixture was stirred at 80 0C for 17 h. The reaction mixture was then cooled to room temperature before being diluted with EtOAc and water. The organic layer was separated, washed with sat. aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give 3-(5,6-dihydro-2H-pyran-3-yl)-2-fluoropyridine. MS (ESI, pos. ion) m/z: 180.0.
Figure imgf000181_0001
STEP 5. 2-FLUORO-3-(TETRAHYDRO-2H-PYRAN-3-YL)PYRIDINE
[00436] Palladium (0.005 g, 0.005 mmol, 10% wt. on activated carbon) was added to a stirred solution of 3-(5,6-dihydro-2H-pyran-3-yl)-2-fluoropyridine (0.10 g, 0.558 mmol) in THF (2 mL). The reaction mixture was placed under a hydrogen atmosphere (balloon) and stirred at room temperature for 4 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo to give 2-fluoro-3-(tetrahydro-2H-pyran-3-yl)pyridine. MS (ESI, pos. ion) m/z: 182.1 (M+l).
Figure imgf000181_0002
STEP 6. (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-(TETRAHYDRO-2H-PYRAN-3- YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00437] 2-Fluoro-3-(tetrahydro-2H-pyran-3-yl)pyridine (0.10 g, 0.55 mmol), (IH- benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.33 g, 1.38 mmol), and cesium carbonate (0.54 g, 1.66 mmol) were mixed in NMP (2 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 72 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with 1 M aqueous sodium hydroxide (Ix), sat. sodium chloride (Ix), dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4-(3-(tetrahydro-2H- pyran-3-yl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 400.1 (M+ 1). IC50 (uM) +++++.
Figure imgf000182_0001
EXAMPLE 184: N-(4-(3-(TETRAHYDRO-2H-PYRAN-3-YL)PYPJDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00438] 2-Fluoro-3-(tetrahydro-2/f-pyran-3-yl)pyridine (0.10 g, 0.55 mmol), 4- (benzo[<i]thiazol-2-ylamino)phenol (0.33 g, 1.38 mmol), and cesium carbonate (0.54 g, 1.66 mmol) were mixed in NMP (2 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 120 0C for 16 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give JV-(4-(3-(tetrahydro-2H-pyran-3-yl)pyridin-2- yloxy)phenyl)benzo[J]thiazol-2-amine. MS (ESI, pos. ion) m/z: 404.1 (M+l). IC50 (uM) +++++.
SCHEME 24
Figure imgf000183_0001
EXAMPLE 185: (±)-N-(4-(3-(TETRAHYDRO-2H-PYRAN-2-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00439]
Figure imgf000183_0002
STEP 1. (±)-N-(4-(3-(3,4-DIHYDRO-2H-PYRAN-2-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00440] A 25 niL reseable vial was charged with bis(tri-tert-butylphosphine) palladium (0) (83 mg, 0.163 mmol) and N-(4-(3-bromopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine (650 mg, 1.632 mmol). The vial was sealed and placed under an atmosphere of nitrogen. After addition of dioxane (5.38 ml), N-cyclohexyl-N-methylcyclohexanamine (1.072 ml, 4.90 mmol) and 3,4-dihydro-2H-pyran (549 mg, 6.53 mmol) were added and the mixture was heated to 105 0C. Following complete consumption of the starting material, the reaction mixture was cooled to room temperature and transferred to a 100 mL round bottom flask, and the solvent was removed under reduced pressure. Following purification by silica gel chromatography the desired product was obtained as a racemic mixture. MS (ESI, pos. ion) m/z: 402.0 (M+l).
Figure imgf000184_0001
STEP 2. (±)-N-(4-(3-(TETRAHYDRO-2H-PYRAN-2-YL)PYPJDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00441] A mixture of N-(4-(3-(3,4-dihydro-2H-pyran-2-yl)pyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine (357 mg, 0.889 mmol) and palladium on carbon, wet (95 mg, 0.089 mmol) in ethanol (0.15M) was placed under an atmosphere of hydrogen (g) and stirred at room temperature. After the starting material was completely consumed, the mixture was filtered through a cake of celite, washed with MeOH & THF and filtrate was concentrated to dryness. The residue was purified by silica gel chromatography to give the desired product as a racemic mixture. MS (ESI, pos. ion) m/z: 404.0 (M+l). IC50 (uM) +++++.
SCHEME 25
Figure imgf000184_0002
Figure imgf000185_0001
EXAMPLE 186: ( IH-BENZO [D]IMID AZOL-2-YL)(4-(3-(( lR,4R)-4- HYDROXYCYCLOHEXYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
Figure imgf000185_0002
STEP 1. (lR,4R)-4-(2-FLUOROPYRIDIN-3-YL)CYCLOHEXANOL; (lS,4S)-4-(2- FLUOROPYRIDIN-3-YL)CYCLOHEXANOL
[00442] 4-(2-fluoropyridin-3-yl)cyclohexanone (0.420 g, 2.174 mmol) was dissolved in 20 mL MeOH and cooled to 0 0C. Sodium boron hydrate (0.123 g, 3.26 mmol) was added slowly portion wise and stirring was continued for 7h. The mixture was evaporated and 3 mL of DCM was added to the residue. The mixture was purified and seperated via glass column chromatography (10-100 % EtOAc in hexanes) providing (lR,4R)-4-(2-fluoropyridin-3- yl)cyclohexanol and (lS,4S)-4-(2-fluoropyridin-3-yl)cyclohexanol as white solids.
Figure imgf000185_0003
STEP 2. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((lR,4R)-4-HYDROXYC YCLOHEXYL) PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00443] (lR,4R)-4-(2-fluoropyridin-3-yl)cyclohexanol (75 mg, 0.384 mmol) and (IH- benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (183 mg, 0.768 mmol) were dissoolved in 1 mL NMP and cesium carbonate (250 mg, 0.768 mmol) was added. The reaction was heated to 210 0C for Ih in a sealed reaction vessel. After cooling to room temperature, the mixture was diluted with 1 mL DMF and filtered. The filtrate was injected w/o further work up procedure onto the HPLC for product purification purposes. The collected HPLC fractions were combined and K2CO3 was added (aq. phase pH 9). The mixture was extracted 3 times with EtOAc (3x 100 mL) and the combined organic phases were dried over MgSO4 and evaporated to give (IH- benzo[d]imidazol-2-yl)(4-(3-((lr,4r)-4-hydroxycyclohexyl)pyridin-2-yloxy)phenyl)methanone as a white solid. MS (ESI, pos. ion) m/z: 414.0 (M+ 1). IC50 (uM) +++++.
Figure imgf000186_0001
EXAMPLE 187: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((lS,4S)-4- HYDR0XYCYCL0HEXYL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
[00444] (ls,4s)-4-(2-fluoropyridin-3-yl)cyclohexanol (0.058 g, 0.297 mmol) and (IH- benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.142 g, 0.594 mmol) were dissoolved in 1 ml NMP and cesium carbonate (0.194 g, 0.594 mmol) was added. The reaction was heated to 210 0C for Ih in a sealed reaction vessel. After cooling to room temperature, the mixture was diluted with 1 ml DMF and filtered. The filtrate was injected w/o further work up procedure onto the HPLC for product purification purposes. The collected HPLC fractions were combined and K2CO3 was added (aq. phase pH 9). The mixture was extracted 3 times with EtOAc (3x 100 ml) and the combined organic phases were dried over MgSO4 and evaporated to give (IH- benzo[d]imidazol-2-yl)(4-(3-((lS,4S)-4-hydroxycyclohexyl)pyridin-2-yloxy)phenyl)methanone as a white solid. MS (ESI, pos. ion) m/z: 414.0 (M+l). IC50 (uM) +++++.
SCHEME 26
Figure imgf000187_0001
EXAMPLE 188: 4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCL0HEX-3-EN0L DMS
Figure imgf000187_0002
STEP 1 : 4-(TERT-BUTYLDIMETHYLSILYLOXY)CYCLOHEX-I-ENYL TRIFLUOROMETHANESULFONATE
[00445] To a 500 niL round bottom was added 4-(tert- butyldimethylsilyloxy)cyclohexanone (7.71 g, 33.8 mmol). A IM solution of NaHMDS (35.4 rnL, 35.4 mmol) in THF was added dropwise after cooling the reaction to -20°C. The resulting orange solution was stirred for 1 h before adding trifluoromethanesulfonic anhydride (10 mL, 35.4 mmol) dropwise over 10 minutes. The yellow suspension was allowed to warm to room temperature with stirring over 12 h. It was diluted with saturated aqueous NaHCO3 before extracting with diethyl ether, drying over sodium sulfate, filtering, and drying under reduced pressure to an orange oil, which was purified by column chromatography (ethyl acetate/hexanes), affording 4-(tert-butyldimethylsilyloxy)cyclohex- 1 -enyl trifluoromethanesulfonate as a pale yellow oil. S
Figure imgf000188_0001
STEP 2: 3-(4-(TERT-BUTYLDIMETHYLSILYLOXY)CYCLOHEX-I-ENYL)^- FLUOROPYRIDINE
[00446] To a sealable vessel was added 4-(tert-butyldimethylsilyloxy)cyclohex- 1 -enyl trifluoromethanesulfonate (1.90 g, 5.27 mmol), sodium carbonate as a 2N solution in water (7.91 mL, 15.81 mmol), and 2-fluoropyridin-3-ylboronic acid (0.891 g, 6.33 mmol) before adding tetrakis(triphenylphosphine)palladium(0) (0.305 g, 0.264 mmol) under argon. The reaction mixture was sealed and set stirring at 800C. After complete consumption of starting material, the black mixture was diluted with water before extracting with dichloromethane, drying over sodium sulfate, filtering, and concentrating under reduced pressure to an orange oil, which was used without purification. MS (ESI, pos. ion) m/z: 308.0 (M+l).
Figure imgf000188_0002
STEP 3: 4-(2-FLUOROPYRIDIN-3-YL)CYCLOHEX-3-ENOL
[00447] To a flask containing 3 -(4-(tert-butyldimethylsilyloxy)cyclohex- 1 -enyl)-2- fluoropyridine (1.5 g, 4.88 mmol) was added anhydrous dichloromethane (48.8 mL) under nitrogen. After cooling to 00C, hydrogen fluoride-pyridine complex (1.696 mL, 19.51 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred until the starting material had been consumed. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane before drying over magnesium sulfate, filtering, and concentrating to a clear oil under reduced pressure. The material was used without purification.
Figure imgf000189_0001
STEP 4: 4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCL0HEX-3-EN0L
[00448] To a vial containing cesium carbonate (1391 mg, 4.27 mmol) was added A- (benzo[d]thiazol-2-ylamino)phenol (1035 mg, 4.27 mmol), and 4-(2-fluoropyridin-3- yl)cyclohex-3-enol (330 mg, 1.708 mmol) followed by NMP (2.2 mL). The reaction was heated at 2000C for 2 h with microwave irradiation. The black mixture was diluted with ethyl acetateand washed with 5N NaOH before drying over sodium sulfate, filtering, and concentrating under reduced pressure to a brown residue. Purification by column chromatography (ethyl acetate/dichlormethane) afforded 4-(2-(4-(benzo[d]thiazol-2- ylamino)phenoxy)pyridin-3-yl)cyclohex-3-enol (44.8 mg, 0.108 mmol, 3, steps, 6.31 % yield) as a pale brown oil. MS (ESI, pos. ion) m/z: 416.1 (M+ 1). IC50 (uM) +++++.
Figure imgf000189_0002
EXAMPLE 189: 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)CYCLOHEXANOL
Figure imgf000189_0003
STEP 1 : 4-(2-FLUOROPYRIDIN-3-YL)CYCLOHEXANOL
[00449] To a flask containing 4-(2-fluoropyridin-3-yl)cyclohex-3-enol (750 mg, 3.88 mmol) and Ethanol (31.100 ml):Tetrahydrofuran (7.78 ml) was added 10% palladium on carbon, (240 mg, 2.255 mmol) before purging the reaction of air and backfilling with hydrogen. It was stirred for 3 h at room temperature before adding an additional 30 mol% Pd/C and stirring at 400C for 16 h. The reaction mixture was cooled and filtered through Celite before concentrating under reduced pressure to yield 4-(2-fluoropyridin-3-yl)cyclohexanol as a pale yellow oil that was used without purification. MS (ESI, pos. ion) m/z: 196.1 (M+l).
Figure imgf000190_0001
STEP 2: 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)CYCLOHEXANOL
[00450] To a vial containing 4-(benzo[d]thiazol-2-ylamino)phenol (819 mg, 3.38 mmol) was added cesium carbonate (918 mg, 2.82 mmol) followed by 4-(2-fluoropyridin-3- yl)cyclohexanol (220 mg, 1.127 mmol) as a solution in NMP (7.5 mL). The reaction mixture was heated to 2000C for 2.5 h with microwave irradiation. The reaction mixture was diluted with water and extracted with 15% IPAxhloroform before drying over magnesium sulfate, filtering, and concentrating to a dark brown residue under reduced pressure. [00451] The dark brown residue was adsorbed onto a plug of silica and purified by column chromatography (methanol/dichloromethane) to yield a clear oil that was a mixture of cis and trans compounds. The oil was purified by SFC to yield two compounds. Chirality was arbitrarily assigned. IC50 (uM) ++H SCHEME 27
Figure imgf000191_0001
EXAMPLE 190 : ( 1 H-BENZO [D]IMID AZOL-2- YL)(4-(3 -(( 1 R,4R)-4-HYDROXY-4- METHYLCYCLOHEXYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
Figure imgf000191_0002
STEP 1. l,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL TRIFLUOROMETH ANE SULFONATE
[00452] To a solution of diisopropylamine, (6.24 niL, 44.2 mmol) in THF (60 niL) at -78 0C under argon was slowly added n-butyllithium (17.7 mL, 44.2 mmol, 2.5 M in hexanes). The mixture was stirred for 30 min at that temperature before 1 ,4-cyclohexanedione mono-ethylene ketal (6.00 g, 38.4 mmol) was added slowly as a solution in THF (20 mL). The mixture was stirred for an additional 30 min at -78 0C and then n-phenyltriflimide (13.7 g, 38.4 mmol) was slowly added as a suspension in THF (50 rnL). This mixture was stirred overnight with gradual warming to room temperature. The solvent was removed in vacuo and the remaining oil was partitioned between 3 : 1 ethyl acetate/hexane and water. The layers were separated and the organic layer was washed with water (3x), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give l,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate.
STEP 2. 2-FLUORO-3-(l,4-DIOXASPIRO[4.5]DEC-7-EN-8-YL)PYRIDINE
[00453] To a mixture of l,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate (10.2 g, 35.4 mmol) and 2-fluoropyridin-3-ylboronic acid (5.00 g, 35.5 mmol) in 1,2- dimethoxyethane (200 mL) and aqueous sodium carbonate (53.2 mL, 106 mmol, 2N) under argon atmosphere was added palladium tetrakis(triphenylphosphine) (1.23 g, 1.06 mmol). The mixture was heated and stirred at 85 0C for 1 h., then cooled to room temperature. Ethyl acetate was added and the mixture was washed with water, saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give 2-fluoro-3-(l,4-dioxaspiro[4.5]dec-7-en-8- yl)pyridine. MS (ESI, pos. ion) m/z: 236.1 (M+l).
Figure imgf000192_0002
STEP 3. 2-FLUORO-3-(l,4-DIOXASPIRO[4.5]DECAN-8-YL)PYRIDINE
[00454] To a solution of 2-fluoro-3-(l,4-dioxaspiro[4.5]dec-7-en-8-yl)pyridine (7.99 g, 34.0 mmol) in THF (40 mL) under argon atmosphere was added palladium on carbon (10% activated, 0.80 g). The mixture was placed under 1 atmosphere of hydrogen and stirred for 5 h at 40 0C. After placing the mixture back under argon atmosphere, the mixture was filtered through celite and the filtrate was concentrated in vacuo to give 2-fluoro-3-(l,4- dioxaspiro[4.5]decan-8-yl)pyridine. MS (ESI, pos. ion) m/z: 238.1 (M+ 1).
Figure imgf000193_0001
STEP 4. 4-(2-FLUOROPYRIDIN-3-YL)CYCLOHEXANONE
[00455] To a solution of 2-fluoro-3-(l,4-dioxaspiro[4.5]decan-8-yl)pyridine (7.88 g, 33.2 mmol) in acetone (350 rnL) was added aqueous hydrochloric acid (39.9 mL, 39.9 mmol, IN). The mixture was heated to 45 0C for 5 h, then cooled to room temperature. Most of the organic solvent was removed in vacuo and ethyl acetate (200 mL) was added. The resulting solution was washed with saturated aqueous sodium bicarbonate (2x), water (Ix), saturated aqueous sodium chloride (Ix), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give 4-(2-fluoropyridin-3-yl)cyclohexanone. MS (ESI, pos. ion) m/z: 194.1 (M+l).
Figure imgf000193_0002
STEP 5. (lR,4R)-4-(2-FLUOROPYRIDIN-3-YL)-l-METHYLCYCLOHEXANOL AND (lS,4S)-4-(2-FLUOROPYRIDIN-3-YL)-l-METHYLCYCLOHEXANOL
[00456] A suspension of dry cerium(III) chloride (1.61 g, 6.52 mmol) in THF (15 mL) under argon was stirred at 40 0C for 2 h, then cooled to -78 0C. Methylmagnesium bromide (2.17 mL, 6.52 mmol, 3M in diethyl ether) was added dropwise over 3 minutes and the mixture was stirred an additional 30 minutes at -78 0C. A solution of 4-(2-fluoropyridin-3- yl)cyclohexanone (1.05 g, 5.43 mmol) in THF (3 mL) was added dropwise and the mixture was stirred at -78 0C for 1 h. The reaction was then quenched with saturated aqueous ammonium chloride, warmed to room temperature, and extracted with ethyl acetate several times. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give (lr,4r)-4-(2-Fluoropyridin-3-yl)-l-methylcyclohexanol and (ls,4s)-4-(2-fluoropyridin-3-yl)-l- methylcyclohexanol as pure stereoisomeric compounds. MS (ESI, pos. ion) m/z: 210.1 (M+l) for each compound.
Figure imgf000194_0001
STEP 6. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((lR,4R)-4-HYDROXY-4- METHYLCYCLOHEXYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00457] A mixture of cesium carbonate (0.51 g, 1.56 mmol) , (lH-benzo[d]imidazol-2- yl)(4-hydroxyphenyl)methanone (0.37 g, 1.563 mmol) , and (lr,4r)-4-(2-fluoropyridin-3-yl)-l- methylcyclohexanol (0.11 g, 0.52 mmol) in NMP (2 mL) was heated to 160 0C for 3 d, cooled to room temperature, and partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with IN aqueous sodium hydroxide (2x), water (Ix), saturated aqueous sodium chloride (Ix), dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give (IH- benzo[d]imidazol-2-yl)(4-(3-((lr,4r)-4-hydroxy-4-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 428.1 (M+l). IC50 (uM) ++H
Figure imgf000194_0002
EXAMPLE 191 : (lR,4R)-4-(2-(4-(BENZO[D]THIAZOL-2- YLAMINO)PHENOXY)PYRIDIN-3-YL)-l-METHYLCYCLOHEXANOL
[00458] A mixture of cesium carbonate (0.50 g, 1.52 mmol) ,4-(benzo[d]thiazol-2- ylamino)phenol (0.37 g, 1.52 mmol), and (lr,4r)-4-(2-fluoropyridin-3-yl)-l- methylcyclohexanol (0.11 g, 0.51 mmol) in NMP (1 mL) in a sealed tube was heated to 120 0C for 24 h, cooled to room temperature and partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with IN aqueous sodium hydroxide (2 x), water (1 x), saturated aqueous sodium chloride (Ix), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give (lr,4r)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol. MS (ESI, pos. ion) m/z: 432.1 (M+l). IC50 (uM) +++++.
SCHEME 28
Figure imgf000195_0001
[00459] EXAMPLE 192: (lH-BENZO[D]IMIDAZOL-2-YL)(4-(3-((lS,4S)-4-
HYDROXY-4-(TRIFLUOROMETHYL)CYCLOHEXYL)PYPJDIN-2-
YLOXY)PHENYL)METHANONE
Figure imgf000195_0002
STEP 1. (lS,4S)-4-(2-FLUOROPYRIDIN-3-YL)-l-
(TRIFLUOROMETHYL)CYCLOHEXANOL AND (li?,4i?)-4-(2-FLUOROPYPJDIN-3-YL)- 1 -(TRIFLUOROMETHYL)CYCLOHEXANOL
[00460] To a stirred mixture of 4-(2-fluoropyridin-3-yl)cyclohexanone (1.00 g, 5.18 mmol) and trimethyl(trifluoromethyl)silane (12.4 mL, 6.21 mmol, 0.5 M solution in THF) at 0 0C under a nitrogen atmosphere was added tetrabutylammonium fluoride (0.26 mL, 0.26 mmol, 1.0 M in THF) via syringe. The reaction mixture was brought to room temperature and stirred for 1 h. 10% Aqueous hydrochloric acid was added, and the mixture was stirred for an additional 1.5 h before being extracted with EtOAc. The organic layer was separated, washed with water (Ix), sat. aqueous sodium chloride (Ix), dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel column chromatography to give approximately a 10:1 mixture of (lr,4r)-4-(2-fluoropyridin-3-yl)-l- (trifluoromethyl)cyclohexanol to (ls,4s)-4-(2-fluoropyridin-3-yl)-l-
(trifluoromethyl)cyclohexanol. The isomers were then separated by reverse phase HPLC. The separated isomers were then each individually partitioned between DCM and sat. aqueous sodium bicarbonate. The organic layers were separated, dried over magnesium sulfate, filtered, and concentrated in vacuo to give (ls,4s)-4-(2-fluoropyridin-3-yl)-l- (trifluoromethyl)cyclohexanol and ( 1 r,4r)-4-(2-fluoropyridin-3 -yl)- 1 - (trifluoromethyl)cyclohexanol as separate white solids. [M+ 1] = 264.1 for both isomers.
Figure imgf000196_0001
STEP 2. (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-((lS,4S)-4-HYDROXY-4- (TRIFLUOROMETHYL)CYCLOHEXYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00461] (l5,45)-4-(2-Fluoropyridin-3-yl)-l-(trifluoromethyl)cyclohexanol (0.05 g, 0.19 mmol), (lH-benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.14 mg, 0.57 mmol), and cesium carbonate (0.19 g, 0.57 mmol) were mixed in NMP (0.5 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 72 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (4x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4- (3-((l5,45)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 482.1 (M+l). IC50 (uM) +++++.
Figure imgf000197_0001
EXAMPLE 193: (l/f-BENZO[D]IMIDAZOL-2-YL)(4-(3-((li?,4i?)-4-HYDROXY-4- (TRIFLU0R0METHYL)CYCL0HEXYL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
[00462] (lr,4r)-4-(2-Fluoropyridin-3-yl)-l-(trifiuoromethyl)cyclohexanol (0.10 g, 0.40 mmol), (lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.28 g, 1.19 mmol), and cesium carbonate (0.39 g, 1.19 mmol) were mixed in NMP (1 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 72 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (4x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4- (3-((lr,4r)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 482.1 (M+l). IC50 (uM) +++++.
SCHEME 29
Figure imgf000198_0001
Figure imgf000198_0002
EXAMPLE 194: (lH-BENZO[D]IMIDAZOL-2-YL)(4-(3-((lS,4S)-4-ETHYL-4- HYDR0XYCYCL0HEXYL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
Figure imgf000198_0003
STEP 1. (lS,4S)-l-ETHYL-4-(2-FLUOROPYRIDIN-3-YL)CYCLOHEXANOL AND ( 1 R,4R)- 1 -ETHYL-4-(2-FLUOROP YRIDIN-3 -YL)C YCLOHEXANOL
[00463] A suspension of dry cerium(III) chloride (0.31 g, 1.24 mmol) in THF (3 rnL) was stirred at 40 0C for 2 h under an argon atmosphere. The suspension was cooled to -78 0C, and ethylmagnesium bromide (1.24 mL, 1.24 mmol, 1.0 M in MTBE) was added dropwise via syringe. The reaction mixture was stirred for 30 min before 4-(2-fluoropyridin-3- yl)cyclohexanone (0.20 g, 1.04 mmol) in THF (0.5 mL) was added dropwise via syringe. The reaction mixture was stirred at -78 0C for an additional 1 h before being quenched with sat. ammonium chloride and extracted with EtOAc (2x). The combined organic layers were washed with sat. aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give the separated isomers (lS,45)-l-ethyl-4-(2-fluoropyridin-3-yl)cyclohexanol and (li?,4i?)-l-ethyl-4-(2-fluoropyridin-3-yl)cyclohexanol. [M+ 1] = 224.1 for both isomers.
Figure imgf000199_0001
STEP 2. (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-((lS,4S)-4-ETHYL-4- HYDR0XYCYCL0HEXYL)PYRIDIN-2-YL0XY)PHENYL)METHAN0NE
[00464] (15f,45)-l-Ethyl-4-(2-fluoropyridin-3-yl)cyclohexanol (0.056 g, 0.26 mmol), (lH-benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.19 g, 0.78 mmol), and cesium carbonate (0.25 g, 0.78 mmol) were mixed in NMP (0.75 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 72 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOA. The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4- (3-((15',45)-4-ethyl-4-hydroxycyclohexyl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 442.2 (M+l). IC50 (uM) +++++.
Figure imgf000199_0002
EXAMPLE 195: (lH-BENZO[D]IMIDAZOL-2-YL)(4-(3-((li?,4i?)-4-ETHYL-4- HYDROXYCYCLOHEXYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00465] (li?,4i?)-l-Ethyl-4-(2-fluoropyridin-3-yl)cyclohexanol (0.04 g, 0.16 mmol), (IH- benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.11 g, 0.47 mmol), and cesium carbonate (0.15 mL, 0.47 mmol) were mixed in NMP (0.5 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 72 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (4x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4- (3-((lr,4r)-4-ethyl-4-hydroxycyclohexyl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 442.2 (M+l). IC50 (uM) +++++.
SCHEME 30
Figure imgf000200_0001
EXAMPLE 196: (4-(3 -((4SJS)- 1 -OXASPIRO [3.5 ]NONAN-7-YL)PYPJDIN-2- YLOXY)PHENYL)(IH-BENZO[D]IMID AZ0L-2-YL)METHAN0NE
Figure imgf000200_0002
STEP 1. 2-FLUORO-3-((4S,7S)-l-OXASPIRO[3.5]NONAN-7-YL)PYRIDINE
[00466] A mixture of sodium hydride (0.31 g, 7.76 mmol, 60% dispersion in mineral oil) and trimethylsulfoxonium iodide (1.82 g, 8.28 mmol) was stirred in DMF (10 mL) under an argon atmosphere at room temperature for 1 h. The mixture was heated to 90 0C and then 4-(2- fluoropyridin-3-yl)cyclohexanone (0.50 g, 2.59 mmol) was added. The reaction mixture was stirred at 90 0C for 16 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was separated, washed with sat. aqueous sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give 2-fluoro-3-((45',75)- l-oxaspiro[3.5]nonan-7-yl)pyridine. MS (ESI, pos. ion) m/z: 222.1 (M+l).
Figure imgf000201_0001
STEP 2. (4-(3-((4S,75)-l-OXASPIRO[3.5]NONAN-7-YL)PYRIDIN-2- YLOXY)PHENYL)(IH-BENZO[D]IMID AZOL-2-YL)METHANONE
[00467] 2-Fluoro-3-((4s,7s)-l-oxaspiro[3.5]nonan-7-yl)pyridine (0.070 g, 0.32 mmol), (lH-benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.23 g, 0.95 mmol), and cesium carbonate (0.31 g, 0.95 mmol) were mixed in NMP (1 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 100 0C for 2 h, 120 0C for 2 h, 140 0C for 72 h, and 150 0C for 24 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give (4-(3-((4s,7s)-l-oxaspiro[3.5]nonan-7-yl)pyridin-2-yloxy)phenyl)(lH- benzo[J]imidazol-2-yl)methanone. MS (ESI, pos. ion) m/z: 440.1 (M+l). IC50 (uM) +++++.
Figure imgf000201_0002
EXAMPLE 197: 4-(2-(4-(lH-BENZO[D]IMIDAZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)CYCLOHEXANONE
[00468] 4-(2-Fluoropyridin-3-yl)cyclohexanone (0.05 g, 0.26 mmol), (IH- benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.19 g, 0.78 mmol), and cesium carbonate (0.25 g, 0.78 mmol) were mixed in NMP (1 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 48 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude product was partially purified by silica gel chromatography. The impure product was then dissolved in a minimal amount of DCM, and hexanes were added until a precipitate formed. The resulting suspension was partially concentrated and filtered to give 4-(2-(4-(lH-benzo[<i]imidazole-2- carbonyl)phenoxy)pyridin-3-yl)cyclohexanone. MS (ESI, pos. ion) m/z: 412.1 (M+l). IC50 (uM) +++++.
Figure imgf000202_0001
EXAMPLE 198: 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYPJDIN-3- YL)CYCLOHEXANONE
[00469] 4-(2-Fluoropyridin-3-yl)cyclohexanone (0.05 g, 0.26 mmol), 4-(benzo[d]thiazol- 2-ylamino)phenol (0.19 g, 0.78 mmol) and cesium carbonate (0.25 g, 0.78 mmol) were mixed in NMP (1 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 120 0C for 16 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (4x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give 4-(2-(4-(benzo[<i]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanone. MS (ESI, pos. ion) m/z: 416.1 (M+l). IC50 (uM) +++++. SCHEME 31
Figure imgf000203_0001
EXAMPLE 199: 4-(2-(4-(lH-BENZO[D]IMIDAZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)CYCLOHEPT ANONE
Figure imgf000203_0002
STEP 1. 4-(2-FLUOROP YRIDIN-3 -YL)CYCLOHEPTANONE
[00470] To a solution of boron trifluoride-diethyl etherate (0.64 g, 4.50 mmol) and 4-(2- fluoropyridin-3-yl)cyclohexanone (0.79 g, 4.09 mmol) in DCM (8 mL) at -25 0C under argon was added (trimethylsilyl)diazomethane (2.25 mL, 5.18 mmol, 2.0 M in hexanes). The reaction was stirred for 2 h at that temperature, water was added, and the mixture was extracted with DCM (2x). The combined organic extracts were washed with 10:1 saturated ammonium chloride/ammonium hydroxide mixture (Ix), water (Ix), saturated aqueous sodium chloride (Ix), and dried over anhydrous magnesium sulfate. The mixture was filtered and the filtrate concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give 4- (2-fluoropyridin-3-yl)cycloheptanone. MS (ESI, pos. ion) m/z: 208.1 (M+l).
Figure imgf000204_0001
STEP 2. 4-(2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)CYCLOHEPTANONE
[00471] A mixture of cesium carbonate (0.34 g, 1.03 mmol), (lH-benzo[d]imidazol-2- yl)(4-hydroxyphenyl)methanone (0.25 g, 1.03 mmol), and 4-(2-fluoropyridin-3- yl)cycloheptanone (0.071 g, 0.343 mmol) in NMP (0.3 mL) under argon was heated to 140 0C for 36 h, then cooled to room temperature. The resulting mixture was partitioned between ethyl acetate and water, the layers were separated, and the organic layer was washed IN aqueous sodium hydroxide (2x), saturated aqueous sodium chloride (Ix), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The oil was purified by silica gel chromatography to give 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3- yl)cycloheptanone. MS (ESI, pos. ion) m/z: 426.1 (M+l). IC50 (uM) +++++.
SCHEME 32
Figure imgf000205_0001
EXAMPLE 200: (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-(OXEPAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
Figure imgf000205_0002
STEP 1. 0XEPAN-4-0NE
[00472] To a stirred solution of dihydro-2H-pyran-4(3H)-one (9.23 rnL, 100 mmol) and boron trifluoride diethyl etherate (13.80 rnL, 110 mmol) in DCM (400 mL) at -25 0C was added (trimethylsilyl)diazomethane (54.90 mL, 110 mmol, 2.0 M in hexanes) slowly via syringe. The reaction mixture was stirred at -25 0C for 2.5 h. The reaction mixture was diluted with water and extracted with DCM. The organic layer was separated, washed with 10:1 sat. ammonium chloride: ammonium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give oxepan-4-one.
Figure imgf000206_0001
STEP 2. (£)-2,3,6,7-TETRAHYDROOXEPIN-4-YL TRIFLUOROMETHANESULFONATE AND (£)-2,5,6,7-TETRAHYDROOXEPIN-4-YL TRIFLUOROMETHANESULFONATE
[00473] To a stirred solution of diisopropylamine (1.97 mL, 14.1 mmol) in THF (20 mL) at -78 0C under an argon atmosphere was added n-butyllithium (5.40 mL, 13.50 mmol, 2.5 M in hexanes). The mixture was stirred for approximately 35 min before oxepan-4-one (1.34 g, 11.74 mmol) in THF (7 mL) was added slowly via syringe. The mixture was stirred for an additional 30 min at -78 0C before n-phenyltrifluoromethanesulfonimide (4.19 g, 11.74 mmol) in THF (10 mL) was added slowly via syringe. The reaction mixture was then stirred overnight with gradual warming to room temperature. The mixture was partially concentrated in vacuo and then partitioned between 3 : 1 EtOAc :hexanes and water. The organic layer was separated, washed with water, washed once with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo to yield approximately a 7:3 mixture of (£)-2,3,6,7-tetrahydrooxepin-4- yl trifluoromethanesulfonate:(ii)-2,5,6,7-tetrahydrooxepm-4-yl trifluoromethanesulfonate. The crude material was taken on to the next step without further purification.
Figure imgf000206_0002
STEP 3. (£)-2-FLUORO-3-(2,3,6,7-TETRAHYDROOXEPIN-4-YL)PYRIDINE AND (E)-2- FLUORO-3-(2,5,6,7-TETRAHYDROOXEPIN-4-YL)PYRIDINE
[00474] Sodium carbonate (15.2 mL, 30.3 mmol. 2.0 M in water) was added via syringe to a stirred mixture of an approximately 7:3 mixture of (£)-2,3,6,7-tetrahydrooxepin-4-yl trifluoromethanesulfonate:(ii)-2,5,6,7-tetrahydrooxepin-4-yl trifluoromethanesulfonate (2.49 g, 10.11 mmol), 2-fluoro-3-pyridineboronic acid (1.43 g, 10.11 mmol), and tetrakis(triphenylphosphine)palladium (0.58 g, 0.51 mmol) in 1 ,2-dimethoxyethane (40 mL) under an argon atmosphere. The reaction mixture was stirred at 80 0C for 3 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was separated, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to give approximately a 7:3 mixture of (£)-2-fluoro-3-(2, 3,6,7- tetrahydrooxepin-4-yl)pyridine and (£)-2-fluoro-3-(2,5,6,7-tetrahydrooxepin-4-yl)pyridine. [M+l] = 194.1.
Figure imgf000207_0001
STEP 4. 2-FLUORO-3-(OXEPAN-4-YL)PYRIDINE
[00475] Palladium (0.20 g, 0.0188 mmol, 10% wt. on activated carbon) was added to a stirred solution of an approximately 7:3 mixture of (£)-2-fluoro-3-(2,3,6,7-tetrahydrooxepin-4- yl)pyridine:(E)-2-fluoro-3-(2,5,6,7-tetrahydrooxepin-4-yl)pyridine (0.75 g, 3.88 mmol) in THF (15 mL). The reaction mixture was placed under a hydrogen atmosphere (balloon) and stirred at room temperature for 4.5 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo to give 2-fluoro-3-(oxepan-4-yl)pyridine. [M+l] = 196.1.
Figure imgf000207_0002
STEP 5. (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-(OXEPAN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
[00476] 2-Fluoro-3-(oxepan-4-yl)pyridine (0.10 g, 0.51 mmol), (lH-benzo[J]imidazol-2- yl)(4-hydroxyphenyl)methanone (0.37 g, 1.54 mmol), and cesium carbonate (0.50 g, 1.54 mmol) were mixed in NMP (1.5 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 140 0C for 96 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography (EtOAc/hexanes) to give (lH-benzo[<i]imidazol-2-yl)(4-(3- (oxepan-4-yl)pyridin-2-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 414.1 (M+ 1). IC50 (uM) +++++.
Figure imgf000208_0001
EXAMPLE 201 : N-(4-(3-(OXEPAN-4-YL)PYRIDIN-2- YL0XY)PHENYL)BENZ0[D]THIAZ0L-2-AMINE
[00477] 2-Fluoro-3-(oxepan-4-yl)pyridine (0.055 g, 0.28 mmol), 4-(benzo[J]thiazol-2- ylamino)phenol (0.20 g, 0.85 mmol), and cesium carbonate (0.28 mL, 0.85 mmol) were mixed in NMP (0.75 mL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 120 0C for 17 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with 1 M aqueous sodium hydroxide, washed with sat. sodium chloride, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude product was purified by silica gel chromatography to yield an orange solid. The solid was slurried in MeOH and filtered to give 7V-(4-(3-(oxepan- 4-yl)pyridin-2-yloxy)phenyl)benzo[<i]thiazol-2-amine. MS (ESI, pos. ion) m/z: 418.1 (M+l). IC50 (uM) +++++.
SCHEME 33
Figure imgf000209_0001
Figure imgf000209_0002
Figure imgf000209_0004
Figure imgf000209_0003
EXAMPLE 202: 5-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)AZEPAN-2-ONE
Figure imgf000209_0005
STEP 1. 4-(2-FLUOROP YRIDIN-3 -YL)CYCLOHEXANONE OXIME
[00478] A suspension of aminooxysulfonic acid (0.35 g, 3.11 mmol) in 96% formic acid (2.5 mL) was added dropwise to a solution of 4-(2-fluoropyridin-3-yl)cyclohexanone (0.50 g, 2.59 mmol) in 96% formic acid (2.5 niL) at room temperature. The solution was stirred for 15 min, then warmed to 40 0C for 2 h, then cooled 0 0C. Ethyl acetate (10 mL) was added and the mixture was neutralized by the dropwise addition of 10 N aqueous sodium hydroxide solution (10 mL) followed by saturated aqueous sodium bicarbonate. The resulting biphasic mixture was separated, the aqueous layer was extracted with ethyl acetate (2x), and the combined extracts were dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to give 4-(2-fluoropyridin-3- yl)cyclohexanone oxime. [M+l] = 209.1.
Figure imgf000210_0001
STEP 2. 5-(2-FLUOROPYRIDIN-3-YL)AZEPAN-2-ONE
[00479] Benzenesulfonyl chloride (0.05 mL, 0.40 mmol) was added to a solution of 4-(2- fluoropyridin-3-yl)cyclohexanone oxime (0.075 g, 0.36 mmol) in pyridine (ImL) at 0 0C. The ice bath was removed and the mixture was stirred for 45 min before being heated to 100 0C for 30 minutes. After cooling to room temperaturee the pyridine was removed in vacuo and the residue was dissolved in 1 : 1 dioxane/water (5 mL) and stirred overnight. Ammonium chloride (50 mg) was added and stirring continued for 30 minutes. The mixture was extracted with ethyl acetate (3x), the combined extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by silica gel chromatography to 5-(2- fluoropyridin-3-yl)azepan-2-one. [M+l] = 209.1.
Figure imgf000210_0002
STEP 3. 5-(2-(4-(IH-BENZO[D]IMIDAZOLE^-CARBONYL)PHENOXY)PYRIDIN-S- YL)AZEP AN-2-0NE
[00480] A mixture of cesium carbonate (0.24 g, 0.72 mmol), (lH-benzo[d]imidazol-2- yl)(4-hydroxyphenyl)methanone (0.17 g, 0.72 mmol), and 5-(2-fluoropyridin-3-yl)azepan-2- one (0.050 g, 0.24 mmol) in NMP (0.25 mL) under argon was heated to 140 0C for 36 h. After cooling to room temperature, the mixture was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with water several times, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting oil was purified by reversed phase HPLC, and the resulting oil was dissolved in DCM and washed with saturated aqueous sodium bicarbonate (2x), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin- 3-yl)cycloheptanone. MS (ESI, pos. ion) m/z: All .1 (M+ 1). IC50 (uM) +++++.
Figure imgf000211_0001
EXAMPLE 203: 5-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)- 1 -METHYLAZEPAN-2-ONE
Figure imgf000211_0002
STEP 1. 5-(2-FLUOROPYRIDIN-3-YL)-l-METHYLAZEPAN-2-ONE
[00481] To a solution of 5-(2-fluoropyridin-3-yl)azepan-2-one (0.15 g, 0.72 mmol) in DMF (2.5 mL) under argon was added sodium hydride (0.021 g, 0.86 mmol). The mixture was stirred at room temperature for 15 min before iodomethane (0.054 mL, 0.86 mmol) was added via syringe. This mixture was stirred for 4 h at room temperature before saturated aqueous ammonium chloride was added. The mixture was extracted with ethyl acetate (2x) and the combined extracts were washed with water (3x), saturated aqueous sodium chloride (Ix), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give 5-(2- fluoropyridin-3-yl)-l-methylazepan-2-one. [M+l] = 223.1.
Figure imgf000212_0001
STEP 2. 5-(2-(4-(IH-BENZO[D]IMIDAZOLE^-CARBONYL)PHENOXY)PYRIDIN-S-YL)- 1 -METHYLAZEP AN-2-0NE
[00482] A mixture of cesium carbonate (0.29 g, 0.88 mmol), (lH-benzo[d]imidazol-2- yl)(4-hydroxyphenyl)methanone (0.21 g, 0.878 mmol), and 5-(2-fluoropyridin-3-yl)-l- methylazepan-2-one (0.07 g, 0.29 mmol) in l-methyl-2-pyrrolidinone (0.5 mL) under argon was heated to 140 0C for 48 h, then cooled to room temperature. The resulting mixture was partitioned between ethyl acetate and water, the layers were separated, and the organic layer was washed with IN aqueous sodium hydroxide (2x), saturated aqueous sodium chloride (Ix), dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The oil was purified by silica gel chromatography 5-(2-(4-(lH-benzo[d]imidazole-2- carbonyl)phenoxy)pyridin-3-yl)-l-methylazepan-2-one. MS (ESI, pos. ion) m/z: 441.1 (M+l). IC50 (uM) +++++.
SCHEME 34
Figure imgf000212_0002
Figure imgf000213_0001
STEP 1. 3-(2-FLUOROPYRIDIN-3-YL)CYCLOHEX-2-ENONE
[00483] A solution of 3-bromo-2-fluoropyridine (11 g, 62.5 mmol), 2-cyclohexen-l-one (24.03 g, 250 mmol), N,N-dicyclohexylmethylamine (30.5 g, 156 mmol) and bis(tri-£- butylphosphine)palladium (o) (0.958 g, 1.875 mmol) in dioxane (80 mL) was heated to 105°C for 6 h. The mixture was cooled to RT and the dioxane was evaporated under reduced pressure. Water (200 ml) was added and the mixture layer was extracted with EtOAc (2 x 200 ml). The combined organic layers were washed with brine and dried over sodium sulfate. Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (20% to 50% EtOAc inhexanes) afforded 3-(2-fluoropyridin-3-yl)cyclohex-2-enone as colorless crystals. MS (ESI, pos. ion) m/z: 191.9 (M+ 1).
Figure imgf000213_0002
STEP 2. (RAC)-3-(2-FLUOROPYRIDIN-3-YL)CYCLOHEX-2-ENOL AND (RAC)-C/5-3- (2-FLUOROPYRIDIN-3-YL)CYCLOHEXANOL
[00484] Sodium borohydrate (1.055 g, 27.9 mmol) was added to a solution of 3-(2- fluoropyridin-3-yl)cyclohex-2-enone (4 g, 20.9 mmol) in MeOH (20 ml). The mixture was stirred for 10 min, cooled in ice-water bath, and saturated aqueous ammonium chloride (5 ml) was added. The mixture was diluted with water (100 ml) and extracted with EtOAc (2 x 100 ml). The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The mixture of products was directly used in the next step.
Figure imgf000213_0003
racemic STEP 3. (RAC)-CZ1S-S-(I-FLUOROPYRIDIN-S-YL)CYCLOHEXANOL
[00485] A suspension of the mixture of products from the previous step (1.8 g) and 10 wt.% palladium on carbon (0.20 g, 0.19 mmol) in THF (20ml) was stirred at RT under 50 psi of hydrogen gas for 1 h. The mixture was filtered through a Celite pad that was washed with THF. The combined filtrates and washings were concentrated under reduced pressure to deliver (rac)-cώ-3-(2-fluoropyridin-3-yl)cyclohexanol as an off-white solid. MS (ESI, pos. ion) m/z: 196.1(M+1). IC50 (uM) +++++.
Figure imgf000214_0001
racemic
EXAMPLE 204: (RAC)-OS-3-(2-(4-(BENZO[D]THIAZOL-2- YLAMINO)PHENOXY)PYRIDIN-3-YL)CYCLOHEXANOL
[00486] A mixture of (rac)-cώ-3-(2-fluoropyridin-3-yl)cyclohexanol (60 mg, 0.307 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (149 mg, 0.615 mmol), and potassium carbonate (85 mg, 0.615 mmol) in NMP (2 ml) was heated in a Biotage™ microwave reactor at 150 0C for 0.5 h and at 180 0C for 0.5 h. Additional cesium carbonate (200 mg, 0.615 mmol) was added and the mixture was heated in a Biotage™ microwave reactor at 180 0C two times for 1 h and once for 2 h. The mixture was partitioned between H O (IO ml) and CH Cl (20 ml), the layers were separated, and the aqueous layer was extracted with CH Cl (3 x 20 ml). The combined organic layers were dried (MgSO^, concentrated under reduced pressure, to deliver a brown oil that was purified by reversed phase HPLC (Gilson Gemini-NX 1Ou Cl 8 HOA, 100 x 50.0 mm, 10% to 95% H2O/MeCN, 0.1% TFA). The product containing fractions were combined, neutralized by the addition of solid Na2CO3, and extracted with CH Cl (3 x 20 mL). The combined organic layers were dried (MgSO^ and concentrated under reduced pressure to deliver (rac)-cώ-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3- yl)cyclohexanol as a tan solid. MS (ESI, pos. ion) m/z: 418.0 (M+ 1). IC50 (uM) ++H SCHEME 35
Figure imgf000215_0001
STEP 1 : (RAC)-77^4Λ«-3-(2-FLUOROPYRIDIN-3-YL)CYCLOHEXANOL
[00487] A mixture of 3-(2-fluoropyridin-3-yl)cyclohex-2-enone (1100 mg, 5.75 mmol) and l,r-bis(di-z-propylphosphino)ferrocene(l,5-cyclooctadiene)rhodium (i) tetrafluoroborate (412 mg, 0.575 mmol) in THF (40 mL) was stirred at 45 0C under an atmosphere of hydrogen gas for 5 h. The mixture was filtered through a Celite pad that was washed with THF. Concentration of the combined filtrated and washings under reduced pressure, followed by flash chromatography on silica gel (0% to 50% EtOAc in hexanes) afforded (rac)-trans-3-(2- fluoropyridin-3-yl)cyclohexanol as a colorless oil together with its cώ-isomer. MS (ESI, pos. ion) m/z: 196.1 (M+l). . IC50 (uM) +++++.
Figure imgf000215_0002
EXAMPLE 205. (RAC)-77^4Λ«-3-(2-(4-(BENZO[D]THIAZOL-2- YLAMINO)PHENOXY)PYRIDIN-3-YL)CYCLOHEXANOL
[00488] A mixture of (rac)-trα/?5-3-(2-fluoropyridin-3-yl)cyclohexanol (70 mg, 0.359 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (174 mg, 0.717 mmol), and cesium carbonate (234 mg, 0.717 mmol) in NMP (2.5 ml) was heated in a Biotage™ microwave reactor at 180 0C for 1 h and at 180 0C for 20 min. The mixture was partitioned between H2O (10 ml) and CH2CI2 (20 ml), the layers were separated, and the aqueous layer was extracted with CH2CI2 (3 x 20 ml). The combined organic layers were dried (MgSC^), concentrated under reduced pressure, and the resulting brown oil was purified by reversed phase HPLC (Gilson Gemini-NX 1Ou Cl 8 11OA, 100 x 50.0 mm, 10% to 95% H2O/MeCN, 0.1% TFA). The product containing fractions were combined, neutralized by the addition of solid Na2CC>3, and extracted with CH2CI2 (3 x 20 mL). The combined organic layers were dried (MgSC^) and concentrated under reduced pressure to deliver (rac)-£ra/?s-3-(2-(4-(benzo[d]thiazol-2- ylamino)phenoxy)pyridin-3-yl)cyclohexanol as a tan solid. MS (ESI, pos. ion) m/z: 418.1 (M+l). IC50 (uM) +++++.
SCHEME 36
Figure imgf000216_0001
STEP 1. (RAC)-S-(I-FLUOROPYRIDIN-S-YL)-I-METHYLCYCLOHEX-I-ENOL
[00489] A 3.0 M solution of methylmagnesium chloride in tetrahydrofuran (4.88 rnL, 14.64 mmol) was added slowly to a solution of 3-(2-fluoropyridin-3-yl)cyclohex-2-enone (2.00 g, 10.46 mmol) in THF (20 ml) at -78 0C. After completion of the addition the reaction mixture was stirred overnight while it gradually warmed up to RT. It was cooled in an ice water bath and distilled water (5 ml) was added slowly. The mixture was concentrated under reduced pressure, saturated aqueous sodium bicarbonate (200 ml) was added, and it was extracted EtOAc (3 x 100 ml). The combined organic layers were washed by brine and dried over sodium sulfate. Filtration and concentration under reduced pressure gave (rac)-3-(2- fluoropyridin-3-yl)-l-methylcyclohex-2-enol as a light yellow liquid. MS (ESI, pos. ion) m/z: 208.0 (M+l).
Figure imgf000217_0001
STEP 2: (RAC)-£-3-(2-FLUOROPYRIDIN-3-YL)-l-METHYLCYCLOHEXANOL
[00490] A suspension of (rac)-3-(2-fluoropyridin-3-yl)-l-methylcyclohex-2-enol (1.8 g, 8.7 mmol) and 10 wt.% palladium on carbon (0.277 g, 2.61 mmol) in THF (20 ml) was stirred in a pressure reactor under 50 psi of hydrogen gas for 7 h. The mixture was filtered through a pad of Celite that was washed with THF. Concentration of the combined filtrates and washings under reduced pressure, followed by flash chromatography on silica gel (20% to 50% EtOAc in hexanes) afforded (rac)-£-3-(2-fluoropyridin-3-yl)-l-methylcyclohexanol (530 mg, 2.53 mmol) as a white solid. MS (ESI, pos. ion) m/z: 210.0 (M+l). IC50 (uM) +++++.
Figure imgf000217_0002
racemic
EXAMPLE 206. (RAC)-£-3 -(2-(4-(BENZO [D]THI AZOL-2- YLAMINO)PHENOXY)PYRIDIN-3-YL)-l-METHYLCYCLOHEXANOL
[00491] A mixture of (rac)-£-3 -(2-fluoropyridin-3 -yl)- 1 -methylcyclohexanol (156 mg, 0.745 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (361 mg, 1.491 mmol), and cesium carbonate (486 mg, 1.491 mmol) in NMP (2 ml) was heated in a microwave reactor at 180 0C for 1.5 h. The mixture was partitioned between H2O (10 ml) and CH2Cl2 (20 ml), the layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 20 ml). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure. The resulting brown oil was purified by reversed phase HPLC (Gilson Gemini-NX 1Ou Cl 8 HOA, 100 x 50.0 mm, 10% to 95% H2O/MeCN, 0.1% TFA). The product containing fractions were combined, neutralized by the addition of solid Na2CO3, and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure to deliver (rac)-E-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)- 1 - methylcyclohexanol as a white solid. MS (ESI, pos. ion) m/z: 432.1 (M+ 1). IC50 (uM) +++++.
SCHEME 37
Figure imgf000218_0001
EXAMPLE 207: 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3-YL)- 1 -METHYLPIPERIDIN-2-ONE
Figure imgf000218_0002
STEP 1. 1-METHYL-S5O-DIHYDROPYRIDIN-I(IH)-ONE
[00492] A solution of diisopropylamine (3.02 mL, 21.21 mmol) in tetrahydrofuran (44.2 niL) under argon was cooled to -78 0C and added butyllithium solution, 2.5M in hexanes (8.48 mL, 21.21 mmol). After 5 min, a solution of l-methylpiperidin-2-one (2 g, 17.67 mmol) in tetrahydrofuran (2 mL) was added dropwise. After stirring for 10 min, a solution of phenylselenenyl chloride (4.06 g, 21.21 mmol) in 16 mL of tetrahydrofuran was added, and the reaction was stirred at -78 0C for 2 h. The reaction was quenched with aqueous saturated NH4CI solution and diluted with CH2CI2; the aqueous layer was back-extracted with CH2CI2 (Ix). The combined organic extracts were dried (MgSO^, filtered, and concentrated in vacuo to afford a crude crop of l-methyl-3-(phenylselanyl)piperidin-2-one in dichloromethane. To the crude l-methyl-3-(phenylselanyl)piperidin-2-one in dichloromethane (50 mL) at 0 0C under argon was added 3-chlorobenzoperoxoic acid (7.92 g, 35.3 mmol). The resulting mixture was allowed to gradually warm to room temperature overnight. The orange suspension was filtered, and the filtrate was concentrated in vacuo and partitioned between CH2CI2 and aqueous saturated NaHCOβ solution; the aqueous layer was back-extracted with CH2CI2 (5x). The combined organic extracts were dried (MgSO^, filtered, and concentrated in vacuo. Flash column chromatography (20% EtOAc/Hexanes to 100% EtOAc) afforded l-methyl-5,6- dihydropyridin-2(lH)-one (1.33 g, 67.7 % yield) as a brown oil. [M+l] = 112.2.
Figure imgf000219_0001
STEP 2. 4-(2-FLUOROPYRIDIN-3-YL)-l -METHYL-5,6-DIHYDROPYRIDIN-2( IH)-ONE
[00493] Into a sealed tube were placed 3-bromo-2-fluoropyridine (0.106 g, 0.602 mmol), l-methyl-5,6-dihydropyridin-2(lH)-one (0.134 g, 1.205 mmol), bis(tri-tert- butylphosphine)palladium (0) (0.046 g, 0.090 mmol), N,N-dicyclohexylmethylamine (0.129 mL, 0.663 mmol), and 1,4-dioxane (0.5 mL). After the mixture was degassed for 5 min, the reaction was heated at 100 0C for 3 h. The cooled reaction was concentrated in vacuo, and the brown residue was directly purified via flash column chromatography (20% EtOAc/Hexanes to 100% EtOAc) to give 4-(2-fluoropyridin-3-yl)-l-methyl-5,6-dihydropyridin-2(lH)-one (0.0153 g, 12.32 % yield) as a tan solid. [M+l] = 207.1.
Figure imgf000220_0001
STEP 3. 4-(2-FLUOROPYRIDIN-S-YL)-I-METHYLPIPERIDIN-I-ONE
[00494] A solution of 4-(2-fluoropyridin-3-yl)-l-methyl-5,6-dihydropyridin-2(lH)-one (0.067 g, 0.325 mmol) in tetrahydrofuran (1.6 niL) was added palladium, 10 wt. % on activated carbon (0.035 g, 0.032 mmol) and hydrogenated (double-walled balloon pressure) at 40 0C for 3 h. The mixture was filtered via a pad of Celite, and the filtrate was concentrated in vacuo to give a relatively pure crop of 4-(2-fluoropyridin-3-yl)-l-methylpiperidin-2-one as a milky oil. [M+l] = 209.0. [00495]
Figure imgf000220_0002
STEP 4. 4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S-YL)-I- METHYLPIPERIDIN-2-ONE
[00496] Into a sealed tube were added 4-(2-fluoropyridin-3 -yl)- 1 -methylpiperidin-2-one (0.06 g, 0.288 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (0.223 g, 0.922 mmol), cesium carbonate (0.310 g, 0.951 mmol), and l-methyl-2-pyrrolidinone (1 mL). After degassing for 5 min, the reaction was heated at 120 0C for 14 h. The cooled mixture was diluted with EtOAc and washed with water; the aqueous layer was back- washed with EtOAc (Ix). The combined organic extracts were washed with aqueous IN NaOH solution, dried (MgSO^, filtered, and concentrated in vacuo. Flash column chromatography (20% to 100% EtOAc/Hexanes) afforded 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)- 1 -methylpiperidin-2-one (0.046 g, 37.1 % yield) as a tan amorphous solid. MS (ESI, pos. ion) m/z: 431.9 (M+l). IC50 (uM) ++H
Figure imgf000221_0001
EXAMPLE 208: 4-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)- 1 -METHYLPIPERIDIN-2-ONE
[00497] The title compound was prepared from 4-(2-fluoropyridin-3 -yl)- 1 - methylpiperidin-2-one (Step 3, Example 1) and (lH-benzo[d]imidazol-2-yl)(4- hydroxyphenyl)methanone by following the procedure described in Step 4 of Example 1. MS (ESI, pos. ion) m/z: All A (M+l). IC50 (uM) +++++.
SCHEME 38
Figure imgf000221_0002
EXAMPLE 209. (i?)-4-(2-(4-(l/f-BENZO[D]IMIDAZOLE-2-
CARBONYL)PHENOXY)PYRIDIN-3-YL)-l-METHYLPYRROLIDIN-2-ONE AND (S)-4- (2-(4-(1H-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3-YL)-l- METHYLPYRROLIDIN-2-ONE
Figure imgf000222_0001
STEP 1. (E)-METHYL 3 -(2-FLUOROP YRIDIN-3 -YL)ACRYLATE
[00498] To Pd[P(t-Bu)3]2 (0.210 g, 0.411 mmol) was added dioxane (6 niL), methyl acrylate (2.00 niL, 22.2 mmol), Λ/,Λ/-dicyclohexylmethylamine (3.60 mL, 17.0 mmol), and 3- bromo-2-fluoropyridine (1.02 g, 5.80 mmol). The reaction mixture was degassed and heated to 110 0C for 5 min. The reaction was cooled to room temperature and diluted with EtOAc. The organic phase was washed with water (1 x), brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (10% to 50% EtOAc in hexanes) gave the product which contained Cy2NMe. The Cy2NMe was removed by dissolving the mixture in DCM (5 mL) and diluting with hexanes (10 mL). The solution was concentrated to a volume of 5 mL and the solid precipitate was collected by filtration and dried under high vacuum to give (E)-methyl 3-(2-fluoropyridin-3-yl)acrylate (0.995 g, 5.49 mmol, 95% yield) as a white solid. MS (ΕSI, pos. ion) m/z: 182.1 (M+ 1).
Figure imgf000222_0002
STEP 2. METHYL 3 -(2-FLUOROP YRIDIN-3 -YL)-4-NITROBUTANO ATE
[00499] To (E)-methyl 3-(2-fluoropyridin-3-yl)acrylate (0.945 g, 5.22 mmol) was added nitromethane (10.0 mL, 186 mmol) and 1,1,3,3-tetramethylguanidine (0.120 mL, 0.956 mmol). The reaction mixture was stirred at room temperature for 30 min, heated to 50 0C for 1 h, and diluted with EtOAc and water. The aqueous phase was extracted with EtOAc (2 x) and the combined organic extracts were washed with brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (20% to 60% EtOAc in hexanes) gave methyl 3-(2-fluoropyridin-3-yl)-4-nitrobutanoate (0.996 g, 4.11 mmol, 79% yield) as a colorless oil. MS (ESI, pos. ion) m/z: 243.1 (M+ 1).
Figure imgf000223_0001
STEP 3. 4-(2-FLUOROPYPJDIN-3-YL)PYRROLIDIN-2-ONE
[00500] To a solution of methyl 3-(2-fluoropyridin-3-yl)-4-nitrobutanoate (0.991 g, 4.09 mmol) in EtOH (20 mL) at 0 0C was added nickel chloride (0.532 g, 4.10 mmol) and sodium borohydride (1.60 g, 42.3 mmol). The reaction mixture was stirred at 0 0C for 30 min, warmed to room temperature over 30 min, and stirred at room temperature for 30 min. The reaction mixture was quenched with saturated aqueous KH2PO4 and diluted with water and EtOAc. The mixture was filtered through a pad of Celite. The filtrate was extracted with EtOAc (6 x) and the combined organic extracts were washed with brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (5% to 10% MeOH in DCM) gave 4-(2-fluoropyridin-3-yl)pyrrolidin-2-one (0.168 g, 0.932 mmol, 23% yield) as a colorless oil. MS (ESI, pos. ion) m/z: 181.1 (M+l).
Figure imgf000223_0002
STEP 4. 4-(2-FLUOROPYRIDIN-S-YL)-I-METHYLPYRROLIDIN^-ONE
[00501] To a solution of 4-(2-fluoropyridin-3-yl)pyrrolidin-2-one (0.254 g, 1.41 mmol) in DMF (5 mL) at 0 0C was added iodomethane (0.090 mL, 1.4 mmol) and sodium hydride (60% weight dispersion in mineral oil, 0.056 g, 1.4 mmol). The reaction mixture was stirred at 0 0C for 30 min, warmed to room temperature, and stirred for 30 min. The reaction mixture was diluted with EtOAc, quenched with water, and diluted with brine and water. The aqueous phase was extracted with EtOAc (6 x) and the combined organic extracts were washed with brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (50% to 100% EtOAc (10% MeOH) in hexanes) gave 4-(2-fluoropyridin-3-yl)-l- methylpyrrolidin-2-one (0.226 g, 1.16 mmol, 83% yield) as a pale yellow oil. MS (ESI, pos. ion) m/z: 195.1 (M+ 1).
Figure imgf000224_0001
STEP 5. (i?)-4-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)-l-METHYLPYRROLIDIN-2-ONE AND (5)-4-(2-(4-(l/f-BENZO[D]IMIDAZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)- 1 -METHYLPYRROLIDIN-2-ONE
[00502] To a mixture of cesium carbonate (563 mg, 1.73 mmol), (lH-benzo[d]imidazol- 2-yl)(4-hydroxyphenyl)methanone (0.381 g, 1.60 mmol), and 4-(2-fluoropyridin-3-yl)-l- methylpyrrolidin-2-one (0.131 g, 0.675 mmol) was added NMP (2 mL). The reaction mixture was degassed and heated to 140 0C for H h. The mixture was cooled to room temperature and diluted with EtOAc and water. The aqueous phase was extracted with EtOAc (4 x) and the combined organic extracts were washed with brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (20% to 60% EtOAc in hexanes) gave 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l- methylpyrrolidin-2-one (0.169 g, 0.410 mmol, 61% yield) as an off- white solid. MS m/z: 413.1 (M+ 1). The mixture of enantiomers was separated by preparatory SFC (Chiralcel OJH (21 x 250 mm), 25% EtOH/0.2% diethylamine) to afford the individual enantiomers (R)-4-(2-(4-(lH- benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)- 1 -methylpyrrolidin-2-one and (S)-4-(2- (4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)- 1 -methylpyrrolidin-2-one. MS (ESI, pos. ion) m/z: 413.1 (M+l). IC50 (uM) +++++.
Figure imgf000224_0002
EXAMPLE 210. 4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3-YL)- 1 -METHYLPYRROLIDIN-2-ONE
[00503] To a mixture of cesium carbonate (0.625 g, 1.92 mmol), 4-(benzo[d]thiazol-2- ylamino)phenol (0.445 g, 1.84 mmol), and 4-(2-fluoropyridin-3-yl)-l -methylpyrrolidin-2-one (0.111 g, 0.572 mmol) was added NMP (2 niL). The reaction mixture was degassed and heated to 100 0C for 30 min, heated to 120 0C for 3.5 h, and diluted with EtOAc and water. The aqueous phase was extracted with EtOAc (3 x), and the combined organic extracts were washed with 1 M NaOH (1 x), brine (1 x), dried over MgSO4, filtered, and concentrated. Purification by flash column chromatography on silica gel (20% to 80% EtOAc (10% MeOH) in hexanes) gave 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l-methylpyrrolidin-2-one (0.174 g, 0.418 mmol, 73% yield) as a white solid and a 1 : 1 mixture of enantiomers. MS (ESI, pos. ion) m/z: 417.1 (M+l). . IC50 (uM) +++++.
SCHEME 39
Figure imgf000225_0001
EXAMPLE 211 : 1 -(4-(2-(4-(I H-BENZO [D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN- 1 -YL)ETHANONE
VNC^oτf STEP 1. 1 -ACETYL-1, 2,3, 6-TETRAHYDROPYRIDIN-4-YL TRIFLUOROMETHANESULFONATE.
[00504] Diisopropylamine (18.0 niL, 128 mmol) was taken up in 50 mL of THF and chilled to -78 0C. Butyllithium, 2.5 M in hexanes (51.0 mL, 128 mmol) was added dropwise. After 10 min, l-acetylpiperidin-4-one (15.O g, 106 mmol) was added in 60 mL of THF with rigorous stirring. After 30 min, n-phenyltriflimide (41.8 g, 117 mmol) was added in 120 mL of THF. The reaction mixture was stirred at -78 0C to RT for 16 h. The reaction mixture was quenched by saturated NaHCOs, followed by extraction with EtOAc and 5% citric acid. The organic layer was washed with 1 N NaOH (2x), water (2x), and brine, then dried over MgSO4. Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (0% to 60% EtOAc/hexanes) afforded 1 -acetyl- 1, 2,3, 6-tetrahydropyridin-4-yl trifluoromethanesulfonate as a yellow oil.
Figure imgf000226_0001
STEP 2. l-(4-(4,4,5,5-TETRAMETHYL-l,3,2-DIOXABOROLAN-2-YL)-5,6- DIHYDROPYRIDIN- 1 (2H)-YL)ETHANONE.
[00505] 1 -acetyl- 1,2, 3, 6-tetrahydropyridin-4-yl trifluoromethanesulfonate (6.77 g, 24.8 mmol), bis(pinacolato)diboron (6.92 g, 27.3 mmol), potassium acetate (2.93 g, 49.6 mmol), and l,r-bis(diphenylphosphino)ferrocene]dichloride palladium(ii)complex with dichloramethane (1.01 g, 1.24 mmol) were taken up in dioxane (83 mL). The mixture was purged with nitrogen and then was heated to 80 0C. After 16 h, the reaction mixture was cooled to RT, and was diluted with 150 mL of EtOAc and washed with 50 mL of water and 50 mL of brine, then dried over MgSO4. Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (0% to 90% EtOAc/hexanes) afforded l-(4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-l(2H)-yl)ethanone as an orange oil.
Figure imgf000226_0002
STEP 3. 1-(4-(2-(4-(IH-BENZO[D]IMIDAZOLE^-CARBONYL)PHENOXY)PYRIDIN-S- YL)-5,6-DIHYDROP YRIDIN-I (2H)-YL)ETHAN0NE.
[00506] (1 H-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2-yloxy)phenyl)methanone (0.895 g, 2.270 mmol), l-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin- l(2H)-yl)ethanone (0.60 g, 2.39 mmol), potassium acetate (1.06 g, 17.9 mmol), and palladium catalyst (0.13 g, 0.18 mmol) were taken up in 24 mL of 3 : 1 MeCN: water. The mixture was purged with nitrogen and heated to 90 0C for 15 h. The reaction mixture was diluted with water and extracted with EtOAc (3χ). The organics were washed with 30 mL of brine and dried over MgSO4. Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel [10 to 100% EtOAc(contains 5% MeOH)/hexane] afforded l-(4- (2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-5,6-dihydropyridin-l(2H)- yl)ethanone as a yellow solid.
Figure imgf000227_0001
STEP 4. l-(4-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)PIPERIDIN- 1 -YL)ETHANONE.
[00507] l-(4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-5,6- dihydropyridin-l(2H)-yl)ethanone (0.42 g, 0.96 mmol), acetic acid, glacial (0.11 mL, 1.92 mmol) and palladium on carbon, 10% (0.20 g, 0.19 mmol) were suspended in tetrahydrofuran (10 mL) in a pressure reactor. The mixture was hydrogenated at 50 psi for 16 h. The catalyst was filtered off and washed with THF. To the solution was added palladium on carbon, 10% (0.204 g, 0.192 mmol) and acetic acid, glacial (0.111 mL, 1.916 mmol) and the mixture was hydrogenated at 50 psi for another 24 h. The mixture was filtered through celite and washed with THF. The solvent was removed under reduced pressure and the residue was partitioned between DCM and saturated NaHCO3. The organic layer was dried and concentrated to give 1- (4-(2-(4-(( 1 H-benzo [d]imidazol-2-yl)(hydroxy)methyl)phenoxy)pyridin-3 -yl)piperidin- 1 - yl)ethanone as off-white solid.
[00508] The material (0.24 g, 0.54 mmol) was taken up in DCM (5.4 mL). Sodium bicarbonate (0.33 g, 5.4 mmol) was added, followed by dess-martin periodinane (0.35 g, 0.81 mmol). After 20 min, the reaction was quenched with 5 mL of aq. Na2S2O3 and 5 rnL of aq. NaHCO3. The mixture was diluted with 5 mL of water and stirred for 15 min. The aqueous layer was extracted with 9:1 CHCI3/IPA (3χ). The combined organics were dried (Na2SO4) and concentrated. The crude material was chromatographed through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 10% to 100% EtOAc in hexane, then 5% MeOH in EtOAc, to provide l-(4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3- yl)piperidin-l-yl)ethanone as light-yellow solid. MS (ESI, pos. ion) m/z: 441.0 (M+ 1). IC50 (uM) +++++.
Figure imgf000228_0001
EXAMPLE 212: 1-(4-(2-(4-(BENZO [D]THI AZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)-5 ,6-DIHYDROP YRIDIN- 1 (2H)-YL)ETHAN0NE
[00509] Same procedure as step 3 of example 2 using 4-(benzo[d]thiazol-2- ylamino)phenol to produce desired product. MS (ESI, pos. ion) m/z: 443.0 (M+l). IC50 (uM)
+++++.
SCHEME 40
Figure imgf000228_0002
EXAMPLE 213: 1 -(4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)PIPERIDIN- 1 -YL)ETHANONE
Figure imgf000229_0001
[00510] STEP 1. l-(4-(2-FLUOROPYRIDIN-3-YL)-5,6-DIHYDROPYRIDIN-l(2H)- YL)ETHANONE. TO a round-bottomed flask was added 3-bromo-2-fluoropyridine (0.54 g, 3.1 mmol), 1 -(4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)-5 ,6-dihydropyridin- 1 (2H)- yl)ethanone (0.96 g, 3.8 mmol), trans-dichlorobis(triphenylphosphine) palladium (II) (0.17 g, 0.25 mmol), and sodium carbonate (0.97 g, 9.2 mmol) in DME (7.5 mL) and Water (2.5 mL). The reaction mixture was stirred at 1000C for 16 h. After cooling to RT, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 x 50 mL). The organic extract was washed with water, brine, dried with Na2SO4, filtered, and concentrated. The crude product was chromatographed through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 10% to 100% EtOAc in hexane, to provide l-(4-(2-fluoropyridin-3-yl)-5,6- dihydropyridin-l(2H)-yl)ethanone (0.14 g, 21 % yield) as a yellow oil. MS (ESI, pos. ion) m/z: 221.0 (M+l).
Figure imgf000229_0002
STEP 2. l-(4-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)PIPERIDIN- 1 -YL)ETHANONE.
[00511] l-(4-(2-fluoropyridin-3-yl)-5,6-dihydropyridin-l(2H)-yl)ethanone (0.14 g, 0.65 mmol), palladium hydroxide, 20 wt % pd (dry basis) on carbon, wet, degussa type elOl ne/w (91 mg, 0.13 mmol) and acetic acid, glacial (19 uL, 0.32 mmol) were suspended in THF (13 mL) in a pressure tube. The reaction mixture was hydrogenated at 50 psi for 5 h then filtered through a pad of celite and washed with THF. The filtrate was concentrated to give l-(4-(2- fluoropyridin-3-yl)piperidin-l-yl)ethanone as clear oil.
Figure imgf000230_0001
STEP 3. 1 -(4-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)PIPERIDIN- 1 -YL)ETHAN0NE
[00512] To 4-(benzo[d]thiazol-2-ylamino)phenol (0.327 g, 1.35 mmol) dissolved in N- Methyl-2-pyrrolidinone (3 mL) was added sodium hydride, 60% dispersion in mineral oil (54 mg, 1.4 mmol). After stirring at RT for 10 min, l-(4-(2-fluoropyridin-3-yl)piperidin-l- yl)ethanone (0.15 g, 0.68 mmol) was added and the reaction mixture was stirred at 140 0C for 16 h. After cooling to RT, the reaction mixture was partitioned between EtOAc and brine. The aqueous layer was back extracted with EtOAc (3χ) and the combined organics were dried (Na2SO4) and concentrated. The crude material was purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 10% to 100% EtOAc in hexane, followed by trituation with Et2O and heaxane to provide l-(4-(2-(4-(benzo[d]thiazol- 2-ylamino)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone (0.137 g, 0.308 mmol, 45.7 % yield) as off-white solid. MS (ESI, pos. ion) m/z: 445.0 (M+l). IC50 (uM) +++++.
SCHEME 41
Figure imgf000231_0001
EXAMPLE 214: TERT-BUTYL 4-(2-(4-( 1H-BENZ0 [D]IMID AZ0LE-2- CARB0NYL)PHEN0XY)PYRIDIN-3-YL)PIPERIDINE-l-CARB0XYLATE
Figure imgf000231_0002
STEP 1. TERT-BUTYL 4-(2-(4-(ETHOXYCARBONYL)PHENOXY)PYRIDIN-S-YL)-S5O- DIHYDROPYRIDINE- 1 (2H)-CARB0XYLATE
[00513] Four glass microwave reaction vessels were charged with ethyl 4-(3- bromopyridin-2-yloxy)benzoate (1.025 g, 3.18 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (1.195 g, 3.86 mmol), sodium carbonate (1.725 g, 16.28 mmol) and trans-dichlorobis(triphenyl-phosphine)palladium (II) (0.140 g, 0.199 mmol). DME (6 mL),Water (3 mL) and Ethanol (2 mL) were added and the reaction mixtures were sealed under argon and heated in a Emrys Optimizer microwave reactor (Personal Chemistry, Biotage AB, Inc., Upssala, Sweden) at 135 0C for 15 min. The reaction mixtures were combined and partitioned between EtO Ac/water. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were evaporated onto silica gel and purified by flash chromatography (Isco (120 gram)) eluting with EtOAc :hexanes (0:1 → 1 :4) to give a light-yellow crystalline solid. MS m/z: 425.1 [M+l].
Figure imgf000232_0001
STEP 2. TERT-BUTYL 4-(2-(4-(ETHOXYCARBONYL)PHENOXY)PYRIDIN-S- YL)PIPERIDINE- 1 -CARBOXYLATE.
[00514] A mixture of tert-butyl 4-(2-(4-(ethoxycarbonyl)phenoxy)pyridin-3 -yl)-5 ,6- dihydropyridine-l(2H)-carboxylate (5.89 g, 13.87 mmol) and palladium hydroxide on carbon (0.950 g, 1.353 mmol) in EtOH (50 mL) was evacuated/purged with hydrogen (1 atm, 3x). After stirring at rt overnight. The mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to give a light-yellow oil. MS m/z: All A [M+l].
Figure imgf000233_0001
STEP 3. TERT-BUTYL 4-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDINE-l-CARBOXYLATE
[00515] A mixture of benzimidazole (0.351 g, 2.97 mmol) and triisopropyl orthoformate (3.9 mL, 17.61 mmol) in toluene (25 mL) was heated in a 100 mL round bottom flask equipped with a Dean-Stark trap and reflux condenser under an atmosphere of nitrogen. After 1 h the solvent was removed in vacuo. The residue was dissolved in THF (8 mL) and to the solution was added a solution of tert-butyl 4-(2-(4-(ethoxycarbonyl)phenoxy)pyridin-3-yl)piperidine-l- carboxylate (1.07 g, 2.509 mmol) in THF (8 mL). The mixture was cooled (-78 0C) and lithium diisopropylamide (2.0M solution in heptane/THF/ethylbenzene, 1.80 mL, 3.60 mmol) was added dropwise resulting in a reddish solution. After 2 h the reaction was quenched with saturated NH4CI and allowed to warm to rt. The mixture was partitioned between EtO Ac/saturated NaHCOβ. The organic layer was washed with brine and dried over Na2SOφ The solution was filtered and the filtrate was evaporated onto silica gel and purified by flash chromatography (Isco, (120 gram)) eluting with 2M NH3 in MeOHiCH2Cl2 (0:1 → 3:97) to give a white amorphous solid. MS (ESI, pos. ion) m/z: 499.1 (M+ 1). IC50 (uM) ++H
Figure imgf000233_0002
EXAMPLE 215: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(PIPERIDIN-4-YL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
[00516] tert-butyl 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3- yl)piperidine-l-carboxylate (300 mg, 0.601 mmol) was dissolved in MeOH (10 mL) and HCl (4.0 M in dioxane, 5 niL) was added and the reaction stirred 16 h at rt. The solution was concentrated to give the crude HCl salt. The product was purified by reverse-phase preparative HPLC, 10% to 80% MeCN (0.1%TFA) in water (0.1% TFA) over 20 minutes to give the trifluoroacetic acid salt as a yellow solid. The salt was freebased by dissolving in MeOH and application to a 5 g Bondesil-SCX ion exchange column. Elution of the product with NH3 in MeOH (2.0 M) and concentration of the product containing fractions gives (IH- benzo[d]imidazol-2-yl)(4-(3-(piperidin-4-yl)pyridin-2-yloxy)phenyl)methanone as a yellow solid. MS (ESI, pos. ion) m/z: 399.0 (M+ 1). IC50 (uM) +++++.
SCHEME 42
Figure imgf000234_0001
EXAMPLE 216: 1 -(5 -(2-(4-(I H-BENZO [D]IMID AZOLE-2-
CARBONYL)PHENOXY)PYRIDIN-3-YL)-3,4-DIHYDROPYRIDIN-l(2H)-
YL)ETHANONE
Figure imgf000234_0002
STEP 1. 1-ACETYL-I AS5O-TETRAHYDROPYRIDIN-S-YL TRIFLUOROMETHANESULFONATE
[00517] To a -78°C solution of diisopropylamine (3.60 niL, 25.5 mmol) in THF (30 niL) was added butyllithium (9.35 mL, 23.38 mmol) dropwise. After the addition was complete the reaction was allowed to stir at -78°C for 15 minutes, then a solution of l-acetylpiperidin-3-one (3.0 g, 21.25 mmol) in THF (5 mL) was added dropwise. After a further 20 minutes, a solution of 1,1,1 -trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (8.35 g, 23.38 mmol) in THF (15 mL) was added dropwise to the reaction. The solution was allowed to slowly warm to room temperature. After 16 hours, the reaction was quenched with sat'd NH4CI and the diluted with water (20 mL). The aqueous solution was basifϊed and extracted with EtOAc (4 X 30 mL). The combined organics were washed with brine and concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with 0% to 70% EtOAc in hexane, to provide l-acetyl-l,4,5,6-tetrahydropyridin-3-yl trifluoromethanesulfonate (2.0 g, 7.32 mmol) as a golden oil. [M+l] = 274.0.
Figure imgf000235_0001
STEP 2. l-(5-(4,4,5,5-TETRAMETHYL-l,3,2-DIOXABOROLAN-2-YL)-3,4- DIHYDROPYRIDIN- 1 (2H)-YL)ETHANONE.
[00518] To a solution of l-acetyl-l,4,5,6-tetrahydropyridin-3-yl trifluoromethanesulfonate (2.5 g, 9.15 mmol), bis(pinacolato)diboron (2.88 g, 11.34 mmol), potassium acetate (1.91 g, 19.46 mmol), and dioxane (60 mL) was added 1,1'- bis(diphenylphosphino)ferrocenedichloro palladium(ii) dichloromethane complex (400 mg, 0.547 mmol). The mixture was purged with nitrogen and then was heated to 80 0C. After 16 hours, the reaction was cooled to room temperature. The mixture was diluted with 150 mL of EtOAc and washed with 50 mL of water and 50 mL of brine, dried over MgSO4, and concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with 0% to 40% EtOAc in hexane, to provide l-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4- dihydropyridin-l(2H)-yl)ethanone (1.2 g, 4.78 mmol) as an orange oil. [M+l] = 252.1.
Figure imgf000236_0001
STEP 3. 1-(5-(2-(4-(IH-BENZO[D]IMIDAZOLE^-CARBONYL)PHENOXY)PYRIDIN-S- YL)-3 ,4-DIHYDROP YRIDIN- 1 (2H)-YL)ETHANONE.
[00519] To a degassed solution of (lH-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2- yloxy)phenyl)methanone (706 mg, 1.791 mmol), l-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-3,4-dihydropyridin-l(2H)-yl)ethanone (0.5 g, 1.991 mmol), potassium acetate (1.5 g, 15.28 mmol), and dioxane (10 mL) was added A-Phos (140 mg, 0.198 mmol). The solution was stirred at 800C. After 16 hours, the reaction was allowed to cool to room temperature, diluted with H2O (10 mL), and the aqueous layer extracted with DCM (5 mL). The combined organic layers were concentrated in vacuo and purified purified by Prep TLC (1 :1 hexanes/EtOAc) to give l-(5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)- 3,4-dihydropyridin-l(2H)-yl)ethanone (1.6 mg, 3.65 μmol) as a light yellow film. MS (ESI, pos. ion) m/z: 439.0 (M+l). IC50 (uM) +++++.
Figure imgf000236_0002
EXAMPLE 217: (S)-l-(3-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-
CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN- 1 -YL)ETHANONE AND (R)- 1 -(3- (2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)PIPERIDIN- 1 -YL)ETHANONE
Figure imgf000237_0001
STEP 1. TERT-BUTYL 5-(2-FLUOROPYRIDIN-S-YL)-S^-DIHYDROPYRIDINE- 1(2H)- CARBOXYLATE
[00520] A microwave vial was charged with 2-fluoro-3-iodopyridine (1.325 g, 5.94 mmol), tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydropyridine-l(2H)- carboxylate (1.8 g, 5.82 mmol), sodium carbonate hydrate (2166 mg, 17.46 mmol), catalyst (211 mg, 0.301 mmol), DME (3 mL), Ethanol (0.857 mL) and Water (1.286 mL). The vial was capped and heated in a Biotage Initiator to 1400C for 15 minutes. The reaction was diluted with water (20 ml) and ethyl acetate (30 ml). The organic layer was washed with water (2 X 10 mL), brine (10 mL), and concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with 0% to 50% EtOAc in hexane, to provide tert-butyl 5-(2-fluoropyridin-3-yl)-3,4- dihydropyridine-l(2H)-carboxylate (673 mg, 2.418 mmol) as a colorless syrup. [M+Na] = 332.1.
Figure imgf000237_0002
STEP 2. 2-FLUORO-3-(PIPERIDIN-3-YL)PYRIDINE DIHYDROCHLORIDE
[00521] To a N2 purged round bottomed flask containing tert-butyl 5 -(2-fluoropyridin-3 - yl)-3,4-dihydropyridine-l(2H)-carboxylate (673 mg, 2.418 mmol) was added 10% Pd/C (50 mg, 0.470 mmol) and EtOH (15 mL). After stirring for 5 minutes, 5N HCl in iPrOH (4.0 mL, 20.00 mmol) was added and the flask capped with a balloon of H2. After 16 hours, LC-MS shows -30% conversion. The balloon was refilled. After a further 5 days, LC-MS shows complete consumption of starting material. The reaction was filtered through a celite cartridge and the cartridge rinsed with DCM: 10% EtOH (50 mL). The filtrate was concentrated in vacuo to give 2-fluoro-3-(piperidin-3-yl)pyridine dihydrochloride as a yellow foam. The material was carried forward without further purification.
Figure imgf000238_0001
STEP 3. 1-(3-(2-FLUOROPYRIDIN-S-YL)PIPERIDIN-I-YL)ETHANONE
[00522] To an ice cooled solution of 2-fluoro-3-(piperidin-3-yl)pyridine dihydrochloride (612 mg, 2.418 mmol), DCM (20 mL) and triethylamine (2022 μL, 14.51 mmol) was added acetic anhydride (229 μL, 2.418 mmol) dropwise. After 1 hour, the reaction was poured into water and the aqueous mixture back extracted once with DCM (10 mL). The combined organics were washed with 0.5M NaOH and concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (12 g), eluting with 0% to 100% EtOAc in hexane, to provide l-(3-(2- fluoropyridin-3-yl)piperidin-l-yl)ethanone (100 mg, 0.450 mmol) as a light yellow syrup. [M+l] = 223.1.
Figure imgf000238_0002
STEP 4. (S)-l-(3-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-CARBONYL)PHENOXY)PYRIDIN- 3-YL)PIPERIDIN-l-YL)ETHANONE AND (R)-l-(3-(2-(4-(lH-BENZO[D]IMIDAZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN- 1 -YL)ETHANONE
[00523] To a solution of (lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (107 mg, 0.450 mmol), NMP (2 mL) and l-(3-(2-fluoropyridin-3-yl)piperidin-l-yl)ethanone (50 mg, 0.225 mmol) was added cesium carbonate (147 mg, 0.450 mmol). The reaction mixture was stirred and heated in a Biotage Initiator at 1600C for 60 minutes, then at 1800C for 2 hours, then at 2000C for 2 hours and finally at 2000C for 1 hour. The starting material has been consumed, but the reaction became messier the longer it was heated. The reaction was filtered through a Acrodisc syringe filter 0.2 mm ultipor nylon membrane. The filtrate was purified by reverse- phase preparative HPLC (Shimadzu) on a Phenomenex Gemini column (5 micron, C 18, 110 A, Axia, 100x50 mm) eluting at 90 niL/min with an linear gradient of 10% to 80% MeCN (0.1%TFA) in water (0.1% TFA) over 20 minutes to give the product as a TFA salt. The desired fractions were poured into 10% Na2COβ (aq)/DCM, and the DCM layer separated, dried over MgSOφ and concentrated in vacuo to give a mixture of (S)-l-(3-(2-(4-(lH- benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3 -yl)piperidin- 1 -yl)ethanone and (R)- 1 -(3 -(2- (4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone as a light yellow solid. MS (ESI, pos. ion) m/z: 441.0 (M+ 1). IC50 (uM) +++++.
Figure imgf000239_0001
EXAMPLE 218: (S)-l-(3-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN- 3-YL)PIPERIDIN- 1 -YL)ETHANONE AND (R)- 1 -(3-(2-(4-(BENZO[D]THIAZOL-2- YLAMINO)PHENOXY)PYRIDIN-3-YL)PIPERIDIN- 1 -YL)ETHANONE
[00524] To a solution of 4-(benzo[d]thiazol-2-ylamino)phenol (109 mg, 0.450 mmol), NMP (2 mL) and l-(3-(2-fluoropyridin-3-yl)piperidin-l-yl)ethanone (50 mg, 0.225 mmol) was added cesium carbonate (147 mg, 0.450 mmol). The reaction mixture was stirred and heated in a Biotage Initiator at 1600C for 60 minutes. LC-MS shows complete conversion. The reaction was filtered through a Acrodisc syringe filter 0.2 mm ultipor nylon membrane. The filtrate was purified by reverse-phase preparative HPLC (Shimadzu) on a Phenomenex Gemini column (5 micron, C 18, 110 A, Axia, 100x50 mm) eluting at 90 mL/min with an linear gradient of 10% to 80% MeCN (0.1%TFA) in water (0.1% TFA) over 20 minutes to give the product as a TFA salt. The desired fractions were poured into 10% Na2COβ (aq)/DCM, and the DCM layer separated, dried over MgSOφ and concentrated in vacuo to give a mixture of (S)-l-(3-(2-(4- (benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone (13.5 mg, 0.030 mmol, 27.0 % yield) and (R)-l-(3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3- yl)piperidin-l-yl)ethanone (13.5 mg, 0.030 mmol) as a off white solid. MS (ESI, pos. ion) m/z: 445.1 (M+l). IC50 (uM) +++++.
SCHEME 43
Figure imgf000240_0001
EXAMPLE 219: (^-1-(2-(2-(4-(IH-BENZO[D]IMIDAZOLE-I-
CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN-l-YL)ETHANONE AND (S)-l-(2-(2- (4-(lH-BENZ0[D]IMID AZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN-l- YL)ETHANONE
Figure imgf000240_0002
STEP 1. TERT-BUTYL 2-(2-FLUOROPYRIDIN-S-YL)PIPERIDINE-I-CARBOXYLATE
[00525] To a -78°C solution of tert-butyl piperidine-1-carboxylate (1.0 niL, 5.20 mmol), dry ether (20 mL) and TMEDA (0.82 mL, 5.47 mmol) was added sec-butyllithium, 1.4M in cyclohexane (3.90 mL, 5.46 mmol) dropwise over 5 minutes. After 2 hours, a solution of zinc chloride, 0.5M in ether (6.8 mL, 6.80 mmol) was added over 7 minutes. After 30 minutes, the mixture was warmed to ambient temperature and stirred for a further 30 minutes then 2-fluoro- 3-iodopyridine (1511 mg, 6.78 mmol), palladium(ii) acetate (127 mg, 0.566 mmol), tri-t- butylphosphonium tetrafluoroborate (268 mg, 0.924 mmol) was added in one portion. After 18 hours, NH4OH (10 mL, 10% aqueous solution) was added dropwise, followed by Et20 (10 mL). The organic layer was extracted, washed with brine, dried (MgSC^) and concentrated in vacuo. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Redi-Sep® pre-packed silica gel column (40 g), eluting with 0% to 40% EtOAc in hexane, to provide tert-butyl 2-(2-fluoropyridin-3-yl)piperidine-l-carboxylate (70 mg, 0.250 mmol) as a colorless oil. [M+Na] = 303.2.
Figure imgf000241_0001
STEP 2. 1-(2-(2-FLUOROPYRIDIN-S-YL)PIPERIDIN-I-YL)ETHANONE
[00526] To a solution of tert-butyl 2-(2-fluoropyridin-3 -yl)piperidine- 1 -carboxylate (70 mg, 0.250 mmol) and DCM (5 mL) was added TFA (0.50 mL, 6.49 mmol). After 1 hour, the reaction was washed with 10% Na2CO3. The organic layer was treated with TEA (0.070 mL, 0.499 mmol), then acetic anhydride (0.024 mL, 0.250 mmol). After 15 minutes, LC-MS shows conversion to the desired product [M+ 1 = 223] . The reaction was washed with water and concentrated in vacuo to give l-(2-(2-fluoropyridin-3-yl)piperidin-l-yl)ethanone as a yellow oil.
Figure imgf000241_0002
(R)-l-(2-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)PIPERIDIN- 1 -YL)ETHANONE AND (S)-I -(2-(2-(4-( 1 H-BENZO [D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)PIPERIDIN- 1 -YL)ETHANONE
[00527] To a solution of 1 -(2-(2-fluoropyridin-3 -yl)piperidin- 1 -yl)ethanone (20 mg, 0.090 mmol), NMP (0.5 mL) was added cesium carbonate (55 mg, 0.169 mmol) and (IH- benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (35 mg, 0.147 mmol). The reaction mixture was stirred and heated in a Biotage Initiator at 2000C for 60 minutes. The reaction was filtered through a Acrodisc syringe filter 0.2 mm ultipor nylon membrane. The filtrate was purified by reverse-phase preparative HPLC (Shimadzu) on a Phenomenex Gemini column (10 micron, C 18, 110 A, Axia, 100x30 mm) eluting at 45 mL/min with an linear gradient of 10% to 80% MeCN (0.1%TFA) in water (0.1% TFA) over 20 minutes to give the product as a TFA salt. The desired fractions were poured into 10% Na2COβ (aq)/DCM, and the DCM layer separated, dried over MgSOφ and concentrated in vacuo to give a mixture of (R)-I -(2-(2-(4- (lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone and (S)-I -(2- (2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone as a brown film. MS (ESI, pos. ion) m/z: 441.0 (M+ 1). IC50 (uM) +++++.
SCHEME 44
Figure imgf000242_0001
EXAMPLE 220: l-(3-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)PYRROLIDIN- 1 -YL)ETHANONE
Figure imgf000242_0002
STEP 1. TERT-BUTYL 3-(2-FLUOROPYRIDIN-S-YL)PYRROLIDINE-I-CARBOXYLATE
[00528] Into an oven-dried 25 mL round bottomed flask was charged dry DMA (2 rnL), zinc dust (0.843 g, 12.9 mmol). The mixture was stirred at RT while the mixture of chlorotrimethylsilane (0.132 mL, 1.04 mmol) and 1 ,2-dibromoethane (0.09 mL, 1.040 mmol) was added slowly. The resulting slurry was aged for 15 min. A solution of tert-butyl 3- iodopyrrolidine-1-carboxylate (3.09 g, 10.4 mmol) in DMA (5.2 mL) was added slowly to the above mixture. Zinc slurry reacted exothermically with the gradual addition of the iodide. After stirring for 30 min, the resulting milky solution was cooled to RT and used directly in the next step.
[00529] Into an oven-dried flask were charged 3-bromo-2-fluoropyridine (1.3 g, 7.39 mmol), Pd catalyst (0.181 g, 0.222 mmol), copper(i) iodide (0.084 g, 0.443 mmol), and DMA (10 mL). The resulting mixture was degassed with alternating vacuum/nitrogen purges. The (1- (tert-butoxycarbonyl)pyrrolidin-3-yl)zinc(II) iodide (3.75 g, 10.34 mmol) solution from previous step was filtered into the mixture. It was degassed one more time and then heated to 80 0C with stirring for 16 h. After cooling to RT, the reaction mixture was partitioned between EtOAc and 1 N NH4Cl. The aqueous layer was back extracted with EtOAc (2x) and the combined EtOAc layer was washed once again with 1 N NH4C1, then with brine, dried (Na2SO4) and concentrated. The crude material as chromatography through a Redi-Sep prepacked silica gel column (120 g), eluting with a gradient of 0% to 40% EtOAc in hexane, to provide tert-butyl 3-(2-fluoropyridin-3-yl)pyrrolidine-l-carboxylate as dark-red oil. [M-56]= 211.2.
Figure imgf000243_0001
STEP 2. 1-(3-(2-FLUOROPYRIDIN-S-YL)PYRROLIDIN-I-YL)ETHANONE
[00530] To tert-butyl 3-(2-fiuoropyridin-3-yl)pyrrolidine-l-carboxylate (0.25 g, 0.939 mmol) dissolved in DCM (3.1 mL) was added trifluoroacetic acid (1.05 mL, 14.1 mmol). The reaction mixture was stirred at RT for 1 h. The solvent was evaporated in vacuo and to the residue dissolved in DCM (1 mL) was added acetic anhydride (0.44 mL, 4.7 mmol) and sodium bicarbonate (0.4 g, 4.7 mmol). The reaction mixture was stirred at RT under N2 for 3 h. The reaction mixture was partitioned between IN NaOH and DCM. The aqueous layer was back extracted with DCM (3χ) and the combined DCM layer was dried (Na2SO4) and concentrated. The crude material was purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0% to 100% EtOAc in hexane, then 10% MeOH in EtOAc, to provide l-(3-(2-fluoropyridin-3-yl)pyrrolidin-l-yl)ethanone as tan oil. [M+H]= 209.2.
Figure imgf000244_0001
STEP 3. l-(3-(2-(4-(lH-BENZO[D]IMIDAZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)PYRROLIDIN- 1 -YL)ETHANONE
[00531] A glass microwave reaction vessel was charged with l-(3-(2-fluoropyridin-3- yl)pyrrolidin-l-yl)ethanone (86 mg, 0.41 mmol), (lH-benzo[d]imidazol-2-yl)(4- hydroxyphenyl)methanone (197 mg, 0.826 mmol), cesium carbonate (309 mg, 0.95 mmol), copper(i) iodide (79 mg, 0.413 mmol), and NMP (1.4 mL). The reaction mixture was degassed and flushed with N2 and heated in a Emrys Optmizer microwave reactor (Personal Chemistry, Biotage AB, Inc., Upssala, Sweden) at 200 0C for 1 h. After cooling to RT, the reaction mixture was partitioned between EtOAc and 1 N NH4Cl. The aqeuous layer was back extracted with EtOAc (2x) and the combined organic layer was washed with water, brine, dried (Na2SO4) and concentrated. The crude material was chromatographed through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0% to 100% EtOAc in hexane, then 5% MeOH in EtOAc, followed by trituation with ethe, dried to provide l-(3-(2-(4-(lH-benzo[d]imidazole-2- carbonyl)phenoxy)pyridin-3-yl)pyrrolidin-l-yl)ethanone as off- white solid. MS (ESI, pos. ion) m/z: All.1 (M+l). IC50 (uM) +++++. SCHEME 45
Figure imgf000245_0001
EXAMPLE 221 : l-(3-(3-(4-(lH-BENZO[D]IMID AZOLE-2-
C ARBONYL)PHENOXY)P YRAZIN-2- YL)PIPERIDIN- 1 -YL)ETHANONE
Figure imgf000245_0002
STEP 1. TERT-BUTYL 3-(2-(4-(ETHOXYCARBONYL)PHENOXY)PYRIDIN-S- YL)AZETIDINE- 1 -CARBOXYLATE
[00532] To a suspension of zinc dust (217 mg, 3.31 mmol) in DMA (2 mL) at rt was added chlorotrimethylsilane (67.3 μL, 0.532 mmol) and 1 ,2-dibromoethane (45.9 μL, 0.532 mmol) slowly. The resulting slurry was stirred 15 min, then tert-butyl 3-iodoazetidine-l- carboxylate (753 mg, 2.66 mmol) was added to the above mixture (mild exotherm). The suspension was stirred at rt 30 min.
[00533] The zinc solution was added via syringe to a solution of ethyl 4-(3 - bromopyridin-2-yloxy)benzoate (600 mg, 1.862 mmol), Pd(dppf)Cl2*CH2Cl2 (65.2 mg, 0.080 mmol), and copper(I) iodide (30.4 mg, 0.160 mmol) in DMA (1.0 mL) that was degassed with Ar sparging. The solution was heated to 80 0C and stirred 1 h. The reaction was quenched with half saturated NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic fractions were dried (MgSO4), concentrated, and purified by ISCO (40 g SiO2, 0-100% EtOAc/Hexane) to give tert-butyl 3 -(2-(4-(ethoxycarbonyl)phenoxy)pyridin-3-yl)azetidine-l -carboxylate as a light brown oil.
Figure imgf000246_0001
STEP 2. (4-(3-(AZETIDIN-S-YL)PYRIDIN^-YLOXY)PHENYL)(IH- BENZO[D]IMID AZOL-2-YL)METHANONE
[00534] To a solution of l-(diisopropoxymethyl)-lH-benzo[d]imidazole (318 mg, 1.280 mmol) in THF (5 mL) at 0 0C is added LiHMDS (0.753 mL, 0.753 mmol) over 1 min. The reaction was stirred 5 min., then 3.5 mL of the 6 mL solution (1.0 theoretical equivalent of the lithium benzoimidazole) was added to a solution of tert-butyl 3-(2-(4-
(ethoxycarbonyl)phenoxy)pyridin-3-yl)azetidine-l -carboxylate (300 mg, 0.753 mmol) in THF (3 mL) at 0 0C. The reaction was stirred at 0 0C 30 min. LCMS showed only 5% conversion. The remaining solution of benzoimidazole was added and the reaction stirred 1 h at 0 0C. LCMS shows 2:1 ratio of starting material to desired product. The reaction was quenched with 2 N HCl (15 mL) and warmed to rt and stirred overnight. The aqueous layer was neutralized with solid Na2CO3 and the aqueous layer extracted with CH2Cl2 (2 x 25 mL). The combined organic fractions were washed with saturated NaCl, dried (MgSO4), and concentrated. The crude material was then taken up in MeOH (3 mL) and 4.0 M HCl in dioxane was added. The reaction was stirred at rt 2 h, then concentrated to give the crude amine hydrochloride, which was taken on to the next step without purification.
Figure imgf000247_0001
STEP 3. 1-(3-(2-(4-(IH-BENZO[D]IMIDAZOLE^-CARBONYL)PHENOXY)PYRIDIN-S- YL)AZETIDIN- 1 -YL)ETHAN0NE
[00535] To a solution of (4-(3-(azetidin-3-yl)pyridin-2-yloxy)phenyl)(lH- benzo[d]imidazol-2-yl)methanone (279 mg, 0.753 mmol) in DMF (1.0 niL) is added triethylamine (0.386 mL, 3.01 mmol) and l-(lH-imidazol-l-yl)ethanone (100 mg, 0.904 mmol). A solid crashed out, so THF (2 mL) was added to give a homogeneous solution and the reaction was stirred at rt 2 h. The reaction mixture was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried (MgSO4) and concentrated, then purified by RPHPLC to give l-(3-(2-(4-(lH-benzo[d]imidazole-2- carbonyl)phenoxy)pyridin-3-yl)azetidin-l-yl)ethanone (35 mg, 0.085 mmol, 11.27 % yield over 2 steps) as a white solid. MS (ESI, pos. ion) m/z: 413.0 (M+ 1). IC50 (uM) +++++.
SCHEME 46
Figure imgf000247_0002
EXAMPLE 222: N-(4-(3-(TETRAHYDROFURAN-2-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000248_0001
STEP 1. N-(4-(3-IODOPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00536] A mixture of 2-fluoro-3-iodopyridine (4.93 g, 22.11 mmol), 4-(benzo[d]thiazol- 2-ylamino)phenol (6.16 g, 25.4 mmol), and cesium carbonate (10.81 g, 33.2 mmol) in DMSO (50 mL) was heated at 80 0C overnight. The reaction was cooled to rt and poured into water (200 mL). The solution was extracted with EtOAc (3x) and the combined organic layers were washed with brine, evaporated onto silica gel and purified by flash chromatography (Isco (240 gram)) eluting with EtOAc:hexanes (0:1 → 1 :1) to give a white crystalline solid. MS (ESI, pos. ion) m/z: 445.8 (M+ 1).
Figure imgf000248_0002
STEP 2. N-(4-(3-(2,3-DIHYDROFURAN-2-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00537] A mixture of N-(4-(3-iodopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine (0.403 g, 0.905 mmol), N-methyldicyclohexylamine (0.400 mL, 1.886 mmol, Aldrich), bis(tri- tert-butylphosphine)palladium (0) (0.045 g, 0.088 mmol, Strem) and 2,5-dihydrofuran (0.500 mL, 6.78 mmol, Aldrich) in 5 mL of dioxane was capped under an atmosphere of argon and stirred at rt for 3h and then heated at 45 0C overnight. The reaction mixture was diluted with MeOH, evaporated onto silica gel and purified by flash chromatography (Isco, (40 gram)) eluting with 2M NH3 in MeOH:CH2Cl2 (0:1 → 3:97) to give a white amorphous solid. MS (ESI, pos. ion) m/z: 386.0 (M+l).
Figure imgf000248_0003
STEP 3. N-(4-(3-(TETRAHYDROFURAN-2-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00538] A mixture of N-(4-(3-(2,3-dihydrofuran-3-yl)pyridin-2- yloxy)phenyl)benzo[d]thiazol-2-amine (0.258 g, 0.666 mmol) and 10% palladium on carbon (0.060 g, 0.564 mmol) in EtOH (5 mL) was evacuated and purged with hydrogen. After 6 h the reaction was diluted with MeOH, evaporated onto silica gel and purified by flash chromatography (Isco (40 gram)) eluting with EtOAc :hexanes (0:1 → 1 :1) to give a white crystalline solid. MS (ESI, pos. ion) m/z: 390.0 (M+l). IC50 (uM) +++++.
SCHEME 47
Figure imgf000249_0001
EXAMPLE 223 : (R)-( IH-BENZO [D]IMID AZOL-2-YL)(4-(3-(TETRAHYDROFURAN-2- YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE AND (S)-(1H-BENZO[D]IMID AZOL-2- YL)(4-(3-(TETRAHYDROFURAN-2-YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
Figure imgf000249_0002
STEP 1. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(2,3-DIHYDROFURAN-3-YL)PYRIDIN-2- YLOXY)PHENYL)METHANONE AND (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(2,3- DIHYDROFURAN-2-YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00539] A mixture of (lH-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2- yloxy)phenyl)methanone (1.522 g, 3.86 mmol), 2,5-dihydrofuran (1.400 mL, 18.98 mmol, Aldrich), N-cyclohexyl-N-methylcyclohexanamine (1.600 mL, 7.54 mmol, Aldrich) and bis(tri- tert-butylphosphine)palladium (0) (0.194 g, 0.380 mmol, Strem) in dioxane (10 mL) was sealed in a microwave vessel under an atmosphere of argon and heated thermally at 80 0C for 6 h. The reaction was diluted with EtOAc and the mixture was extracted with water (Ix) and brine (Ix). The organic mixture was evaporated onto silica gel and purified by flash chromatography (Isco (120 gram)) eluting with EtOAc:hexanes (0:1 → 1 :2) to give 650 mg of (lH-benzo[d]imidazol- 2-yl)(4-(3-(2,3-dihydrofuran-2-yl)pyridin-2-yloxy)phenyl)methanone and 325 mg of (IH- benzo[d]imidazol-2-yl)(4-(3-(2,3-dihydrofuran-3-yl)pyridin-2-yloxy)phenyl)methanone.
Figure imgf000250_0001
STEP 2. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-(TETRAHYDROFURAN-2-YL)PYRIDIN- 2-YLOXY)PHENYL)METHANONE
[00540] A mixture of (lH-benzo[d]imidazol-2-yl)(4-(3-(2,3-dihydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone (0.650 g, 1.695 mmol) and palladium hydroxide, 20 wt % pd (dry basis) on carbon, wet, degussa type elOl ne/w (0.210 g, 0.299 mmol, Aldrich) in dioxane (10 mL) was evacuated/purged with hydrogen (1 atm, 3x) at rt for 6 h. The reaction was filtered and the filtrate was concentrated to dryness. The material was taken onto the next step without further purification.
[00541] A mixture of (lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanol (0.659 g, 1.7 mmol) and (lH-benzo[d]imidazol-2-yl)(4-(3- (tetrahydrofuran-2-yl)pyridin-2-yloxy)phenyl)methanone (0.655 g, 1.700 mmol) and manganese(IV) oxide activated (1.37 g, 15.76 mmol, Strem) in CHCI3 (50 mL) was heated under argon at 50 0C for 1 h. The reaction was cooled to rt, filtered through Celite and concentrated in vacuo to give the desired product. MS (ESI, pos. ion) m/z: 386.0 (M+ 1). IC50 (uM) +++++. SCHEME 48
Figure imgf000251_0001
Y= NH, Z= S Y= C=O, Z= NH
Figure imgf000251_0002
EXAMPLE 224: N-(4-(3-(TETRAHYDROFURAN-3-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000251_0003
STEP 1. 3-(2,3-DIHYDROFURAN-3-YL)-2-FLUOROPYRIDINE
[00542] To a 500 niL round bottomed flask charged with 2-fluoro-3-iodopyridine (15.05 g, 67.5 mmol, Asymchem), tetrabutylammonium chloride (18.80 g, 67.6 mmol, Alfa Aesar), potassium carbonate (28.60 g, 207 mmol, Aldrich) and palladium(ii) acetate (1.48 g, 6.59 mmol, Strem) was added DMF (75 mL) followed by 2,5-dihydrofuran (50.00 mL, 678 mmol, Aldrich) and the reaction mixture was stirred vigorously at 25 0C for 2 h. The mixture was poured into 500 mL of water and the mixture was extracted with EtOAc (3x). The combined organic layers were evaporated onto silica gel and purified by flash chromatography (Isco (330 gram)) eluting with EtOAc :hexanes (0:1 1 :2) to give a clear colorless oil. MS (ESI, pos. ion) m/z: 166.1 (M+l).
Figure imgf000252_0001
STEP 2. 2-FLUORO-3-(TETRAHYDROFURAN-3-YL)PYRIDINE
[00543] A mixture of 3-(2,3-dihydrofuran-3-yl)-2-fluoropyridine (5.26 g, 31.8 mmol) and palladium hydroxide, 20 wt % pd (dry basis) on carbon, wet (2.500 g, 3.56 mmol) in THF (50 mL) was evacuated/purged with hydrogen (3x). The mixture was stirred vigorously under hydrogen (1 atm) at rt overnight. The mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to give a clear colorless oil. MS (ESI, pos. ion) m/z: 168.1 (M+l).
Figure imgf000252_0002
STEP 3. N-(4-(3-(TETRAHYDROFURAN-3-YL)PYRIDIN-2- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00544] A glass microwave reaction vessel was charged with 2-fluoro-3- (tetrahydrofuran-3-yl)pyridine (1.00 g, 5.98 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (1.56 g, 6.44 mmol) and cesium carbonate (4.88 g, 14.98 mmol) in DMSO (10 mL). The reaction mixture was sealed under argon and was heated thermally at 100 0C for 24 h.. The reaction was cooled to rt and diluted with water. The product turned into a gum and the aqueous solution was decanted. The gum was stirred over MeOH for 1 h resulting in a precipitate that was filtered, washed with MeOH and dried in vacuo to give the title compound as a white crystalline solid. MS (ESI, pos. ion) m/z: 389.9 (M+l). IC50 (uM) +++++. SCHEME 49
Figure imgf000253_0001
EXAMPLE 225. (l-(2-FLUOROETHYL)-lH-BENZO[D]IMID AZOL-2-YL)(4-(3- (TETRAHYDROFURAN-3-YL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00545] To a slurry of cesium carbonate (0.441 g, 1.354 mmol) and (IH- benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)methanone (0.350 g, 0.908 mmol) in DMF (5 mL) was added l-bromo-2-fluoroethane (0.090 mL, 1.21 mmol) at rt. After 1.5 h the mixture was partitioned between DCM/water. The aqueous layer was extracted with DCM (3x) and the combined organic layers were washed with water and dried over Na2SOφ The solution was filtered and concentrated in vacuo. The residue was dissolved in DMSO/MeOH and purified by reverse-phase HPLC (Gilson; Gemini-NX lOμm C18 11OA AXIA, 100 x 50 mm column) eluting with 0.1%TF A-H2O:0.1%TFA CH3CN (9:1 → 1 :9). The fractions containing the desired product were combined and concentrated in vacuo. The residue was dissolved in MeOH and loaded onto an SCX II cartridge eluting with MeOH then 2M NH3 in MeOH to give an off-white crystalline solid. MS (ESI, pos. ion) m/z: 432.0 (M+l). IC50 (uM) +++++.
SCHEME 50
Figure imgf000254_0001
EXAMPLE 226: 3-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)CYCLOPENT-2-ENONE
[00546] A suspension of (lH-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2- yloxy)phenyl)methanone (500 mg, 1.268 mmol), 2-cyclopenten-l-one (0.410 niL, 5.07 mmol), 105 0C and bis(tri-tert-butylphosphine)palladium (0) (64.8 mg, 0.127 mmol) in Dioxane (4 mL) was capped, degassed and backfilled with argon. The reaction was heated at 105 0C. After 6 h, the reaction was cooled to 23 0C, concentrated in vacuo and purified by silica gel chromatography (eluant: 40-100% EtOAc/hexane), affording the product as a yellow solid. MS (ESI, pos. ion) m/z: 396.1 (M+l). IC50 (uM) +++++.
SCHEME 51
Figure imgf000255_0001
EXAMPLE 227: ( IH-BENZO [D]IMID AZOL-2-YL)(4-(3 -(3- HYDROXYCYCLOPENTYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
STEP 1. 3-(2-(4-((lH-BENZO[D]IMID AZOL-2- YL)(HYDROXY)METHYL)PHENOXY)PYRIDIN-3-YL)CYCLOPENT-2-ENOL
[00547] A suspension of 3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3- yl)cyclopent-2-enone (2125 mg, 5.37 mmol) and cerium (iii) chloride (1325 mg, 5.37 mmol) in tetrahydrofuran (300 mL) and methanol (30.0 mL) was cooled to 0 0C under nitrogen. Sodium borohydrate (813 mg, 21.50 mmol) was added in 4 lots over 20 min. The reaction was warmed to 23 0C over 2 h. After a total reaction time of 4 h, the reaction was quenched with saturated ammonium chloride solution (10 ml, slowly - effervescence). The solution was diluted with EtOAc (500 mL) and washed with saturated ammonium chloride solution (100 mL) and brine (100 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 1-8% methanol/dichloromethane), affording the product as a yellow film.
Figure imgf000256_0001
STEP 2. 3-(2-(4-((lH-BENZO[D]IMID AZOL-2- YL)(HYDROXY)METHYL)PHENOXY)PYRIDIN-3-YL)CYCLOPENTANOL
[00548] A solution of 3-(2-(4-((lH-benzo[d]imidazol-2- yl)(hydroxy)methyl)phenoxy)pyridin-3-yl)cyclopent-2-enol (780 mg, 1.953 mmol) in Tetrahydrofuran (50 mL) was treated with palladium, 10% wt. on activated carbon (208 mg, 0.195 mmol) under nitrogen. The reaction flask was equipped with a hydrogen balloon and cycled through vacuum-hydrogen cycles (3x). The reaction was heated to 40 0C under hydrogen. After 5 h, the reaction was cooled to 23 0C, and filtered through celite. The filter cake was washed with tetrahydrofuran (200 mL), the filtrates combined and concentrated, affording the product as a white solid. MS (ESI, pos. ion) m/z: 402.1 (M+ 1).
Figure imgf000256_0002
STEP 3. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3 -(3 -HYDROXYC YCLOPENT YL)P YRIDIN- 2-YLOXY)PHENYL)METHANONE
[00549] A solution of 3-(2-(4-((lH-benzo[d]imidazol-2- yl)(hydroxy)methyl)phenoxy)pyridin-3-yl)cyclopentanol (780 mg, 1.943 mmol) in tetrahydrofuran (20 mL) and dichloromethane (50 mL) was treated with manganese dioxide (1351 mg, 15.54 mmol). The reaction was stirred at 23 0C under nitrogen. After 3h, the reaction was filtered through celite, the filter cake washed with tetrahydrofuran (200 mL), the filtrates combined, concentrated in vacuo and purified by silica gel chromatography (eluant: 1- 5% methanol/dichloromethane), affording the product as a white solid. MS (ESI, pos. ion) m/z: 400.1 (M+l). IC50 (uM) +++++.
Figure imgf000257_0001
EXAMPLE 228: 3-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCLOPENT-2-ENONE
[00550] A solution of N-(4-(3-bromopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine (600 mg, 1.506 mmol), 2-cyclopenten-l-one (0.609 mL, 7.53 mmol), n- methyldicyclohexylamine (0.959 mL, 4.52 mmol) and bis(tri-tert-butylphosphine)palladium (0) (77 mg, 0.151 mmol) in Dioxane (4 mL) was capped, degassed and backfilled with argon. The reaction was heated to 90 0C. After 6h, the reaction was heated to 110 0C. After 36h, the reaction was cooled to 23 0C, diluted with EtOAc (150 mL) and washed with water (100 mL) and brine (100 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 0.5-3% methanol/dichloromethane), affording the product as a yellow solid. MS (ESI, pos. ion) m/z: 400.1 (M+l).
SCHEME 52
Figure imgf000258_0001
EXAMPLE 229: 3-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCL0PENTAN0L
Figure imgf000258_0002
STEP 1. 3-(2-FLUOROPYRIDIN-3-YL)CYCLOPENT-2-ENONE
[00551] A solution of 3-bromo-2-fluoropyridine (4 g, 22.73 mmol), 2-cyclopenten- 1 -one (7.35 mL, 91 mmol), n-methyldicyclohexylamine (12.05 mL, 56.8 mmol) and bis(tri-tert- butylphosphine)palladium (0) (0.581 g, 1.136 mmol) in 1,4-dioxane (50 mL) was heated to 105 0C in a capped vessel. After 21 h, the reaction was cooled to 23 0C, diluted with EtOAc (400 mL) and washed with water (150 mL) and brine (150 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 15-50% EtOAc/hexane), affording the product as a yellow solid. MS (ESI, pos. ion) m/z: 178.0 (M+l).
Figure imgf000259_0001
STEP 2. 3-(2-FLUOROPYRIDIN-3-YL)CYCLOPENT-2-ENOL
[00552] A solution of 3-(2-fluoropyridin-3-yl)cyclopent-2-enone (1582 mg, 8.93 mmol) in Tetrahydrofuran (20 niL) and Methanol (20 mL) was cooled to 0 °C under nitrogen. Cerium (III) chloride (2201 mg, 8.93 mmol) was added, followed by sodium borohydrate (676 mg, 17.86 mmol) in 4 lots, over 15 min. After 30 min, the reaction was quenched with saturated ammonium chloride solution (20 mL - effervescence!), and partitioned between dichloromethane (100 mL) and saturated ammonium chloride solution (30 mL). The organic layer was separated, and the aqueous layer was extracted with dichloromethane (50 mL). The organic layers were combined, dried over MgSOφ and concentrated, affording the product as a yellow oil. MS (ESI, pos. ion) m/z: 180.1 (M+ 1).
Figure imgf000259_0002
STEP 3. 3-(2-FLUOROPYRIDIN-3-YL)CYCLOPENTANOL
[00553] A solution of 3-(2-fluoropyridin-3-yl)cyclopent-2-enol (1184 mg, 6.61 mmol) in tetrahydrofuran (40 mL) was treated with palladium, 10% wt. on activated carbon (703 mg, 0.661 mmol). The reaction mixture was evacuated under vacuum and backfilled with hydrogen (3X), and stirred under hydrogen at 23 0C. After 4 h, the reaction was filtered through celite, the filter cake washed with 1 :1 methanol: dichloromethane (50 mL), the filtrates combined and concentrated, affording the product as a yellow oil. MS (ESI, pos. ion) m/z: 182.0 (M+l).
Figure imgf000259_0003
STEP 4. 3-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCL0PENTAN0L
[00554] A suspension of 3-(2-fluoropyridin-3-yl)cyclopentanol (869 mg, 4.80 mmol), 4- (benzo[d]thiazol-2-ylamino)phenol (2324 mg, 9.59 mmol) and cesium carbonate (3281 mg, 10.07 mmol) in N-methyl-2-pyrrolidinone (8 mL) was heated to 130 0C under nitrogen. After 9h, the reaction was cooled to 23 0C, diluted with EtOAc (500 mL) and washed with IN NaOH solution (6 x 150 mL) and brine (150 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 1-4% methanol/dichloromethane), affording the product as a tan solid. MS (ESI, pos. ion) m/z: 404.1 (M+l). IC50 (uM) +++++.
SCHEME 53
Figure imgf000260_0001
Y= CO, Z= NH Y= NH, Z= S
Figure imgf000260_0002
EXAMPLE 230: 3-(2-(4-(lH-BENZO[D]IMID AZOLE-2- CARBONYL)PHENOXY)PYRIDIN-3-YL)CYCLOPENT ANONE
Figure imgf000261_0001
STEP 1. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-IODOPYRIDIN-2- YLOXY)PHENYL)METHANONE
[00555] A solution of 2-fluoro-3-iodopyridine (3.052 g, 13.69 mmol), (IH- benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (4.89 g, 20.53 mmol) and cesium carbonate (7.58 g, 23.27 mmol) in N-Methyl-2-pyrrolidinone (20 mL) was degassed and heated to 115 0C. After 64 h, the reaction was cooled to 23 0C, diluted with EtOAc (250 mL) and washed with water (100 mL) and brine (75 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 0.5-1.5% methanol/dichloromethane), affording the product as a yellow solid. MS (ESI, pos. ion) m/z: 404.1 (M+l). OH
STEP 2. CYCLOPENT-2-ENOL
[00556] To a round bottom flask was added 2-cyclopenten- 1 -one (18.73 mL, 224 mmol), Methanol (559 mL), and cerium(iii) chloride heptahydrate (83 g, 224 mmol) with stirring at 00C before adding sodium borohydrate (15.75 mL, 447 mmol) portionwise over 2 h. Each addition of the hydride gave a large exotherm. Upon complete addition, off- white suspension was allowed to stir at room temperature for 16 h before removing the solvent under reduced pressure, yielding a light purple solid. The crude solid was solubilized with ethyl acetate and washed with a saturated solution OfNH4OH in water. The combined organics were dried over sodium sulfate and concentrated to a clear oil. The oil was diluted with water and extracted with ethyl acetate (3 x 40 mL), dried over sodium sulfate, filtered, and concentrated under high vacuum, affording cyclopent-2-enol as a clear oil.
Figure imgf000262_0001
STEP 3. 3-(2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)PYRIDIN-3- YL)CYCLOPENTANONE
[00557] A suspension of (lH-benzo[d]imidazol-2-yl)(4-(3-iodopyridin-2- yloxy)phenyl)methanone (4.138 g, 9.38 mmol), cyclopent-2-enol (3.16 g, 37.5 mmol), tetrabutylammonium chloride (2.87 g, 10.32 mmol), potassium acetate (1.841 g, 18.76 mmol) and palladium (II) acetate (0.211 g, 0.938 mmol) in acetonitrile (30 mL) (argon bubbled through for 30 min) and water (3.00 mL) in a round bottom flask was capped with a septum, degassed, backfilled with argon and heated to 85 0C. After 23 h, the reaction was cooled to 23 0C, diluted with dichloromethane (200 mL) and washed with brine (2 x 150 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 35-50% EtOAc/hexane), affording the product as an off-white solid. MS (ESI, pos. ion) m/z: 398.1 (M+l). IC50 (uM) +++++. [00558]
Figure imgf000262_0002
EXAMPLE 231 : 3-(2-(4-(BENZO[D]THIAZOL-2-YLAMINO)PHENOXY)PYRIDIN-3- YL)CYCLOPENTANONE
[00559]
Figure imgf000262_0003
STEP 1. N-(4-(3-IODOPYRIDIN-2-YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00560] A suspension of 2-fluoro-3-iodopyridine (1.674 g, 7.51 mmol), 4- (benzo[d]thiazol-2-ylamino)phenol (2.73 g, 11.26 mmol) and cesium carbonate (4.16 g, 12.76 mmol) in N-methyl-2-pyrrolidinone (10 mL) was degassed and heated to 120 0C. After 3h 30 min, the reaction was cooled to 23 0C, diluted with EtOAc (200 mL) and washed with water (100 mL) and brine (100 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 0-1% methanol/dichloromethane), affording the product as an off- white solid. MS (ESI, pos. ion) m/z: 445.9 (M+l).
Figure imgf000263_0001
STEP 2. 3-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S- YL)CYCLOPENTANONE
[00561] A suspension of N-(4-(3-iodopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine (493 mg, 1.107 mmol), cyclopent-2-enol (373 mg, 4.43 mmol), potassium acetate (217 mg, 2.214 mmol), tetrabutylammonium chloride (338 mg, 1.218 mmol) and Palladium (II) acetate (24.86 mg, 0.111 mmol) in acetonitrile (3 mL) and water (0.300 mL) was degassed and backfilled with argon. The reaction was heated to 90 0C for 18h. Palladium (II) acetate (24.86 mg, 0.111 mmol) was added, and the reaction was capped, degassed and filled with argon, and heated to 135 0C in a microwave for Ih. The crude reaction mixture was diluted with dichloromethane (75 mL) and washed with brine (75 mL), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 35-50% EtOAc/hexane), affording a white solid. It was futher purified on a prep HPLC system (and free-based by partitioning between dichloromethane and saturated sodium bicarbonate solution), affording the product as a white solid. MS (ESI, pos. ion) m/z: 402.1 (M+l). IC50 (uM) +++++. SCHEME 54
Figure imgf000264_0001
EXAMPLE 232: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((lS,3S)-3-HYDROXY-3- (TRIFLUOROMETHYL)CYCLOPENTYL)PYRIDIN-2-YLOXY)PHENYL)METHANONE
[00562]
Figure imgf000264_0002
STEP 1 : 3-(2-FLUOROPYRIDIN-3-YL)CYCLOPENT-2-ENONE
[00563] To a round bottom flask was added bis(tri-t-butyl)phosphine palladium (0.591 g, 1.156 mmol) before sealing and evacuating and backfilling with nitrogen. Subsequently, cyclopent-2-enone (7.48 mL, 93 mmol), N-cyclohexyl-N-methylcyclohexanamine (14.73 mL, 69.4 mmol), and 3-bromo-2-fluoropyridine (4.07 g, 23.13 mmol) were added before adding dioxane (25 mL). The reaction mixture was stirred under nitrogen at 1100C for 16 h. The reaction mixture was cooled to room temperature and diluted with water and extracted with ethyl acetate before drying over magnesium sulfate, filtering, and concentrating under reduced pressure. The crude compound was purified by column chromatography (ethyl acetate/dichloromethane) to give 3-(2-fluoropyridin-3-yl)cyclopent-2-enone as an orange solid. MS (ESI, pos. ion) m/z: 178.0 (M+l).
Figure imgf000265_0001
STEP 2. 3-(2-FLUOROPYRIDIN-3-YL)-l-(TRIFLUOROMETHYL)CYCLOPENT-2-ENOL.
[00564] A solution of 3-(2-fluoropyridin-3-yl)cyclopent-2-enone (1.9g, 10.72 mmol) in tetrahydrofuran (30 mL) was treated with (trifluoromethyl)trimethylsilane (1.906 g, 13.40 mmol), followed by tetra-n-butylammonium fluoride, 1.0M in THF (0.536 mL, 0.536 mmol). The reaction turned dark, and was stirred under nitrogen at 23 0C.
[00565] After 2 h, more (trifluoromethyl)trimethylsilane ( 1.906 g, 13.40 mmol) and tetra-n-butylammonium fluoride, 1.0M in THF (0.536 mL, 0.536 mmol) were added. After a total of 4 h, 10% hydrochloric acid solution (50 ml) was added, and the reaction was stirred for 15 min. The solution was diluted with EtOAc (200 ml) and washed with 10% hydrochloric acid solution (50 ml), water (50 ml) and brine (50 ml), dried over MgSOφ concentrated in vacuo and purified by silica gel chromatography (eluant: 10-45% EtOAc/hexane), affording the product as a yellow oil. MS (ESI, pos. ion) m/z: 248.0 (M+l).
Figure imgf000265_0002
STEP 3. 3-(2-FLUOROPYRIDIN-S-YL)-I-(TRIFLUOROMETHYL)CYCLOPENTANOL
[00566] A solution of 3-(2-fluoropyridin-3-yl)- 1 -(trifluoromethyl)cyclopent-2-enol (940 mg, 3.80 mmol) in tetrahydrofuran (35 mL) was treated with palladium, 10% wt. on activated carbon (202 mg, 0.190 mmol). The reaction mixture was purged through 3 vacuum-hydrogen cycles, and was stirred under hydrogen at 23 0C. After 18 h, the reaction was filtered through celite and the filter cake was washed with tetrahydrofuran (50 mL). The combined filtrates were concentrated, affording the product as a yellow oil. MS (ESI, pos. ion) m/z: 250.0 (M+l).
Figure imgf000266_0001
STEP 4. (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((lS,3S)-3-HYDROXY-3- (TRIFLUOROMETHYL)CYCLOPENTYL)PYRIDIN-I-YLOXY)PHENYL)METHANONE
[00567] To a vial containing cesium carbonate (1634 mg, 5.02 mmol), (IH- benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (717 mg, 3.01 mmol), and 3-(2- fluoropyridin-3-yl)-l-(trifluoromethyl)cyclopentanol (500 mg, 2.006 mmol) was added NMP (13.400 ml). The mixture was heated at 2000C for 5 h with microwave irradiation. The reaction mixture was diluted with ethyl acetate and washed with 5N NaOH before drying the organic layer over magnesium sulfate, filtering, and concentrating under reduced pressure. The resulting orange oil was purified by column chromatography (ethyl acetate/dichloromethane) to give a pale orange oil. The material was diluted with ethyl acetateand washed with water and IO N NaOH before separating the mixture by SFC into its components, which consisted of two products identified as enantiomers by NMR. MS (ESI, pos. ion) m/z: 468.2 (M+ 1). IC50 (uM) +++++.
Figure imgf000266_0002
EXAMPLE 233: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((l S,3R)-3-HYDROXY-3- METHYLCYCLOPENTYL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
Figure imgf000266_0003
STEP 1 : 3-(2-FLUOROPYRIDIN-S-YL)-I-METHYLCYCLOPENT-I-ENOL
[00568] To a solution of 3-(2-fluoropyridin-3-yl)cyclopent-2-enone (1 g, 5.64 mmol) in THF (28.2 niL) was added methylmagnesium bromide (4.70 mL, 14.11 mmol) dropwise over 5 minutes. The dark brown solution was stirred for 3 h at room temperature before, slowly quenching with aqueous ammonium chloride. The crude reaction was diluted with water and extracted with ethyl acetate, drying over magnesium sulfate, filtering, and concentrating to a dark brown oil under reduced pressure. The crude compound was purified by column chromatography (ethyl acetate/dichloromethane) to afford 3-(2-fluoropyridin-3-yl)-l- methylcyclopent-2-enol as a clear oil. MS (ESI, pos. ion) m/z: 194.1 (M+l).
Figure imgf000267_0001
STEP 2: 3-(2-FLUOROPYRIDIN-S-YL)-I-METHYLCYCLOPENTANOL
[00569] To a l50 mL round bottom flask was added 3 -(2-fluoropyridin-3 -yl)- 1 - methylcyclopent-2-enol (282.8 mg, 1.449 mmol, 78 % yield) and ethanol (14.900 ml) before adding palladium on carbon, 10% by weight (150 mg, 1.410 mmol) followed by a tetrahydrofuran (3.73 ml) rinse. The reaction vessel was purged of air and backfilled with hydrogen before stirring at room temperature for 2 h. The reaction mixture was filtered through a pad of Celite with ethyl acetate and concentrated under reduced pressure to a pale yellow oil. MS (ESI, pos. ion) m/z: 196.2 (M+l).
Figure imgf000267_0002
STEP 3: (1H-BENZO[D]IMID AZOL-2-YL)(4-(3-((l S,3R)-3-HYDROXY-3- METHYLCYCLOPENTYL)PYRIDIN-2- YLOXY)PHENYL)METHANONE
[00570] To a vial containing 3 -(2-fluoropyridin-3 -yl)- 1 -methylcyclopentanol (570 mg, 2.92 mmol), (lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (1043 mg, 4.38 mmol), and cesium carbonate (2378 mg, 7.30 mmol) was added NMP (5.389 mL) before sealing and purging the vessel of air with nitrogen. The reaction mixture was set to heated at 1800C for 5 h with microwave irradiation. It was diluted with ethyl acetate and washed with 5 N NaOH. The organic layer was dried over magnesium sulfate, filtered, and concetrated under reduced pressure to a brown oil. The crude mixture of diastereomers was purified by SFC to yield four compounds. MS (ESI, pos. ion) m/z: 414.2 (M+ 1). IC50 (uM) +++++.
Figure imgf000268_0001
EXAMPLE 234: 3-(2-(4-(BENZO[D]THIAZOL^-YLAMINO)PHENOXY)PYRIDIN-S-YL)- 1 -METHYLCYCLOPENTANOL
[00571] To a 20 mL microwave vial was added cesium carbonate (1460 mg, 4.48 mmol), 4-(benzo[d]thiazol-2-ylamino)phenol (565 mg, 2.331 mmol), and 3-(2-fluoropyridin-3-yl)-l- methylcyclopentanol (350 mg, 1.793 mmol) as a solution in NMP (3585 μL). The reaction mixture was heated to 1800C for 3 h with microwave irradiation. The reaction was diluted with water and extracted with ethyl acetate before drying over magnesium sulfate, filtering, and concentrating under reduced pressure to a dark brown oil. Three purifications of the diastereomeric mixture by SFC gave four compounds. MS (ESI, pos. ion) m/z: 418.2 (M+l). IC50 (uM) +++++.
SCHEME 55
Figure imgf000269_0001
Figure imgf000269_0002
EXAMPLE 235: 1 H-BENZIMID AZOL-2-YL(4-((3 -(U-DIOXIDOTETRAHYDRO^H- THIOPYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
Figure imgf000269_0003
STEPl : 3,6-DIHYDRO-2H-THIOPYRAN-4-YL-TRIFLUOROMETHANESULFONATE
[00572] To a stirred solution of dihydro-2H-thiopyran-4(3H)-one (5.0 g, 43.0 mmol) in THF (30 rnL) at -780C was added LDA (25.8 rnL, 51.6 mmol) dropwise. After stirring for Ih, a solution of 2-(n,n-bis(trifluoromethylsulfonyl)amino)-5-chloropyridine (17.74 g, 45.2 mmol) in THF (50 mL) was added. The reaction mixture was then warmed to RT and stirred overnight, quenched by saturated NH4Cl, extracted with ether (3x), dried over MgSO4, concentrated and purified by ISCO (0-10% EtOAc/Hexanes) to give the yellow oil. MS (M+l): 249.2.
Figure imgf000270_0001
STEP 2: 2-(3,6-DIHYDRO-2H-THIOPYRAN-4-YL)4,4,5,5-TETRAMETHYL- 1,3,2- DIOXABOROLANE
[00573] A mixture of 3 ,6-dihydro-2H-thiopyran-4-yl trifluoromethanesulfonate (4.5 g, 18.13 mmol), 4,4,4>,4>,5,5,5>,5>-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (6.90 g, 27.2 mmol), potassium acetate (5.34 g, 54.4 mmol), and PdCl2(dppf)2 (1.480 g, 1.813 mmol) in p- dioxane/H2O (10:1, 22 ml) was heated at 100 0C for 24h, cooled, diluted with EtOAc, washed with H2O, dried over MgSO4, concentrated and purified by ISCO (0-10% EtOAc/Hexanes) to give the yellow oil. MS (M+l): 227.1.
Figure imgf000270_0002
STEP 3: 3-(3,6-DIHYDRO-2H-THIOPYRAN-4-YL)-2-FLUOROPYRIDINE
[00574] A mixture of 3 ,6-dihydro-2H-thiopyran-4-yl trifluoromethanesulfonate (4.O g, 16.11 mmol), 2-fluoropyridin-3-ylboronic acid (2.498 g, 17.72 mmol), sodium carbonate (5.12 g, 48.3 mmol), and dichlorobis(tri-o-tolylphosphine)palladium(ii) (0.633 g, 0.806 mmol) in p- dioxane/H2O (10:1, 22 mL) was heated at 135^C in 30 min. by microwave. The reaction mixture was cooled, diluted with H2O, extracted with EtOAc (3x), dried over MgSO4, concentrated and purified by ISCO (0-40% EtOAc/Hexanes) to give the expected product was a light brown oil. MS (M+l): 196.2.
Figure imgf000270_0003
STEP 4: 3-(l,l-DIOXIDOTETRAHYDRO-2H-THIOPYRAN-4-YL)-2-FLUOROPYRIDINE
[00575] A solution of 3-(3,6-dihydro-2H-thiopyran-4-yl)-2-fluoropyridine (1.30 g, 6.66 mmol) in EtOH (15 ml) was hydrogenated at RT in palladium on carbon (0.709 g, 0.666 mmol) for 14h. The solid was filtered and the filtrate was concentrated to give the light yellow oil. [00576] To a stirred mixture of 2-fluoro-3-(tetrahydro-2H-thiopyran-4-yl)pyridine (1.2 g, 6.08 mmol), 4-methylmorpholine 4-oxide (1.781 g, 15.21 mmol) in acetone/water (7:3, 30 mL) was added osmium(VIII) oxide (0.631 mL, 0.304 mmol). Stirring was continued at RT overnight. A saturated solution of sodium hydrogensulfite (10 mL) was added and stirred in 15min., extracted with EtOAc (3x), dried over MgSO4, concentrated to give the tan solid. MS (M+l): 230.2.
Figure imgf000271_0001
STEP 5: lH-BENZIMIDAZOL-2-YL(4-((3-(l,l-DIOXIDOTETRAHYDRO-2H- THIOPYRAN-4-YL)-2-PYRIDINYL)OXY)PHENYL)METHANONE
[00577] A mixture of (lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.485 g, 2.035 mmol), 3-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-2-fluoropyridine (0.311 g, 1.356 mmol), and cesium carbonate (1.326 g, 4.07 mmol) in NMP (5 mL) in a sealed tube was heated at 2000C in 2h. The reaction mixture was cooled, taken in H2O, filtered the dark brown solid, purified by ISCO (50% EtOAc/Hexanes) to give the expected product as a tan solid. MS (ESI, pos. ion) m/z: 448.1 (M+l). . IC50 (uM) ++H
SCHEME 56
Figure imgf000272_0001
EXAMPLE 236: N-(4-(5-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIMIDIN-4- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
Figure imgf000272_0002
STEP 1. 4-CHLORO-5-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYRIMIDINE
[00578] To a l50 niL sealable flask was added potassium phosphate (4.21 g, 19.83 mmol), dppf (0.264 g, 0.476 mmol), diacetoxypalladium (0.053 g, 0.238 mmol), 4-chloro-5- iodopyrimidine (1.907 g, 7.93 mmol), and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (1.75 g, 8.33 mmol) as a solution in DME (45.3 mL)/water (7.56 mL). The vessel was sealed and heated to 800C for 20 h. The reaction mixture was cooled to room temperature and diluted with water before extracting with ethyl acetate. The combined organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure to a dark brown oil that was used without purification. MS (ESI, pos. ion) m/z: 176.2 (M+l).
Figure imgf000273_0001
STEP 2: 4-(5-(3,6-DIHYDRO-2H-PYRAN-4-YL)PYPJMIDIN-4-YLOXY)ANILINE
[00579] To a l50 niL sealable tube was added 4-aminophenol (388 mg, 3.56 mmol), 4- chloro-5-(3,6-dihydro-2H-pyran-4-yl)pyrimidine (700 mg, 3.56 mmol), and cesium carbonate (1218 mg, 3.74 mmol) with DMSO (23.700 ml). The vessel was sealed and heated to 1000C for 2 h. The reaction mixture was cooled to room temperature and diluted with water before extracting with ethyl acetate. The combined organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure to a dark brown oil that was used without purification. MS (ESI, pos. ion) m/z: 270.0 (M+l).
Figure imgf000273_0002
STEP 3: 4-(5-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIMIDIN-4-YLOXY)ANILINE
[00580] To a pressure vessel was added palladium hydroxide, palladium on carbon (396 mg, 2.82 mmol), ethanol (18.800 ml), and 4-(5-(3,6-dihydro-2H-pyran-4-yl)pyrimidin-4- yloxy)aniline (760 mg, 2.82 mmol). The vessel was purged of air and backfilled with hydrogen (45 psi) before heating to 500C for 60 h. It was cooled to room temperature, filtered through Celite, and concentrated under reduced pressure to afford the product as a dark yellow oil. MS (ESI, pos. ion) m/z: 272.1 (M+l).
Figure imgf000273_0003
STEP 4: N-(4-(5-(TETRAHYDRO-2H-PYRAN-4-YL)PYRIMIDIN-4- YLOXY)PHENYL)BENZO[D]THIAZOL-2-AMINE
[00581] To a microwave vial was added 2-chlorobenzo[d]thiazole (68.5 μL, 0.553 mmol) and 4-(5-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-yloxy)aniline (150 mg, 0.553 mmol) with isopropanol (1.1 rnL). The reaction was irradiated at 1200C for 3 h with microwave irradiation. The crude reaction was concentrated under reduced pressure. Preparative HPLC afforded the target compound as a salt. The material was washed with sat. aq. sodium bicarbonate and extracted with dichloromethane before concentrating the combined organics under reduced pressure to a pale yellow oil. MS (ESI, pos. ion) m/z: 405.0 (M+l). IC50 (uM)
SCHEME 57
Figure imgf000274_0001
EXAMPLE 237: (1H-BENZO[D]IMID AZOL-2-YL)(4-(5-(l,2,3,6-TETRAHYDROPYRIDIN- 4-YL)PYRIMIDIN-4-YLOXY)PHENYL)METHANONE
Figure imgf000274_0002
STEP 1 : TERT-BUTYL 4-(4-CHLOROPYRIMIDIN-S-YL)-S5O-DIHYDROPYRIDINE- 1 (2H)-CARBOXYLATE
[00582] To a sealable tube was added potassium phosphate (1.308 g, 6.16 mmol), dppf (0.051 g, 0.092 mmol), palladium (II) acetate (0.014 g, 0.062 mmol), 4-chloro-5- iodopyrimidine (0.741 g, 3.08 mmol), and tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (1 g, 3.23 mmol) followed by DME (17.60 mL) and water (2.93 mL) before sealing the reaction under argon and stirring at 85°C for 4 h. It was cooled to room temperature and diluted with water before extracting with dichloromethane drying over magnesium sulfate, filtering, and concentrating under reduced pressure to a dark brownish-orange residue that was used without purification. MS (ESI, pos. ion) m/z: 296.2 (M+l).
Figure imgf000275_0001
STEP 2: TERT-BUTYL 4-(4-(4-(lH-BENZO[D]IMID AZOLE-2-
CARBONYL)PHENOXY)PYRIMIDIN-5-YL)-5,6-DIHYDROPYRIDINE-l(2H)-
CARBOXYLATE
[00583] To a vial was added tert-butyl 4-(4-chloropyrimidin-5-yl)-5,6-dihydropyridine- l(2H)-carboxylate (320 mg, 1.082 mmol), DMSO (5.4 mL), cesium carbonate (370 mg, 1.136 mmol), and (lH-benzo[d]imidazol-2-yl)(4-hydroxyphenyl)methanone (258 mg, 1.082 mmol) before sealing and heating to 1000C for 45 minutes. The reaction mixture was diluted with waterand extracted with ethyl acetate before drying over magnesium sulfate, filtering, and concentrating under reduced pressure. The crude material was taken after purifying by column chromatography (10% methanol/dichloromethane), affording tert-butyl 4-(4-(4-(1H- benzo[d]imidazole-2-carbonyl)phenoxy)pyrimidin-5-yl)-5,6-dihydropyridine-l(2H)- carboxylate. MS (ESI, pos. ion) m/z: 498.3 (M+l).
Figure imgf000276_0001
STEP 3: (1H-BENZO[D]IMID AZOL-2-YL)(4-(5-(l, 2,3,6-TETRAHYDROPYRIDIN-4- YL)PYRIMIDIN-4-YLOXY)PHENYL)METHANONE
[00584] To a round bottom was added tert-butyl 4-(4-(4-(lH-benzo[d]imidazole-2- carbonyl)phenoxy)pyrimidin-5-yl)-5,6-dihydropyridine-l(2H)-carboxylate (500 mg, 1.005 mmol), formic acid (10 ml), and hydrochloric acid, 5.0N (0.256 ml, 7.03 mmol) with stirring. The reaction was quenched after 15 minutes with saturated aqueous sodium bicarbonate and extracted with dichloromethane before drying over sodium sulfate, filtering, and concentrating under reduced pressure, affording (lH-benzo[d]imidazol-2-yl)(4-(5-(l,2,3,6-tetrahydropyridin- 4-yl)pyrimidin-4-yloxy)phenyl)methanone as a pale yellow solid. IC50 (uM) +++++.
Figure imgf000276_0002
EXAMPLE 238: 1 -(4-(4-(4-(BENZO [D]THI AZOL-2-YL AMINO)PHENOXY)PYRIMIDIN- 5-YL)-5,6-DIHYDROPYRIDIN-l(2H)-YL)ETHANONE
[00585] To a round bottom flask was added (lH-benzo[d]imidazol-2-yl)(4-(5-(l,2,3,6- tetrahydropyridin-4-yl)pyrimidin-4-yloxy)phenyl)methanone (60.8 mg, 0.153 mmol) with DCM (1 mL) under nitrogen. With stirring, acetyl chloride (12 μL, 0.168 mmol) was added dropwise to a yield a suspension that quickly became a solution. After complete addition of the chloride, triethylamine (32.0 μL, 0.229 mmol) was added in one aliquot. The reaction was diluted with water after 10 minutes and extracted with dichloromethane before drying over sodium sulfate, filtering, and concentrating under reduced pressure to a yellow oil. It was purified by column chromatography (2M NHs/MeOH/DCM). The resulting oil was resolubilized in dichloromethane and flushed through a plug of silica to yield 1-(4-(4-(4-(1H- benzo[d]imidazole-2-carbonyl)phenoxy)pyrimidin-5-yl)-5,6-dihydropyridin-l(2H)-yl)ethanone as a pale yellow oil. MS (ESI, pos. ion) m/z: 440.2 (M+ 1). IC50 (uM) ++++.
SCHEME 58
LDA, I2 NaOMe
Figure imgf000277_0002
THF, -78 0C MeOH, O 0C tO RT
Figure imgf000277_0003
Figure imgf000277_0001
Figure imgf000277_0004
EXAMPLE 239: (IH-BENZO[D]IMID AZOL-2-YL)(4-(2'-FLUORO-6-METHOXY-3,4'- BIPYRIDIN-2-YL0XY)PHENYL)METHAN0NE
Figure imgf000277_0006
STEP 1. 2,6-DIFLUORO-3-IODOPYRIDINE
[00586] To a stirred solution of lithium diisopropylamide (4.34 mL, 8.69 mmol, 2.0 M solution in heptane/THF/ethylbenzene) in THF (20 mL) at -78 °C under a nitrogen atmosphere was added 2,6-difluoropyridine (0.79 mL, 8.69 mmol). The mixture was stirred at -78 0C for 45 min before iodine (2.21 g, 8.69 mmol) in THF (10 mL) was added via syringe. The reaction was stirred for an additional 30 min at -78 0C. The reaction mixture was diluted with EtOAc and washed with 10% aqueous sodium sulfite. The organic layer was separated, dried over magnesium sulfate, filtered, and concentrated. The resulting crude product was purified by silica gel chromatography to give 2,6-difluoro-3-iodopyridine.
Figure imgf000278_0001
STEP 2. 2-FLUORO-3-IODO-6-METHOXYPYRIDINE AND 6-FLUORO-3-IODO-2- METHOXYPYRIDINE
[00587] Sodium metal (0.14 g, 5.89 mmol) was dissolved in MeOH (3 mL) under a nitrogen atmosphere. The solution was cooled to 0 0C before 2,6-difluoro-3-iodopyridine (1.42 g, 5.89 mmol) in MeOH (3 mL) was added via syringe. The reaction mixture was stirred at 0 0C for 3 h before being allowed to warm to room temperature gradually overnight. The reaction mixture was concentrated and then partitioned between EtOAc and water. The organic layer was separated, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated to give a mixture of 2-fluoro-3-iodo-6-methoxypyridine and 6-fluoro-3-iodo- 2-methoxypyridine.
Figure imgf000278_0002
STEP 3. (IH-BENZO[D]IMID AZOL-2-YL)(4-(3-IODO-6-METHOXYPYRIDIN-2- YLOXY)PHENYL)METHANONE AND (IH-BENZO[D]IMID AZOL-2-YL)(4-(5-IODO-6- METΗ0XYPYRIDIN-2-YL0XY)PΗENYL)METΗAN0NE
[00588] A mixture of 2-fluoro-3-iodo-6-methoxypyridine and 6-fluoro-3-iodo-2- methoxypyridine (0.40 g, 1.59 mmol), (lH-benzo[J]imidazol-2-yl)(4- hydroxyphenyl)methanone (0.76 g, 3.18 mmol), and cesium carbonate (1.04 g, 3.18 mmol) were mixed in NMP (4 rnL). The reaction mixture was placed under a nitrogen atmosphere and stirred at 120 0C for 5 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (2x). The combined organic layers were washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The resulting crude product was purified by silica gel chromatography to give a mixture of (lH-benzo[<i]imidazol- 2-yl)(4-(3-iodo-6-methoxypyridin-2-yloxy)phenyl)methanone and (lH-benzo[<i]imidazol-2- yl)(4-(5-iodo-6-methoxypyridin-2-yloxy)phenyl)methanone. [M+ 1] = 472.0 for both isomers.
Figure imgf000279_0001
STEP 4. (IH-BENZO[D]IMID AZOL-2-YL)(4-(2'-FLUORO-6-METHOXY-3,4'-BIPYRIDIN- 2-YL0XY)PHENYL)METHAN0NE
[00589] A mixture of (lH-benzo[d]imidazol-2-yl)(4-(3-iodo-6-methoxypyridin-2- yloxy)phenyl)methanone and (lH-benzo[d]imidazol-2-yl)(4-(5-iodo-6-methoxypyridin-2- yloxy)phenyl)methanone (0.22 g, 0.45 mmol), 2-fluoropyridine-4-boronic acid (0.077 g, 0.55 mmol), and tetrakis(triphenylphosphine)palladium (0.053 g, 0.046 mmol) were mixed in dioxane (2 mL) under an argon atmosphere. Sodium carbonate (0.64 mL, 1.28 mmol, 2.0 M in water) was added via syringe, and the reaction mixture was stirred at 80 0C for 16 h. The reaction mixture was then stirred at 100 0C for an additional 24 h before being cooled to room temperature. The reaction mixture was diluted with water and extracted with EtOAc (2x). The combined organic layers were washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The resulting crude product was purified by silica gel chromatography to give a mixture of (lH-benzo[<i]imidazol-2-yl)(4-(2'-fluoro-6-methoxy-3,4'- bipyridin-2-yloxy)phenyl)methanone and (lH-benzo[<i]imidazol-2-yl)(4-(2'-fluoro-2-methoxy- 3,4'-bipyridin-6-yloxy)phenyl)methanone. The regioisomers were then separated by reverse phase ΗPLC. The desired regioisomer was then partitioned between DCM and sat. aqueous sodium bicarbonate. The organic layers were separated, dried over magnesium sulfate, filtered, and concentrated to give (lH-benzo[<i]imidazol-2-yl)(4-(2'-fluoro-6-methoxy-3,4'-bipyridin-2- yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 440.9 (M+ 1). IC50 (uM) ++++. SCHEME 59
Figure imgf000280_0001
EXAMPLE 240: (IH-BENZO[D]IMID AZOL-2-YL)(4-(5-(2-FLUOROPYRIDIN-4-YL)-2- METHOXYP YRIMIDIN-4-YLOXY)PHENYL)METHANONE
Figure imgf000280_0002
STEP 1. 5-IODO-2-METHOXYPYRIMIDIN-4(lH)-ONE
[00590] 2-Methoxypyrimidin-4(lH)-one (1.00 g, 7.93 mmol) and n-iodosuccinimide (3.57 g, 15.86 mmol) were mixed in DMF (8 mL) under a nitrogen atmosphere. The reaction mixture was stirred at 70 0C for 2.5 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3x). The combined organic layers were washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The resulting solid was suspended in DCM, filtered, and washed with DCM to give 5-iodo-2- methoxypyrimidin-4(lH)-one. [M+ 1] = 252.9.
Figure imgf000281_0001
STEP 2. (IH-BENZO[D]IMID AZOL-2-YL)(4-(5-IODO-2-METHOXYPYRIMIDIN-4- YLOXY)PHENYL)METHANONE
[00591] To a stirred mixture of 5-iodo-2-methoxypyrimidin-4(lH)-one (0.25 g, 0.99 mmol) and (lH-benzo[<i][l,2,3]triazol-l-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate(V) (0.53 g, 1.19 mmol) in acetonitrile (8 mL) was added 1,8- diazabicyclo[5.4.0]undec-7-ene (0.30 mL, 1.98 mmol). The reaction mixture was stirred at room temperature for 30 min before (lH-benzo[<i]imidazol-2-yl)(4-hydroxyphenyl)methanone (0.47 g, 1.98 mmol) was added. The reaction mixture was stirred at room temperature for an additional 19 h. The reaction mixture was concentrated. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[<i]imidazol-2-yl)(4-(5-iodo-2- methoxypyrimidin-4-yloxy)phenyl)methanone . [M+ 1 ] = 473.1.
Figure imgf000281_0002
STEP 3. (IH-BENZO[D]IMID AZOL-2-YL)(4-(5-(2-FLUOROPYRIDIN-4-YL)-2- METΗOXYPYRIMIDIN-4-YLOXY)PΗENYL)METΗANONE
[00592] (lH-benzo[d]imidazol-2-yl)(4-(5-iodo-2-methoxypyrimidin-4- yloxy)phenyl)methanone (0.095 g, 0.20 mmol), 2-fluoropyridine-4-boronic acid (0.043 g, 0.30 mmol), and tetrakis(triphenylphosphine)palladium (0.023 g, 0.020 mmol) were mixed in dioxane (0.8 mL) under an argon atmosphere. Sodium carbonate (0.30 mL, 0.60 mmol, 2.0 M in water) was added via syringe, and the reaction mixture was stirred at 90 0C for 44 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was separated, washed with sat. sodium chloride, dried over magnesium sulfate, filtered, and concentrated. The resulting crude product was purified by silica gel chromatography to give (lH-benzo[d]imidazol-2-yl)(4-(5-(2-fluoropyridin-4-yl)-2- methoxypyrimidin-4-yloxy)phenyl)methanone. MS (ESI, pos. ion) m/z: 442.2 (M+ 1). IC50 (uM)
TABLE IIIA: EXAMPLES 241 TO 255 ARE TABULATED BELOW.
Figure imgf000282_0001
Figure imgf000283_0001
Figure imgf000284_0001
TABLE IIIB: EXAMPLES 241 TO 255 WERE PREPARED AS FOLLOWS:
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
SCHEME 60
NaOH (aq )
MeOH, 100°C
Figure imgf000287_0002
Figure imgf000287_0003
EXAMPLE 256: 2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)-N-(2- (PYRIDIN-2-YL)ETHYL)NICOTINAMIDE
Figure imgf000287_0004
STEP 1 :- ETHYL 2-(4-(IH-BENZO[D]IMIDAZOLE-I-CARBONYL)PHENOXY) NICOTINATE
[00593] To the solution of (lH-benzo[d]imidazol-2-yl)(4-(3-bromopyridin-2- yloxy)phenyl)methanone. (17.0 g, 43.1 mmol) in ethanol (600 mL) was added dppf (0.716 g, 1.29 mmol) and Pd(OAc)2 (77 mg, 0.344 mmol) and sodium acetate (14.13 g, 172 mmol) in 2.0 L. autoclave and apply CO(g) 15 kg/cm2 pressure. Then the reaction mixture was heated up to 135°C and maintained at that temperature for 1 h. Th reaction mass was concentrated under vacuum and diluted with water ,then extracted by ethyl acetate(3 x 500 mL). The combined organic extracts were dried over sodium sulfate and concentrate under vacuum to give the title compound as dark brown solid. MS (ESI, pos. ion) m/z: 389.1 (M+l).
Figure imgf000288_0001
STEP 2:- 2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)NICOTINIC ACID
[00594] To the solution of ethyl 2-(4-(lH-benzo[d]imidazole-2-carbonyl)Phenoxy) nicotinate (12.O g, 30.9 mmol) in methanol (100 mL) was added aqueous solution of NaOH (1.85 g,46.3 mmol, 30 mL). The reaction maixture was heated up to reflux for 1 h. The reaction mixture was concentrated, diluted with water and filtered. The aqueous layer was washed with ethyl acetate and acidified by addition of 2N HCl to pH 6. The brown precipitate was collected by filtration, dried to give the title compound. MS (ESI, pos. ion) m/z: 360.1 (M+l).
Figure imgf000288_0002
STEP 3. 2-(4-(lH-BENZO[D]IMID AZOLE-2-CARBONYL)PHENOXY)-N-(2-(PYRIDIN-2- YL)ETHYL)NICOTINAMIDE
[00595] HATU (122 mg, 0.321 mmol) was added to a mixture of 2-(4-(1H- benzo[d]imidazole-2-carbonyl)phenoxy)nicotinic acid (105 mg, 0.292 mmol) and diisopropylethylamine (102 μL, 0.584 mmol) in DMF (1 mL) and the mixture was stirred at RT for 10 min. 2-Phenethylamine (55.4 μL, 0.438 mmol) was added, and the mixture was stirred at RT for 1 h. The mixture was purified by chromatography on silica gel to deliver 2-(4-(1H- benzo[d]imidazole-2-carbonyl)phenoxy)-N-phenethylnicotinamide as an off-white solid. MS (ESI, pos. ion) m/z: 463.1 (M+l). IC50 (uM) +.
TABLE IVA: EXAMPLES 257 TO 276 ARE TABULATED BELOW:
Figure imgf000289_0001
Figure imgf000290_0001
Figure imgf000291_0001
Figure imgf000292_0002
TABLE IVB: EXAMPLES 258 TO 277 WERE PREPARED AS FOLLOWS:
Figure imgf000292_0001
Figure imgf000293_0001
Figure imgf000294_0001
Figure imgf000295_0002
TABLE (V): EXAMPLES 277 TO 326 AND THEIR PREPARATIONS ARE TABULATED
BELOW.
[00596] The racemic mixtures were/can be separated by chiral HPLC to give the following chiral compounds by known methods. Prep* means preparative experiment was performed according to the tabulated previous examples or schemes.
Figure imgf000295_0001
Figure imgf000296_0001
Figure imgf000297_0001
Figure imgf000298_0001
Figure imgf000299_0001
Figure imgf000300_0001
Figure imgf000301_0001
Figure imgf000302_0001
Figure imgf000303_0001
Figure imgf000304_0001
BIOLOGICAL EXAMPLES
EXAMPLE 1
MPDE 10A7 ENZYME ACTIVITY AND INHIBITION
[00597] Enzyme Activity. An IMAP TR-FRET assay was used to analyze the enzyme activity (Molecular Devices Corp., Sunnyvale CA). 5 μL of serial diluted PDElOA (BPS Bioscience, San Diego, CA) or tissue homogenate was incubated with equal volumes of diluted fluorescein labeled cAMP or cGMP for 60 min in 384-well polystyrene assay plates (Corning, Corning, NY) at room temperature. After incubation, the reaction was stopped by adding 60 μL of diluted binding reagents and was incubated for 3 hours to overnight at room temperature. The plates were read on an Envision (Perkin Elmer, Waltham, Massachusetts) for time resolved fluorescence resonance energy transfer. The data were analyzed with GraphPad Prism (La Jolla, CA).
[00598] Enzyme Inhibition. To check the inhibition profile, 5 μL of serial diluted compounds were incubated with 5 μL of diluted PDElO enzyme (BPS Bioscience, San Diego, CA) or tissue homogenate in a 384-well polystyrene assay plate (Corning, Corning, NY) for 30 min at room temperature. After incubation, 10 μL of diluted fluorescein labeled cAMP or cGMP substrate were added and incubated for 60 min at room temperature. The reaction was stopped by adding 60 μL of diluted binding reagents and plates were read on an Envision (Perkin Elmer, Waltham, Massachusetts) for time resolved fluorescence resonance energy transfer. The data were analyzed with GraphPad Prism (La Jolla, CA). [00599] Exemplary compounds of the invention having useful activity as measured by IC50 are shown in Table VI below. The tabulated IC50 data represent an average IC50 data for each compound.
TABLE VI: AVERAGE IC50 FOR REPRENTATIVE COMPOUNDS OF THE INVENTION:
Figure imgf000305_0001
Figure imgf000306_0001
Figure imgf000307_0001
Figure imgf000308_0001
Figure imgf000309_0001
Figure imgf000310_0001
Figure imgf000311_0001
Figure imgf000312_0001
Figure imgf000313_0001
Figure imgf000314_0001
Figure imgf000315_0001
Figure imgf000316_0001
Figure imgf000317_0001
Figure imgf000318_0001
Figure imgf000319_0001
Figure imgf000320_0001
Figure imgf000321_0001
Figure imgf000322_0001
Figure imgf000323_0001
Figure imgf000324_0001
Figure imgf000325_0001
Figure imgf000326_0001
Figure imgf000327_0001
Figure imgf000328_0001
Figure imgf000329_0001
Figure imgf000330_0001
Figure imgf000331_0001
Figure imgf000332_0001
Figure imgf000333_0001
Figure imgf000334_0001
Figure imgf000335_0001
Figure imgf000336_0001
Figure imgf000337_0001
Figure imgf000338_0001
Figure imgf000339_0001
Figure imgf000340_0001
Figure imgf000341_0001
Figure imgf000342_0001
Figure imgf000343_0001
Figure imgf000344_0001
Figure imgf000345_0001
Figure imgf000346_0001
Figure imgf000347_0001
Figure imgf000348_0001
Figure imgf000349_0001
Figure imgf000350_0001
Figure imgf000351_0001
Figure imgf000352_0001
Figure imgf000353_0001
Figure imgf000354_0001
Figure imgf000355_0001
Figure imgf000356_0001
Figure imgf000357_0001
EXAMPLE 2
APOMORPHINE INDUCED DEFICITS IN PREPULSE INHIBITION OF THE STARTLE RESPONSE IN RATS, AN IN VIVO TEST FOR ANTIPSYCHOTIC ACTIVITY
[00600] The thought disorders that are characteristic of schizophrenia may result from an inability to filter, or gate, sensorimotor information. The ability to gate sensorimotor information can be tested in many animals as well as in humans. A test that is commonly used is the reversal of apomorphine-induced deficits in the prepulse inhibition of the startle response. The startle response is a reflex to a sudden intense stimulus such as a burst of noise. In this example, rats are exposed to a sudden burst of noise, at a level of 120 db for 40 msec, e.g., the reflex activity of the rats is measured. The reflex of the rats to the burst of noise may be attenuated by preceding the startle stimulus with a stimulus of lower intensity, at 3 db to 12 db above background (65 db), which attenuates the startle reflex by 20% to 80%. [00601] The prepulse inhibition of the startle reflex, described above, may be attenuated by drugs that affect receptor signaling pathways in the CNS. One commonly used drug is the dopamine receptor agonist apomorphine. Administration of apomorphine reduces the inhibition of the startle reflex produced by the prepulse. Antipsychotic drugs such as haloperidol prevents apomorphine from reducing the prepulse inhibition of the startle reflex. This assay can be used to test the antipsychotic efficacy of PDElO inhibitors, as they reduce the apomorphine -induced deficit in the prepulse inhibition of startle.
EXAMPLE 3
CONDITIONED AVOIDANCE RESPONDING (CAR) IN RATS, AN IN VIVO TEST FOR ANTIPSYCHOTIC ACTIVITY
[00602] Conditioned avoidance responding (CAR) occurs, for instance, when an animal learns that a tone and light predict the onset of a mild foot shock. The subject learns that when the tone and light are on, it must leave the chamber and enter a safe area. All known antipsychotic drugs reduce this avoidance response at doses which do not cause sedation. Examining the ability of test compounds to suppress the conditioned avoidance has been widely used for close to fifty years to screen for drugs with useful antipsychotic properties. [00603] In this example, an animal is placed in a two-chambered shuttle box and presented with a neutral conditioned stimulus (CS) consisting of a light and tone, followed by an aversive unconditioned stimulus (US) consisting of a mild foot shock through a floor grid in the shuttle box chamber. The animal is free to escape the US by running from one chamber to the other, where the grid is not electrified. After several presentations of the CS-US pair, the animal typically learns to leave the chamber during the presentation of the CS and avoid the US altogether. Animals treated with clinically-relevant doses of antipsychotic drugs have a suppression of their rate of avoidances in the presence of the CS even though their escape response to the shock itself is unaffected.
[00604] Specifically, conditioned avoidance training is conducted using a shuttle box (Med Associates, St. Albans, VT). The shuttle box is divided into 2 equal compartments that each contain a light source, a speaker that emits an 85 dB tone when activated and an electrified grid that can deliver a scrambled foot shock. Sessions consist of 20 trials per day (intertrial interval of 25-40 sec) during which a 10 sec illumination and a concurrent 10 sec tone signals the subsequent delivery of a 0.5 rnA shock applied for a maximum of 10 sec. Active avoidance, defined as the crossing into the opposite compartment during the 10 sec conditioning stimuli (light and tone) prevents the delivery of the shock. Crossing over to the other compartment after the delivery of the shock terminates shock delivery and is recorded as an escape response. If an animal does not leave the conditioning chamber during the delivery of the shock it is recorded as an escape failure. Training is continued daily until the avoidance of 16 or more shocks out of 20 trials (80% avoidance) on 2 consecutive days is achieved. After this criterion is reached the rats are given one day of pharmacological testing. On test day, rats are randomly assigned to experimental groups, weighed and injected intraperitoneally (i.p.) (1 cc tuberculin syringe, 26 3/8 gauge needle) or per os (p.o.) (18 gauge feeding needle) with either control or compound solutions. Compounds are injected at 1.0ml/kg for i.p. and 10 mL/kg for p.o. administration. Compounds can be administered either acutely or chronically. For testing, each rat is placed in the shuttle box, and given 20 trials with the same parameters as described above for training trials. The number of avoidances, escapes, and escape failures are recorded.
EXAMPLE 4
PCP-INDUCED HYPERACTIVITY (PCP-LMA)
[00605] Equipment Used: 4 X 8 home cage photobeam activity system (PAS) frame from San Diego Instruments. Open PAS program and prepare an experimental session using the following variables:
Multiphase experiment
300 sec/interval (5 min)
12 intervals (1 h)
Individual on screen switches.
Start recording after first beam break.
End session after end of interval.
CAGE PREPARATION:
[00606] Techniplast™ rat cage with filter top, but no wire lid. Place -400 mL bedding and one food pellet in cage and place 250 mL techniplast water bottle in holder on filter top. Place the prepped cage in the PAS frame. Make sure bedding or pellet doesn't block the photobeams. Animal preparation;
MARK RATS AND RECORD THEIR WEIGHTS. BRING RATS TO TESTING ROOM.
PHASE I: HABITUATION
[00607] Start the experiment session. Place the rat in the enclosure. The computer should start recording when it detects the rat breaking the beam. The computer will record for 1 h. During the habituation phase, prepare risperidone (positive control): Measure out risperidone, calculate final volume at 1 mg/mL concentration and add 1% glacial acetic acid of the final volume to dissolve risperidone. When risperidone is dissolved, add saline to final volume to make a concentration of 1 mg/mL. Fill syringes (3 mL syringes with 23 g 1/2 needle or oral gavage needle) with Amgen compound solution (5 mL/kg) or risperidone (1 mL syringe with 23gl/2 needle) control (1 mL/kg) s.c.
PHASE II: COMPOUND PRE-TREATMENT
[00608] Make sure Phase I has ended. Remove rat from enclosure, start the next phase using on-screen individual switch, administer compound p.o or i.p. and control s.c. and place rat back in the enclosure. The computer should start recording when it detects the rat breaking the beam. The computer will record for 1 h.
[00609] During phase II, prepare pep : Dissolve pep in saline to a concentration of
5 mg/mL.
[00610] Fill syringes (1 mL syringes with 26g3/8 needle) with pep solution (1 mL/kg).
PHASE III: PCP ADMINISTRATION.
[00611] Make sure phase II is ended. Remove rat from enclosure, start the next phase using on-screen individual switch, administer pep s.c. and place rat back in the enclosure. The computer will record for 1 h.
CLEAN-UP:
[00612] End-session to terminate experiment and so that computer will compile data. Export raw data to excel file for data analysis. Euthanize rats and take necessary tissue/sample for PK. DATA GENERATION:
[00613] Export raw data to excel file for data analysis. Total time of movement is recorded as the number of photobeam breaks by the computer. Total time of movement (seconds) is combined into 5 minute bins and averaged for each treatment group for an N of 7- 10 animals. Data are analyzed for statistical significance using a two-way ANOVA followed by a Bonferroni's post-hoc test for multiple comparisons.
[00614] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. [00615] All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted. [00616] The compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles, for the treatment of PDElO- related diseases, such as acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally. [00617] Treatment of diseases and disorders herein is intended to also include the prophylactic administration of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of preventative treatment, such as, for example, pain, inflammation and the like.
[00618] The dosage regimen for treating PDE 10-receptor-mediated diseases, cancer, and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein. [00619] The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.
[00620] For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods. [00621] The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg. [00622] Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known are using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. [00623] Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
[00624] A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation. [00625] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. [00626] For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
[00627] The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. [00628] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
[00629] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.
[00630] Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
[00631] Likewise, the compounds of this invention may exist as isomers, that is compounds of the same molecular formula but in which the atoms, relative to one another, are arranged differently. In particular, the alkylene substituents of the compounds of this invention, are normally and preferably arranged and inserted into the molecules as indicated in the definitions for each of these groups, being read from left to right. However, in certain cases, one skilled in the art will appreciate that it is possible to prepare compounds of this invention in which these substituents are reversed in orientation relative to the other atoms in the molecule. That is, the substituent to be inserted may be the same as that noted above except that it is inserted into the molecule in the reverse orientation. One skilled in the art will appreciate that these isomeric forms of the compounds of this invention are to be construed as encompassed within the scope of the present invention.
[00632] The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
[00633] Examples of acids that may be employed to from pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
[00634] Also encompassed in the scope of the present invention are pharmaceutically acceptable esters of a carboxylic acid or hydroxyl containing group, including a metabolically labile ester or a prodrug form of a compound of this invention. A metabolically labile ester is one which may produce, for example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound. A prodrug form is one which is not in an active form of the molecule as administered but which becomes therapeutically active after some in vivo activity or biotransformation, such as metabolism, for example, enzymatic or hydro lytic cleavage. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p- methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use. Esters of a compound of this invention, may include, for example, the methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety. Metabolically labile esters, may include, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl, α-methoxyethyl, groups such as α-((Ci-C4)alkyloxy)ethyl, for example, methoxy ethyl, ethoxy ethyl, propoxy ethyl, iso-propoxy ethyl, etc.; 2-oxo-l,3- dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo-l,3,dioxolen-4-ylmethyl, etc.; C1-C3 alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylthiomethyl, etc.; acyloxymethyl groups, for example, pivaloyloxymethyl, α-acetoxymethyl, etc.; ethoxycarbonyl-1 -methyl; or α-acyloxy-α-substituted methyl groups, for example α- acetoxy ethyl.
[00635] Further, the compounds of the invention may exist as crystalline solids which can be crystallized from common solvents such as ethanol, N,N-dimethyl-formamide, water, or the like. Thus, crystalline forms of the compounds of the invention may exist as polymorphs, solvates and/or hydrates of the parent compounds or their pharmaceutically acceptable salts. All of such forms likewise are to be construed as falling within the scope of the invention. [00636] While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.
[00637] The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
[00638] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

We Claim:
1. A compound having the structure of formula I:
Figure imgf000367_0001
or any pharmaceutically-acceptable salt thereof, wherein:
Each of X1, X2, X3, X4, and X5 is independently N or C; wherein no more than two of X1, X2, X3 and X4 are N;
X6 is N or C;
Each of X7, X9, X10, and X12 is independently N or C; each of X8 and X11 is C; wherein no more than three of X7, X9, X10, and X12 are N;
Y is NH, NR5, CH(OH), C(=O), -CRaRb, or CF2; or alternatively Y and R3 form a 5- to 6- membered ring fused to the ring containing both said Y and R3;
Z is NH, NR6, S, SO, SO2, O, or C; wherein Z is only C when X5 is N; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2;
R1 is selected from the group consisting of
(a) H, F, Cl, Br, I, Ci_8alk, Ci_4haloalk, -ORa, -NRaRa, -N(Ra)C(=0)Rb, -C(=0)NRaRa, -C(=O)Rd, -C(=O)-O-Ra, -ORC, -NRaRc, -N(Rc)C(=0)Rb, -N(Ra)C(=0)Rc, -C(=0)NRaRb, or -C(=0)NRaRc;
(b) a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic ring or a saturated, partially-saturated or unsaturated 8-, 9-, 10-, 11-, or 12-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3, or 4 N atoms and 0, 1, or 2 atoms selected from O and S, and wherein each said ring is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo; with a proviso that said unsaturated 6-membered monocyclic ring is not of formula:
Figure imgf000368_0001
; wherein each Di and D2 are independently N or C; and said partially unsaturated 5-membered monocyclic ring is not of formula:
Figure imgf000368_0002
(c) group -L-R7, wherein L is CH2, NH, N(C1-4alk), -C(=O)NRaRa(Ci_4alk), O, S, S=O, or S(=O)2;
(d) Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, d_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=0)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk, Ci_4haloalk, or -NRaCi_4alk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, 0Ra, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, Ci_4haloalk, or -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2_6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, C^haloalk, -OH, -OCi_4alk, -NH2, -NHC1-4SiIk, -OC(=O)d_4alk, or -N(CMalk)CMalk;
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co-4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo; and
Rd is a nitrogen-linked saturated, partially-saturated, or unsaturated 5-, 6- or 7-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional nitrogen atoms and containing 0 or 1 sulfur or oxygen atom, the heterocycle being substituted by 0, 1, 2 or 3 substituents selected from oxo, halo, Ci_4alk, Ci_3haloalk, -OCi_4alk, -NH2, -NHCi_4alk, and
Figure imgf000369_0001
2. The compound of Claim 1 wherein the group
Xx8*X^x10 I Il
is selected from the group consisting of ; .
Figure imgf000370_0001
Or wherein the group
Figure imgf000370_0002
3. The compound as in any one of the preceding claims wherein the group
Figure imgf000370_0003
4. The compound as in any one of the preceding claims wherein Y is NH; -C(=0); or wherein Y is NH and Y and R3 form a 5- to 6- membered ring fused to the ring containing both said Y and R3.
5. The compound as in any one of the preceding claims wherein Z is NH, N-Ci_4alk N-haloCi_4alk S, or -C=.
6. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of H, F, Cl, Br, I, -0Ra, Ci_8alk, d_4haloalk, -C(=O)-O-Ra, -C(=0)NRaRa, -ORC, and -C(=0)NRaRc.
7. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of a saturated A-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains O, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1 or 2 groups selected from F, Cl, Br, d_6alk, Ci_4haloalk, -ORa, -CN, -C(=O)Rb, -C(=O)ORa, and oxo.
8. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of a partially-saturated or unsaturated A-, 5-, 6-, or 7-membered monocyclic ring, wherein each said ring contains 0, 1, 2, or 3 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1 or 2 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -CN, -C(=O)Rb, -C(=O)ORa, and oxo; with a proviso that said unsaturated 6-membered monocyclic ring and said unsaturated 5-membered monocyclic ring is not of formula:
Figure imgf000371_0001
• wherein each Di and D2 are independently N or C.
9. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of a saturated, partially-saturated or unsaturated 9- or 10-membered bicyclic ring, wherein each said ring contains 0, 1, 2, 3 or 4 N atoms and 0, 1, or 2 O atoms, and wherein each said ring is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -NRaRa, -NRaRc, R7, R8 and oxo.
10. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, phenyl, 2-pyridyl, 3-pyridyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by 0, 1 or 2 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, CN, -C(=O)Rb, -C(=O)ORa, -SRa, R7, and oxo.
11. The compound as in any one of the preceding claims wherein R1 is Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORb, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2_6alkNRaRa, -OC2_6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, R8 and oxo.
12. The compound as in any one of the preceding claims wherein R1 is selected from the group consisting of:
Figure imgf000372_0001
13. The compound as in any one of the preceding claims wherein the group of formula:
Figure imgf000372_0002
is selected from the group consisting of
Figure imgf000373_0001
14. The compound as in any one of the preceding claims wherein the group of formula:
Figure imgf000373_0002
is selected from the group consisting of
Figure imgf000373_0003
15. A compound having the structure of formula II:
Figure imgf000373_0004
or any pharmaceutically-acceptable salt thereof, wherein: Z is NH, NR6, S or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is O, 1, 2, 3 or 4;
X1 is N or C;
X5 is N or C;
X6 is N or C;
Ring A is a carbon-linked-saturated or carbon-linked- partially-unsaturated 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially-saturated, or nitrogen- linked-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, d_4alk, d_4haloalk, or -NRaCi_4alk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, ORa, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2, 3, or 4 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
R9 is independently selected from the group consisting of H, F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, C^haloalk, -OH, -OCi_4alk, -NH2, -NHCi_4alk, -OC(=O)Ci_4alk, or -N(Ci_4alk)Ci_4alk; and
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co-4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo.
16. The compound of Claim 15 wherein ring A is selected from the group consisting of cyclohexyl, cyclopentyl, cyclopentenyl, cyclohexenyl, cycloheptyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiopyranyl, oxaspiro[3.5]nonyl, azepanyl, oxepanyl, quinolinyl, all of which are substituted by 0, 1, 2 or 3 groups selected from all of which are substituted by 0, 1 or 2 groups selected from F, Cl, Br, d_6alk, d_4haloalk, -ORa, CN, -C(=O)Rb, -C(=O)ORa, -SRa, R7, and oxo.
17. The compound of Claim 15 wherein ring A is selected from the group consisting of:
Figure imgf000376_0001
18. A compound having the structure of formula III:
Figure imgf000376_0002
or any pharmaceutically-acceptable salt thereof, wherein:
Z is NH, NR6, S, or O; m is 0, 1, 2, 3 or 4; n is 0, 1 or 2; p is 0, 1 or 2; y is 0, 1, 2, 3 or 4;
X1 is N or C;
X5 is N or C;
X6 is N or C;
Ring A is a carbon-linked-saturated or carbon-linked- partially-unsaturated A-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered carbocyclic ring containing 0, 1 or 2 N atoms and containing 0 or 1 S or O atom; or a nitrogen-linked-saturated, nitrogen-linked-partially-saturated, or nitrogen- linked-unsaturated 4-, 5-, 6-, 7-, 8-, 9-, 10-, H-, or 12-membered ring heterocycle containing the linking nitrogen and 0, 1 or 2 additional N atoms and containing 0 or 1 S or O atom;
R2 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or Ci_4haloalk;
R3 is, independently in each instance, F, Cl, Br, CN, OH, OCi_4alk, Ci_4alk or C^haloalk;
R4 is independently in each instance, F, Cl, CH3, CN, CF3, CHF2, CH2F, ORa, or NRaRa;
R5 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R6 is Ci_8alk, Ci_4haloalk, -C(=O)Rb, or Rc;
R7 is a saturated, partially-saturated or unsaturated 3-, A-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2, 3, or 4 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R8 and oxo;
R8 is a Ci_6alk substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2_6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa and oxo;
R9 is independently selected from the group consisting of H, F, Cl, Br, Ci_6alk, Ci_4haloalk, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -NRaRc, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8 and oxo;
Ra is independently, at each instance, H or Rb;
Rb is independently, at each instance, phenyl, benzyl or Ci_6alk, the phenyl, benzyl and Ci_6alk being substituted by O, 1, 2 or 3 substituents selected from halo, Ci_4alk, d_3haloalk, -OH, -OCi_4alk, -NH2, -NHCi_4alk, -OC(=O)Ci_4alk, or -N(Ci_4alk)Ci_4alk; and
Rc is a Co-4alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7- membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atom selected from O and S, wherein said Co-4alk and said ring moiety may be substituted by 0, 1, 2 or 3 groups selected from F, Cl, Br, Ci_6alk, Ci_4haloalk, R7, -ORa, -OCi_4haloalk, CN, -C(=O)Rb, -C(=O)ORa, -C(=O)NRaRa, -C(=NRa)NRaRa, -OC(=O)Rb, -OC(=O)NRaRa, -OC2.6alkNRaRa, -OC2.6alkORa, -SRa, -S(=O)Rb, -S(=O)2Rb, -S(=O)2NRaRa, -NRaRa, -N(Ra)C(=O)Rb, -N(Ra)C(=O)ORb, -N(Ra)C(=O)NRaRa, -N(Ra)C(=NRa)NRaRa, -N(Ra)S(=O)2Rb, -N(Ra)S(=O)2NRaRa, -NRaC2.6alkNRaRa, -NRaC2.6alk0Ra, -Ci_6alkNRaRa, -Ci_6alkORa, -Ci_6alkN(Ra)C(=O)Rb, -Ci_6alkOC(=O)Rb, -Ci_6alkC(=O)NRaRa, -Ci_6alkC(=O)ORa, R7, R8, and oxo.
19. A method of treating conditions that may be treated with PDElO inhibitors comprising the step of administering a compound according to any one of the preceding claims.
20. The method of Claim 19 wherein said condition is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
21. The method of Claim 19 wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
22. A pharmaceutical composition comprising a compound according to any one of the preceding claims and a pharmaceutically-acceptable diluent or carrier.
23. A compound of claim 1, or any pharmaceutically-acceptable salt thereof, selected from the group consisting of:
(lH-Benzo[d]imidazol-2-yl)(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)methanone;
(4-(3 -Ethynylpyridin-2-yloxy)phenyl)( 1 -methyl- 1 H-benzo [d]imidazol-2-yl)methanone;
4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile;
(4-(3,3'-Bipyridin-2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone;
(4-(3-(9H-purin-6-yl)pyridin-2-yloxy)phenyl)(l H-benzo [d]imidazol-2-yl)methanone;
2-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)benzyl)-lH-benzo[d]imidazole;
(1 H-benzo [d]imidazol-2-yl)(4-(3-(piperidin-l-yl)pyridin-2-yloxy)phenyl)methanone;
(4-(3-chloropyridin-2-yloxy)phenyl)(6-fluoro-l H-benzo [d]imidazol-2-yl)methanone;
(4-(3-bromopyridin-2-yloxy)phenyl)(lH-imidazo[4,5-b]pyridin-2-yl)methanone;
(5 -fluoro- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(trifluoromethyl)pyridin-2-yloxy)- phenyl)methanone;
(lH-imidazo[4,5-b]pyridin-2-yl)(4-(3-(trifluoromethyl)pyridin-2- yloxy)phenyl)methanone;
(5,6-difluoro-lH-benzo[d]imidazol-2-yl)(4-(3-(trifluoromethyl)pyridin-2- yloxy)phenyl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(3-bromopyridin-2-yloxy)phenyl)methanone;
(4-(3 -bromopyridin-2-yloxy)phenyl)( 1 -methyl- 1 H-benzo [d]imidazol-2-yl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3-hydroxy-3 -methylbut- 1 -ynyl)pyridin-2- yloxy)phenyl)methanone;
4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzoic acid;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile;
(1 H-benzo [d]imidazol-2-yl)(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-methylpyridin-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-(trifluoromethyl)pyridin-4-yl)pyridin-2- yloxy)phenyl)methanone; tert-butyl 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-5,6- dihydropyridine- 1 (2H)-carboxylate;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)benzoic acid; (lH-benzo[d]imidazol-2-yl)(4-(3-(4-(methylsulfonyl)phenyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3 -(methylsulfonyl)phenyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(4-methoxyphenyl)pyridin-2-yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(3 -methoxyphenyl)pyridin-2-yloxy)phenyl)methanone;
(4-(3 -bromopyridin-2-yloxy)phenyl)( 1 -(tetrahydro-2H-pyran-2-yl)- 1 H-benzo [d]imidazol- 2-yl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(pyrimidin-5 -yl)pyridin-2-yloxy)phenyl)methanone;
(4-(3,3'-bipyridin-2-yloxy)phenyl)(lH-benzo[d]imidazol-2-yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(quinolin-5 -yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(quinolin-4-yl)pyridin-2-yloxy)phenyl)methanone;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-3,4'-bipyridine-2'-carbonitrile;
(lH-benzo[d]imidazol-2-yl)(4-(2'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(6-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(3 -(2 -methoxyquino lin-3 -yl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(2 -methoxyphenyl)pyridin-2-yloxy)phenyl)methanone;
(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)(l-methyl-lH-benzo[d]imidazol-2- yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(pyrrolidin-l-yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-morpholinopyridin-2-yloxy)phenyl)methanone;
(4-(2',6'-dimethoxy-3,3'-bipyridin-2-yloxy)phenyl)(l -methyl- 1 H-benzo [d]imidazol-2- yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(4'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(5'-(methylthio)-3,3'-bipyridin-2- yloxy)phenyl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(2'-chloro-3,4'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)methanone; (4-(2'-chloro-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
(l-methyl-l/f-benzo[d]imidazol-2-yl)(4-(2'-methyl-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-fluoro-3,3'-bipyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2'-hydroxy-3,4'-bipyridin-2-yloxy)phenyl)methanone;
2-(4-(2'-(trifluoromethyl)-3,4'-bipyridin-2-yloxy)benzyl)-lH-benzo[d]imidazole;
(lH-benzo[d]imidazol-2-yl)(4-(4-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)methanone;
(4-(4-methoxy-2,3'-bipyridin-2'-yloxy)phenyl)(l -methyl- lH-benzo[d]imidazol-2- yl)methanone;
4-(2-(4-(l -methyl- 1 H-benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)pyridin- 2(lH)-one;
(6-fluoro- 1 -methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahy dro-2H-pyran-4-yl)pyridin- 2-yloxy)phenyl)methanone and (5 -fluoro- 1 -methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahy dro- 2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methanone;
(4-(5-chloro-2'-methyl-3,4'-bipyridin-2-yloxy)phenyl)(l -methyl- 1 H-benzo [d]imidazol-2- yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(2',5-dimethyl-3,4'-bipyridin-2-yloxy)phenyl)methanone;
(4-(2',5-dimethyl-3,4'-bipyridin-2-yloxy)phenyl)(l-methyl-lH-benzo[d]imidazol-2- yl)methanone;
(1 H-benzo [d]imidazol-2-yl)(4-(5-chloro-2'-methyl-3,4'-bipyridin-2- yloxy)phenyl)methanone;
N-(4-(3-Cyclopropylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)nicotinic acid;
2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)-N-(cyclopropylmethyl)nicotinamide;
N-(4-(3-Morpholinopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(4-methoxypiperidin-l-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-morpholinopyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine; 2-(4-( 1 -methyl- 1 H-benzo [d]imidazol-2-ylamino)phenoxy)nicotinonitrile ;
1 -methyl-N-(4-(3 -(morpholinomethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine; benzo[d]thiazol-2-yl(4-(3-bromopyridin-2-yloxy)phenyl)methanone;
Benzo[d]thiazol-2-yl(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanol;
N-(4-(3-(l,2,3,6-Tetrahydropyridin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine;
1 -(4-(2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperazin- 1 -yl)ethanone;
N-(4-(3,3'-Bipyridin-2-yloxy)phenyl)-N-methylbenzo[d]thiazol-2-amine;
N-(4-(3,3'-Bipyridin-2-yloxy)phenyl)-l -methyl- lH-benzo[d]imidazol-2-amine;
N-(4-(3 -(T etrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)-l H-benzo [d]imidazol-2- amine;
N-(4-(3-bromopyridin-2-yloxy)phenyl)-l H-benzo [d]imidazol-2-amine;
6,7-difluoro-N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
6,7-difluoro-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine; l-methyl-N-(4-(3-methylpyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; l-methyl-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4-methyl-N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(4-(pyridin-2-yloxy)phenyl)-l H-benzo [d]imidazol-2-amine;
N-(4-(3-fluoropyridin-2-yloxy)phenyl)-l -methyl- 1 H-benzo [d]imidazol-2-amine;
5 -fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
2-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenylamino)- 1 H-benzo [d]imidazole-5 - carbonitrile;
6-chloro-5 -fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-l-methyl-lH-benzo[d]imidazol-2-amine;
N-(4-(3-chloropyridin-2-yloxy)phenyl)-l -methyl- lH-benzo[d]imidazol-2-amine; 4-fluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
5 ,7-difluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
5 ,6-difluoro-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H-benzo [d]imidazol-2- amine;
N-(2-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
1 -isopropyl-5 -(trifluoromethyl)-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- IH- benzo[d]imidazol-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-7H-purin-8-amine;
1 -methyl-5 -(trifluoromethyl)-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
5 -fluoro- 1 -methyl-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
5 -chloro- 1 -ethyl-N-(4-(3 -(trifluoromethyl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
4-fluoro-N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4,6-difluoro-N-(4-(3-(2-methylpyridin-4-yl)pyridin-2-yloxy)phenyl)-lH- benzo[d]imidazol-2-amine;
N-(4-(3-fluoropyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(3-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(6-(3-(trifluoromethyl)pyridin-2-yloxy)pyridin-3-yl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-lH-imidazo[4,5-b]pyridin-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-morpholinopyridin-2-yloxy)phenyl)-lH-imidazo[4,5-c]pyridin-2-amine;
N-(4-(3-cyclopropylpyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(2-fluoro-4-(3-(trifluoromethyl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(5-(3-(trifluoromethyl)pyridin-2-yloxy)pyridin-2-yl)-lH-benzo[d]imidazol-2-amine;
2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)-N-(furan-2-ylmethyl)nicotinamide; N-(4-(3-bromopyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; 1 -((2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)pyridin-3 -yl)methyl)pyrrolidin-3 -ol; 4-(2-(4-(benzo[d]thiazole-2-carbonyl)phenoxy)pyridin-3-yl)benzonitrile; (4-(3,3'-bipyridin-2-yloxy)phenyl)(benzo[d]thiazol-2-yl)methanone; benzo[d]thiazol-2-yl(4-(3-morpholinopyridin-2-yloxy)phenyl)methanone; 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzonitrile; 3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzonitrile; N-(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3 -(2-methoxypyrimidin-5 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine; N-(4-(3 -(pyrimidin-5 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine; methyl 4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)benzoate; N-(4-(3-(3-methoxyphenyl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(6'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(6'-chloro-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(2'-methyl-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(2'-fluoro-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(quinolin-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol--amine;
N-(4-(3-(2,3-dihydrobenzofuran-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(benzo[d][l,3]dioxol-5-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-cyclohexenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(quinolin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(2'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; l-methyl-N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; N-(4-(6'-methyl-3,3'-bipyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine; N-(4-(3-cyclopentenylpyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(5'-(methylthio)-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; N-(4-(4'-methoxy-3,3'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine; (1 H-benzo [d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-Imidazo [4,5 -b]pyridin-2-yl)(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanol;
2-(difluoro(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)methyl)- 1 H- benzo[d]imidazole;
(4-(3 -(3 ,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)( 1 -methyl- 1 H- benzo[d]imidazol-2-yl)methanone;
( 1 -methyl- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
1 -(4-Methoxybenzyl)-N-(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
7-Methoxy-N-(4-(3 -(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)- 1 H- benzo[d]imidazol-2-amine;
N-(4-(3-(Tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(tetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]oxazol-2-amine;
N-(4-(3-(4-fluorotetrahydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2- amine;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)tetrahydro-2H-pyran-4-ol;
(lH-benzo[d]imidazol-2-yl)(4-(3-(4-(difluoromethyl)tetrahydro-2H-pyran-4-yl)pyridin- 2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-3-yl)pyridin-2- yloxy)phenyl)methanone;
N-(4-(3 -(Tetrahydro-2H-pyran-3 -yl)pyridin-2-yloxy)phenyl)benzo [J]thiazol-2-amine;
(±)-N-(4-(3-(tetrahydro-2H-pyran-2-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(1 H-benzo [d]imidazol-2-yl)(4-(3-((lR,4R)-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,4S)-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohex-3-enol;
4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lr,4r)-4-hydroxy-4-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone; (lR,4R)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(lH-Benzo[d]imidazol-2-yl)(4-(3-((lS,4S)-4-hydroxy-4- (trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone;
(lH-Benzo[J]imidazol-2-yl)(4-(3-((li?,4i?)-4-hydroxy-4- (trifluoromethyl)cyclohexyl)pyridin-2-yloxy)phenyl)methanone;
(l/f-benzo[J]imidazol-2-yl)(4-(3-((15',45)-4-ethyl-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(l/f-benzo[<i]imidazol-2-yl)(4-(3-((li?,4i?)-4-ethyl-4-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(4-(3 -((4SJS)- 1 -Oxaspiro [3.5 ]nonan-7-yl)pyridin-2-yloxy)phenyl)( IH- benzo[<i]imidazol-2-yl)methanone;
4-(2-(4-(lH-Benzo[<i]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclohexanone;
4-(2-(4-(Benzo[<i]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanone;
4-(2-(4-(lΗ-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cycloheptanone;
(lH-Benzo[<i]imidazol-2-yl)(4-(3-(oxepan-4-yl)pyridin-2-yloxy)phenyl)methanone;
Λ/-(4-(3-(oxepan-4-yl)pyridin-2-yloxy)phenyl)benzo[J]thiazol-2-amine;
5-(2-(4-(lΗ-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)azepan-2-one;
5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l-methylazepan-2- one;
(rac)-cώ-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(rac)-trα/?5-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(rac)-E-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
4-(2-(4-(Benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l-methylpiperidin-2-one;
4-(2-(4-(lH-Benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l-methylpiperidin-2- one;
(i?)-4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l- methylpyrrolidin-2-one;
(5)-4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-l- methylpyrrolidin-2-one;
4-(2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)pyridin-3 -yl)- 1 -methylpyrrolidin-2-one l-(4-(2-(4-(lΗ-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone; l-(4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-5,6-dihydropyridin-l(2H)- yl)ethanone; l-(4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin-l-yl)ethanone; tert-butyl 4-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidine-l- carboxylate;
(lH-benzo[d]imidazol-2-yl)(4-(3-(piperidin-4-yl)pyridin-2-yloxy)phenyl)methanone; l-(5-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)-3,4- dihydropyridin- 1 (2H)-yl)ethanone;
(S)-l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone ;
(R)-l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone;
(S)- 1 -(3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin- 1 -yl)ethanone
(R)-l-(3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone;
(R)-I -(2-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l - yl)ethanone ;
(S)-I -(2-(2-(4-(I H-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone; l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)pyrrolidin-l- yl)ethanone; l-(3-(3-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-l- yl)ethanone;
N-(4-(3-(tetrahydrofuran-2-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(R)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone (S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone;
N-(4-(3 -(tetrahydrofuran-3 -y l)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
( 1 -(2-fluoroethyl)- 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
3 -(2-(4-(I H-benzo [d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopent-2-enone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone; 3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopent-2-enone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
3 -(2-(4-(benzo [d]thiazol-2-ylamino)phenoxy)pyridin-3 -yl)- 1 -methylcyclopentanol; lH-benzimidazol-2-yl(4-((3-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-2- pyridinyl)oxy)phenyl)methanone;
N-(4-(5-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-yloxy)phenyl)benzo[d]thiazol-2-amine;
(lH-benzo[d]imidazol-2-yl)(4-(5-(l,2,3,6-tetrahydropyridin-4-yl)pyrimidin-4- yloxy)phenyl)methanone; l-(4-(4-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyrimidin-5-yl)-5,6-dihydropyridin- l(2H)-yl)ethanone;
(l/f-Benzo[J]imidazol-2-yl)(4-(2'-fluoro-6-methoxy-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(4-fluorotetrahydro-2H-pyran-4-yl)pyridin-2- yloxy)phenyl)methanone;
(4-(3 -(4-fluorotetrahydro-2H-pyran-4-y l)pyridin-2-y loxy)phenyl)( 1 -methyl- 1 H- benzo[d]imidazol-2-yl)methanone; l-(4-(2-(4-(l-methyl-lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin- l-yl)ethanone;
(±)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydro-2H-pyran-2-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((ls,4s)-4-hydroxy-4-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(ls,4s)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(rac)-cώ-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(rac)-trα/?5-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone; (rac)-E-(lH-benzo[d]imidazol-2-yl)(4-(3-(3-hydroxy-3-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydroflιran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(pyridin-2- yl)ethyl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-phenethylnicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-phenylpropyl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-phenylpropan-2- yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-phenylpropan-2- yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-methoxy-3-phenylpropan-2- yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(thiophen-2- yl)ethyl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-methoxypropan-2- yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-(pyridin-2- yl)ethyl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-hydroxyethyl)nicotinamide;
(rac)-2-(4-(l H-benzo [d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-methyl-2-(pyridin-2- y l)propy l)nicotinamide ;
2-(4-( 1 H-benzo [d]imidazole-2-carbonyl)phenoxy)-N-( 1 - benzylcyclopropyl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-(4- methoxyphenyl)propan-2-yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-hydroxy-3-(4- hydroxyphenyl)propan-2-yl)nicotinamide;
2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2,3-dihydro-lH-inden-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(2-phenylpropyl)nicotinamide; 2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)-2- methylpropan-2-yl)nicotinamide;
(rac)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan-2- yl)nicotinamide;
(R)-( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2- yloxy)phenyl)methanone;
(S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-3-yl)pyridin-2- yloxy)phenyl)methanone;
(R)-N-(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
(S)-N-(4-(3 -(tetrahydrofuran-3 -yl)pyridin-2-yloxy)phenyl)benzo [d]thiazol-2-amine;
(S)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone;
(R)-(lH-benzo[d]imidazol-2-yl)(4-(3-(tetrahydrofuran-2-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 R,3 S)-3 -(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 S ,3R)-3 -(hydroxymethyl)cyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxycyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lr,4r)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lr,4s)-4-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol; (lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclohexanol;
(R)-l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone;
(S)-l-(3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)piperidin-l- yl)ethanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
((lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxycyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)cyclopentanol;
(S)-3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
(R)-3-(2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)pyridin-3-yl)cyclopentanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3S)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3R)-3-hydroxy-3-methylcyclopentyl)pyridin-2- yloxy)phenyl)methanone;
(lS,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lR,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol; (lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclopentanol;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lS,3S)-3-hydroxy-3- (trifluoromethyl)cyclopentyl)pyridin-2-yloxy)phenyl)methanone;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(4-fluorophenyl)propan-2- yl)nicotinamide;
(S)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- yl)nicotinamide;
(R)-2-(4-(lH-benzo[d]imidazole-2-carbonyl)phenoxy)-N-(l-(pyridin-2-yl)propan-2- y l)nicotinamide . ;
(lS,3S)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
(lR,3R)-3-(2-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyridin-3-yl)-l- methylcyclohexanol;
( 1 H-benzo [d]imidazol-2-yl)(4-(3 -(( 1 S ,3 S)-3 -hydroxy-3 -methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-((lR,3R)-3-hydroxy-3-methylcyclohexyl)pyridin-2- yloxy)phenyl)methanone; or any pharmaceutically-acceptable salt thereof.
24. A compound selected from the group consisting of:
(4-(3,4'-bipyridin-2-yloxy)phenyl)(lH-benzo[d]imidazol-2-yl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(2-methoxypyridin-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(l -methyl- lH-pyrazol-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(l-cyclopropyl-lH-pyrazol-4-yl)pyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)methanone; (5-fluoro-lH-benzo[d]imidazol-2-yl)(4-(2'-fluoro-3,4'-bipyridin-2- yloxy)phenyl)methanone;
(lH-benzo[d]imidazol-2-yl)(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)methanone;
N-(4-(3,4'-Bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
4,6-difluoro-N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4-fluoro-N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
4-fluoro-N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2-amine;
4,6-difluoro-N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)-lH-benzo[d]imidazol-2- amine;
N-(4-(3-(pyridin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3'-methoxy-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(3-(pyrimidin-4-yl)pyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
N-(4-(2'-(trifluoromethyl)-3,4'-bipyridin-2-yloxy)phenyl)benzo[d]thiazol-2-amine;
(lH-Benzo[<i]imidazol-2-yl)(4-(5-(2-fluoropyridin-4-yl)-2-methoxypyrimidin-4- yloxy)phenyl)methanone; or any pharmaceutically acceptable salt thereof.
25. A method of treating conditions that may be treated with PDE 10 inhibitors comprising the step of administering a compound according to Claim 24.
26. The method of Claim 25 wherein said condition is selected from the group consisting of psychoses, Parkinson's disease, dementias, obsessive compulsive disorder, tardive dyskinesia, choreas, depression, mood disorders, impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases, and compulsions with pallidal disease.
27. The method of Claim 25 wherein said condition is selected from the group consisting of schizophrenia, bipolar disorder, and obsessive-compulsive disorder.
28. A pharmaceutical composition comprising a compound according to Claim 24 and a pharmaceutically-acceptable diluent or carrier.
PCT/US2009/064643 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors WO2010057126A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2011005093A MX2011005093A (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors.
JP2011536570A JP2012508777A (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
EA201100749A EA201100749A1 (en) 2008-11-14 2009-11-16 DERIVATIVES OF PYRIDINE AND PYRIMIDINE AS INHIBITORS OF PHOSPHODYSTERASE 10
CA2742833A CA2742833C (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
BRPI0921598A BRPI0921598A2 (en) 2008-11-14 2009-11-16 pyridine and pyrimidine derivatives as phosphodiesterase inhibitors 10
AU2009313773A AU2009313773B2 (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
ES09752706T ES2413808T3 (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
EP09752706.3A EP2364306B1 (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
IL212670A IL212670A0 (en) 2008-11-14 2011-05-03 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
TN2011000220A TN2011000220A1 (en) 2008-11-14 2011-05-05 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
MA33931A MA32891B1 (en) 2008-11-14 2011-06-10 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS 10

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US61/114,595 2008-11-14
US16621509P 2009-04-02 2009-04-02
US61/166,215 2009-04-02

Publications (1)

Publication Number Publication Date
WO2010057126A1 true WO2010057126A1 (en) 2010-05-20

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064643 WO2010057126A1 (en) 2008-11-14 2009-11-16 Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

Country Status (17)

Country Link
US (2) US8318718B2 (en)
EP (1) EP2364306B1 (en)
JP (1) JP2012508777A (en)
KR (1) KR20110086603A (en)
AR (1) AR074343A1 (en)
AU (1) AU2009313773B2 (en)
BR (1) BRPI0921598A2 (en)
CA (1) CA2742833C (en)
CR (1) CR20110279A (en)
EA (1) EA201100749A1 (en)
ES (1) ES2413808T3 (en)
IL (1) IL212670A0 (en)
MA (1) MA32891B1 (en)
MX (1) MX2011005093A (en)
TN (1) TN2011000220A1 (en)
TW (1) TW201030001A (en)
WO (1) WO2010057126A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
WO2012018058A1 (en) 2010-08-04 2012-02-09 武田薬品工業株式会社 Fused heterocyclic ring compound
WO2012018909A1 (en) 2010-08-04 2012-02-09 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012020780A1 (en) 2010-08-10 2012-02-16 武田薬品工業株式会社 Heterocyclic compound and use thereof
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2012124782A1 (en) 2011-03-16 2012-09-20 武田薬品工業株式会社 Condensed heterocyclic compound
US8354411B2 (en) 2009-02-05 2013-01-15 Takeda Pharmaceutical Company Limited 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
WO2012170976A3 (en) * 2011-06-10 2013-04-11 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2014142322A1 (en) 2013-03-15 2014-09-18 第一三共株式会社 Benzothiophene derivative
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9512118B2 (en) 2011-06-22 2016-12-06 Takeda Pharmaceutical Company Limited Crystal of fused heterocyclic compound
US9518065B2 (en) 2013-09-27 2016-12-13 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
CN110563664A (en) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 Method for preparing racemic (4AS,7S,7AS) -tert-butyl-7-hydroxy hexahydro-cyclopenta [ B ] [1,4] oxazine-4 (4AH) -formic acid ester
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
WO2022238327A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
RS54788B1 (en) * 2011-08-25 2016-10-31 Merck Sharp & Dohme Pyrimidine pde10 inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US11447486B2 (en) 2014-07-31 2022-09-20 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344223A1 (en) 2003-09-24 2005-04-21 Merck Patent Gmbh New 2-anilino-1,3-benzoxazole derivatives, are inhibitors of kinases, especially tyrosine- or Raf-kinases, useful e.g. for treating solid tumors, angiogenesis, diabetic retinopathy, inflammation or psoriasis
WO2005042520A1 (en) 2003-10-24 2005-05-12 Merck Patent Gmbh Benzimidazolyl derivatives
US20070155779A1 (en) 2006-01-05 2007-07-05 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
WO2007100646A1 (en) 2006-02-24 2007-09-07 Amgen Inc. Multi-cyclic compounds and method of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
PT1635828E (en) 2003-04-04 2008-07-01 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DE10337942A1 (en) * 2003-08-18 2005-03-17 Merck Patent Gmbh aminobenzimidazole derivatives
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (en) * 2005-04-12 2006-10-19 Merck Patent Gmbh Novel aza heterocycles as kinase inhibitors
JP2009503073A (en) 2005-08-02 2009-01-29 アイアールエム・リミテッド・ライアビリティ・カンパニー 5-Substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
EP2303859A4 (en) 2008-06-20 2012-08-22 Metabolex Inc Aryl gpr119 agonists and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344223A1 (en) 2003-09-24 2005-04-21 Merck Patent Gmbh New 2-anilino-1,3-benzoxazole derivatives, are inhibitors of kinases, especially tyrosine- or Raf-kinases, useful e.g. for treating solid tumors, angiogenesis, diabetic retinopathy, inflammation or psoriasis
WO2005042520A1 (en) 2003-10-24 2005-05-12 Merck Patent Gmbh Benzimidazolyl derivatives
US20070155779A1 (en) 2006-01-05 2007-07-05 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
WO2007100646A1 (en) 2006-02-24 2007-09-07 Amgen Inc. Multi-cyclic compounds and method of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUJISHIGE ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 18438 - 18445
KEHLER J ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, vol. 17, no. 2, 1 February 2007 (2007-02-01), pages 147 - 158
KEHLER J ET AL: "The potential therapeutic use of phosphodiesterase 10 inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 17, no. 2, 1 February 2007 (2007-02-01), pages 147 - 158, XP002529529, ISSN: 1354-3776 *
LOUGHNEY ET AL., GENE, vol. 234, 1999, pages 109 - 117
SODERLING ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 7071 - 7076

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US8435995B2 (en) 2009-02-05 2013-05-07 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8916566B2 (en) 2009-02-05 2014-12-23 Takeda Pharmaceutical Company Limited Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders
US8778944B2 (en) 2009-02-05 2014-07-15 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US9550756B2 (en) 2009-02-05 2017-01-24 Takeda Pharmaceutical Company Limited Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders
US8513251B2 (en) 2009-02-05 2013-08-20 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8354411B2 (en) 2009-02-05 2013-01-15 Takeda Pharmaceutical Company Limited 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
US9226921B2 (en) 2010-06-24 2016-01-05 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
US8846713B2 (en) 2010-06-24 2014-09-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US8563575B2 (en) 2010-06-24 2013-10-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8940758B2 (en) 2010-06-24 2015-01-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP2013534223A (en) * 2010-08-04 2013-09-02 武田薬品工業株式会社 Fused heterocyclic compounds
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012018058A1 (en) 2010-08-04 2012-02-09 武田薬品工業株式会社 Fused heterocyclic ring compound
WO2012018909A1 (en) 2010-08-04 2012-02-09 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012020780A1 (en) 2010-08-10 2012-02-16 武田薬品工業株式会社 Heterocyclic compound and use thereof
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
US9249162B2 (en) 2011-01-11 2016-02-02 Sunovion Pharmaceuticals Inc. Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors
US9856274B2 (en) 2011-01-11 2018-01-02 Sunovion Pharmaceuticals Inc. Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
US10570156B2 (en) 2011-01-11 2020-02-25 Sunovion Pharmaceuticals Inc. Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9670181B2 (en) 2011-02-18 2017-06-06 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9029388B2 (en) 2011-03-16 2015-05-12 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
JP5973990B2 (en) * 2011-03-16 2016-08-23 武田薬品工業株式会社 Fused heterocyclic compounds
WO2012124782A1 (en) 2011-03-16 2012-09-20 武田薬品工業株式会社 Condensed heterocyclic compound
CN106831732A (en) * 2011-06-10 2017-06-13 默克专利有限公司 The composition and method of pyrimidine and pyridine compounds of the production with BTK inhibitory activity
CN106831732B (en) * 2011-06-10 2019-12-24 默克专利有限公司 Compositions and methods for producing pyrimidine and pyridine compounds having BTK inhibitory activity
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
EA031153B1 (en) * 2011-06-10 2018-11-30 Мерк Патент Гмбх Use of pyrimidine compounds with btk inhibitory activity
JP2016185953A (en) * 2011-06-10 2016-10-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
JP2018115165A (en) * 2011-06-10 2018-07-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Compositions and methods for production of pyrimidine and pyridine compounds with btk inhibitory activity
JP2014517016A (en) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrimidine having BTK inhibitory activity and composition of pyrimidine compound and method for producing the same
CN103814016A (en) * 2011-06-10 2014-05-21 默克专利有限公司 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
US9580449B2 (en) 2011-06-10 2017-02-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
WO2012170976A3 (en) * 2011-06-10 2013-04-11 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US10016448B2 (en) 2011-06-10 2018-07-10 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
EA027584B1 (en) * 2011-06-10 2017-08-31 Мерк Патент Гмбх Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US10413562B2 (en) 2011-06-10 2019-09-17 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
US9512118B2 (en) 2011-06-22 2016-12-06 Takeda Pharmaceutical Company Limited Crystal of fused heterocyclic compound
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014142322A1 (en) 2013-03-15 2014-09-18 第一三共株式会社 Benzothiophene derivative
US9464076B2 (en) 2013-03-15 2016-10-11 Daiichi Sankyo Company, Limited Benzothiophene derivative
US9518065B2 (en) 2013-09-27 2016-12-13 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US9902710B2 (en) 2013-12-05 2018-02-27 Exonhit Therapeutics, Sa Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
CN110563664A (en) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 Method for preparing racemic (4AS,7S,7AS) -tert-butyl-7-hydroxy hexahydro-cyclopenta [ B ] [1,4] oxazine-4 (4AH) -formic acid ester
WO2022238327A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors

Also Published As

Publication number Publication date
US20100125062A1 (en) 2010-05-20
AU2009313773A1 (en) 2010-05-20
KR20110086603A (en) 2011-07-28
AU2009313773B2 (en) 2013-03-21
ES2413808T3 (en) 2013-07-17
CR20110279A (en) 2011-09-22
CA2742833A1 (en) 2010-05-20
US20130079325A1 (en) 2013-03-28
TW201030001A (en) 2010-08-16
CA2742833C (en) 2013-12-31
JP2012508777A (en) 2012-04-12
BRPI0921598A2 (en) 2016-02-10
AR074343A1 (en) 2011-01-12
MA32891B1 (en) 2011-12-01
US8759532B2 (en) 2014-06-24
IL212670A0 (en) 2011-07-31
MX2011005093A (en) 2011-09-27
EP2364306A1 (en) 2011-09-14
EA201100749A1 (en) 2011-10-31
US8318718B2 (en) 2012-11-27
EP2364306B1 (en) 2013-04-24
TN2011000220A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
EP2364306B1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
EP2364308B1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
EP2376455B1 (en) Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
AU2011253003B2 (en) Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
AU2011253003A1 (en) Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
AU2011253143A1 (en) Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
AU2011253058A1 (en) Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09752706

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009313773

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 592414

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 212670

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2742833

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: /P/2011/00005

Country of ref document: BW

WWE Wipo information: entry into national phase

Ref document number: 12011500904

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2009313773

Country of ref document: AU

Date of ref document: 20091116

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001092

Country of ref document: CL

Ref document number: 2011536570

Country of ref document: JP

Ref document number: 001036-2011

Country of ref document: PE

Ref document number: MX/A/2011/005093

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2011-000279

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 11066599

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2009752706

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4419/DELNP/2011

Country of ref document: IN

Ref document number: 201100749

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20117013477

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201107347

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0921598

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110516